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ABSTRACT OF THE DISSERTATION
Uropathogenic Escherichia coli Employ a Conserved Intracellular Infection Pathway that
can be Inhibited by Novel Anti-Virulence Therapeutics
By
Corinne Katherine Cusumano
Doctor of Philosophy in Biology and Biomedical Sciences
(Molecular Microbiology and Microbial Pathogenesis)
Washington University in St. Louis, 2009
Professor Scott J. Hultgren, Chairperson

Urinary tract infections (UTIs) affect 13 million women annually in the United
States and are predominately caused by uropathogenic Escherichia coli (UPEC). In a
murine cystitis model, UPEC utilize a multistep pathogenic pathway in which they invade
and form intracellular bacterial communities (IBCs) within bladder facet cells. Type 1 pili
expressing the adhesin, FimH, are necessary for UPEC binding and invasion of
urothelial cells and formation of IBCs. UPEC ultimately disperse from the IBC, many
with filamentous morphology, and infect other host urothelial cells. Using a panel of
UPEC clinical isolates, this work evaluates the conservation of the IBC pathway across
UPEC, the function of a UPEC pathogenicity island (PAI) in the UPEC pathway, and the
therapeutic effect of inhibition of FimH.
Investigation of 18 clinical isolates revealed that the majority of isolates proceed
through the IBC cascade confirming its relevance in UPEC infection. Due to the
commonality of the UPEC pathway, this panel of clinical isolates was used to investigate
other determinants important in UPEC infection. One potential virulence determinant is
pUTI89, isolated from UTI89. pUTI89 has many characteristics of a PAI thus it was
evaluated for its presence in UPEC isolates and its role in pathogenesis. Evidence of
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pUTI89 was found in 67% of UPEC isolates tested. Studies revealed that while there
was no observable phenotype in vitro in the absence of pUTI89, there was a significant
defect in binding, invasion and colonization at early time points post-infection, however,
infection levels were restored by 24h post-infection. Since pUTI89 is not essential to
UPEC infection, type 1 pili were used to develop a therapeutic against UPEC infection.
Binding and invasion are critical to the UPEC pathway, thus inhibition of these early
steps could result in unsuccessful colonization of the bladder. Knowledge of the FimH
mannose-binding pocket enabled the rational development of mannosides that
competitively inhibit binding to mannosylated uroplakins on the bladder surface.
These studies demonstrated the commonality of the IBC pathway among UPEC
isolates as well as the importance of pUTI89 in early stages of UPEC infection.
Knowledge of the UPEC pathway facilitated the development of novel therapeutics to
inhibit binding and invasion and reduce infection.
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CHAPTER ONE
INTRODUCTION TO THE DISSERTATION

Urinary Tract Infections
The urinary tract is a common site of infection in women, resulting in an estimated 8
million outpatient visits yearly in the U.S. with an estimated cost exceeding $2.5 billion
(22). It is thought that acute urinary tract infections (UTI) develop when bacteria from
the fecal flora colonize the vaginal and periurethral areas and are subsequently
introduced into the bladder by ascension via the urethra. The vast majority of patients
are female. Women have a 50% chance of developing an acute UTI within their lifetime
(45, 51). This gender difference in UTI is presumed to be due to the anatomical
differences between males and females, with females having a relatively short urethra
as well as a shorter distance between the urethral opening and the anus. In addition,
higher rates of infection are associated with some subpopulations, such as the elderly,
diabetics, those with anatomical abnormalities and pregnant women (4, 49). UTI can
lead to a number of serious sequelae including renal scarring and premature birth (4,
49). Nosocomial infection is extremely common and can result in sepsis with significant
morbidity and mortality particularly for elderly patients (18). Uropathogenic Escherichia
coli (UPEC) is the leading causative agent of UTI, responsible for up to 85% of
community-acquired UTI and 25% of nosocomial UTI (50).

Recurrent infection
Recurrence is a serious problem for many women. Women who present with an initial
episode of acute UTI have a 25-44% chance of developing a second and a 3% chance

1

of experiencing three episodes within six months of the initial UTI (19). Recurrence
occurs despite appropriate antibiotic treatment and clearance of the initial infection from
the urine. A large percentage of recurrent UTI (rUTI) are caused by the same strain of
bacteria as the initial infection. One study followed 58 women and found that 68% of
recurrences were caused by the same initial index strain of UPEC as determined by
restriction fragment length polymorphism (RFLP) analysis (54). In a separate study,
50% of recurrent strains isolated from female college students appeared genotypically
identical to the bacterial strain corresponding to the initial UTI (20). Another long-term
prospective study demonstrated that the same strain of UPEC can cause a rUTI up to 3
years later (9). The high frequency of same-strain recurrences supports the notion that
a UPEC reservoir can exist in the affected individual. The current dogma is that all rUTI
result from the re-inoculation of the urinary tract with bacteria originating from a reservoir
within the gastrointestinal tract (GIT) and/or vagina (26). Consistent with this idea, it has
been demonstrated that the GIT and the vagina/periurethral areas can support UPEC
reservoirs (54, 64). In addition, vaginal epithelial cells from women that are prone to
rUTIs tend to support higher levels of bacterial adherence, as compared to cells from
healthy control patients (59). However, the presence of perineal bacterial or GIT
colonization does not explain how a first time urinary tract infection predisposes for the
risk of recurrence in girls or women with anatomically normal urinary tracts (61, 62).
Furthermore, daily application of antibacterial ointment to the perineal area fails to
prevent recurrent infections, even though such a treatment would be expected to block
fecal/vaginal-to-urinary tract transmission (11). Women who get frequent rUTIs have
been offered a variety of prevention strategies. Often these women are given antibiotics
to take upon first presentation of symptoms, after sexual intercourse, or daily as UTI
prophylaxis (42, 65, 66). These courses, however, promote uropathogen antibiotic
resistance. Additional studies have looked at cranberry products (5), Lactobacillus
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probiotic therapy (70), and vaccination against bacterial adhesins (35, 36). While many
of these strategies are promising, they have yet to be validated in large-scale clinical
trials.

UPEC Pathogenic Cycle
Clinically, it has been presumed that UPEC infection consists of a relatively simple
extracellular colonization of the luminal surface after inoculation of fecal flora into the
bladder via the urethra. In contrast, using a murine model of UPEC infection of the
urinary tract, we have detailed an unexpectedly complex UPEC pathogenesis cycle that
involves both intracellular and extracellular niches (Figure 1). Using genetic,
biochemical and cell biological approaches together with a variety of imaging techniques
including transmission, quick freeze-deep etch and scanning electron microscopy, as
well as confocal and time lapse video microscopy, it has been discovered that UPEC
invade bladder facet cells via a FimH-dependent mechanism (2, 31, 40). After invasion,
cytoplasmic intracellular bacterial communities (IBCs) are formed. Rapid replication of
the initial invading bacteria results in the formation of an early IBC of loosely-packed rodshaped bacteria (31). The bacteria continue to replicate and progress to form a large
densely packed mid-stage IBC of morphologically coccoid bacteria (31), with biofilm-like
characteristics including positive periodic acid-Schiff (PAS) staining (3) and differential
gene expression throughout the community (3, 73). After the IBC matures, bacteria
detach from the biomass, often become filamentous, and spread to neighboring cells
forming new generation IBCs. Filamentous bacteria are more resistant to neutrophil
killing resulting in evasion of neutrophil phagocytosis and promoting bacterial survival.
Thus, the IBC pathway facilitates massive expansion of the invading bacteria in a niche
protected from host defenses. Population dynamic studies using ex vivo gentamicin
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protection assays demonstrated that ~104 UPEC of an initial 107 inoculum invaded the
bladder tissue within 15 minutes after infection and that one percent of the invaded
bacteria went on to form IBCs, resulting in an average of 100 IBCs per infected mouse
bladder. If this is extrapolated to the human situation, innate defenses in the bladder
most likely prevent the majority of bacterial inoculation events into the bladder from
leading to disease. However, the ramifications of the IBC cascade are striking. Invasion
of a single infecting bacterium can lead to rapid expansion of the infection via IBC
formation, replicating within hours to 104 bacteria and even higher numbers followed by
dispersal of the bacteria from the biomass and spreading to neighboring cells to reinitiate
the IBC cascade. This process allows the bacteria to gain a critical foothold. Bacterial
descendents of the acute IBC cascade have been shown using our murine model, to be
able to form a quiescent intracellular reservoir (QIR) that can persist, protected from
antibiotics and seemingly undetected by the host immune system even after the acute
infection is resolved and bacteria are no longer detectable in the urine (41, 60). Bacteria
in the QIR can later seed a recurrent infection (60), manifested by IBC formation,
bacteriuria and inflammation. Growing understanding of the bacterial mechanisms of
virulence and the subsequent host responses have led to new avenues of research and
identification of powerful new therapeutic targets, diagnostic regimens, and the design of
anti-virulence compounds.

UPEC Clinical Isolates and the UPEC Pathogenic Cycle
Due to the unique nature of the UPEC pathogenic cycle in UTI89, translational studies
were performed in an effort to show that the majority of UPEC isolates form IBCs when
introduced into the murine bladder and that IBCs and filamentous bacteria occur in the
urine of human UTI patients (21, 52). The study began with the enrollment of hundreds
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of women into three different studies to obtain the four different clinical syndromes of
UTI. The four common syndromes of UTI are asymptomatic bacteriuria (ASB), acute
cystitis, recurrent cystitis (rUTI) and pyelonephritis. ASB is clinically defined as greater
than 105 bacteria present in the urine without symptoms of UTI such as dysuria,
frequency and/or urgency. Acute cystitis is a one-time UTI event without a subsequent
UTI event during the course of the study, whereas, rUTI requires recurrent events within
3 months of the initial UTI. Lastly, pyelonephritis was defined as fever, back pain and/or
costovertebral angle tenderness (CVAT) as well as a positive urine culture as with acute
UTI. In an effort to determine if a specific genotype would associate with a specific
clinical syndrome, putative UPEC virulence factors were examined by PCR. Not
surprising, there was no correlation between clinical syndrome and virulence genotype.
Since the study enrolled human subjects, genetic backgrounds and pain thresholds are
different between subjects likely contributing to the difference in clinical manifestation of
different isolates. To confirm the UPEC pathogenic cycle is common among UPEC
isolates, strains from the study were inoculated in the mouse model of UTI and IBC
formation was evaluated at 3, 6 and 24 hours post-infection. Results revealed that IBC
formation is an almost universal characteristic of UPEC isolates. Fifteen of 18 isolates
formed IBCs and the 3 isolates that were unsuccessful at IBC formation had evidence of
the UPEC pathogenic cycle upon co-inoculation with UTI89. Additionally, another study
was performed to identify hallmarks of the UPEC pathogenic cycle within human urine.
This study revealed the presence of exfoliated umbrella cells containing IBCs and
filamentous bacteria present in the urine of human subjects. Also, evidence of IBCs
were seen significantly more often in Gram-negative isolates than Gram-positive
isolates. These two studies demonstrated that IBC formation is common among UPEC
and evident within humans. Now that a panel of UPEC isolates that proceed through the
IBC cascade is available, perhaps this will facilitate the development of a virulence
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profile identifying E. coli isolates as UPEC. This will enable rational drug design to target
virulence factors essential for UPEC infection.

Urovirulence Determinants
E. coli is an incredibly diverse bacterial species that can colonize numerous niches in the
environment and the animal host. Generally, E. coli within the intestinal flora exist as
commensals that form a beneficial symbiotic relationship with their host (75). However,
some strains of E. coli can diverge from their commensal cohorts and cause disease
within the intestinal tract and elsewhere within the host. These pathogenic strains are
broadly characterized as either diarrheagenic E. coli or extraintestinal pathogenic E. coli
(ExPEC) (32, 53). ExPEC have maintained the ability to exist in the gut without
consequence, but have the capacity to disseminate and colonize other host niches
resulting in disease. Among ExPEC, strains of UPEC are most commonly associated
with human disease. Despite the well-studied nature of UPEC, especially in regards to
virulence factors and colonization strategies, no single feature accurately defines an
isolate as UPEC. All UPEC isolates contain the fim operon encoding type 1 pili, which is
necessary for binding and invasion within the urinary tract. However, since the majority
of E. coli strains possess this operon, it cannot define an E. coli as UPEC. A better
understanding of UPEC-associated virulence factors and the coordination of their
activities during the course of a UTI might significantly enhance our ability to both predict
and rationally redirect disease outcome. The most likely place to discover UPECassociated virulence factors is within pathogenicity islands.

Pathogenicity Islands
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Compared to K12 lab strains and commensal E. coli isolates, UPEC harbor more genes
encoding virulent capsule antigens, iron acquisition systems, adhesins, and secreted
toxins. These genes are often encoded within regions referred to as pathogenicity
islands (PAIs). PAIs were first described in pathogenic E. coli, but have now been
discovered in pathogenic bacteria of species other than E. coli, both Gram-positive and
Gram-negative. PAIs posses most, if not all, of the following characteristics: they (i)
carry genes encoding one or more virulence factors, (ii) are present in the genomes of
pathogenic organisms but absent from the genomes of nonpathogenic organisms of the
same or closely related species, (iii) occupy relatively large genomic regions, (iv) often
consist of DNA regions that differ from the core genome in G+C content and in different
codon usage, (v) are often flanked by small directly repeated (DR) sequences, (vi) are
often associated with transfer RNA (tRNA) genes, (vii) often carry cryptic or functional
genes encoding mobility factors such as integrases, transposases, and insertion
sequence (IS) elements or parts of these elements, and (viii) often represent unstable
DNA regions (23). Due to mobility factors, PAIs often do not represent homogeneous
pieces of DNA but rather are made up of mosaic-like structures which have been
generated by a multistep process of genomic acquisition, loss, and rearrangement. PAIs
frequently contain genes encoding regulators of virulence factor genes located on the
same island. However, various arrangements of regulators and regulatory factors are
possible, including PAI-encoded regulators that are specific for PAI genes, PAI-encoded
regulators that also regulate genes located outside the PAI, and regulators encoded
outside the PAI that regulate genes encoded on the PAI.
The analysis of the structure of PAIs revealed that these genetic elements have
been generated after lateral gene transfer processes. The acquisition of new genes
following horizontal gene transfer either directly by transformation with naked DNA,
transduction with phages, or uptake of plasmids or chromosomal fragments by
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conjugation, results in the generation of new variants of pathogens. Thus, PAIs
contributed to the development of pathogenic variants, preferentially in macroevolution.
The ongoing processes of rearrangements, deletions, and transfer of PAIs, however,
also have a strong impact on microevolution and adaptation of pathogenic microbes
during acute infectious processes. In organisms such as UPEC, whole PAI elements
can be deleted. It is suggested that the deletion processes may play a role in the
adaptation of pathogenic microbes during certain stages of infection. Therefore, genetic
flexibility of pathogenic microbes may create selection advantages over other, less
flexible organisms and may finally result in proper replication in host organisms or other
ecological niches.

pUTI89
The majority of PAIs are located on the chromosome; however, they can also be part of
bacterial plasmids, considered ‘PAI precursors’ or ‘Pre-PAIs’ (37). UPEC PAIs encode
adherence factors, toxins and iron uptake systems. Interestingly, these same virulence
factors can be plasmid or phage encoded on intestinal E. coli isolates whereas in UPEC
they are located chromosomally, i.e. alpha-hemolysin. Thus UPEC PAIs could represent
former plasmid-derived sequences. UTI89 carries a large extrachromosomal element
with many characteristics of UPEC PAIs, however it is not incorporated into the
chromosome suggesting that it may be a ‘PAI precursor’. This plasmid, pUTI89, is
approximately 114 kb and like plasmid F, contains the tra operon, as well as genes from
known virulence plasmids. Due to the potential of pUTI89 to be a ‘pre-PAI’ and the need
to identify genes encoding UPEC-specific virulence factors most likely present on PAIs,
this plasmid could provide a snapshot for the acquisition of this PAI among future
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bacteria and enable identification of novel virulence factors. Thus a study was done to
determine if pUTI89 is important for virulence of UPEC.
Evidence of pUTI89 is present in the majority of clinical isolates tested
suggesting maintenance within the community and importance in some aspect of
virulence. To assess its role in pathogenesis, pUTI89 was cured from UTI89 to obtain a
plasmid-less strain. The in vitro characteristics of UTI89 and ΔpUTI89 were then
evaluated. Based on growth, type 1 pili expression and function, and biofilm formation,
the two isolates were virtually indistinguishable suggesting that pUTI89 is not involved in
these in vitro characteristics which are used to mimic in vivo virulence capabilities.
However, it has been shown that in the absence of a Chlamydia trachomatis plasmid
there was no observable phenotype in vitro, yet in vivo experiments revealed
significantly lower ID50 and lack of glycogen accumulation (10). Thus, the plasmid-less
strain was tested in vivo to see if a similar phenomenon existed. Using the mouse
model of UTI, bacterial load, IBC formation and intracellular and extracellular survival
were examined. All of these parameters of infectivity, revealed a significant defect in the
ΔpUTI89 strain to colonize the bladder at early timepoints post-infection. Interestingly,
within 24 hours post-infection, normal infection was restored as measured by bacterial
titers in the bladder. Through selected deletions of operons on pUTI89, the cjr operon
was implicated in the observed defect. The cjr operon, studied in enteroinvasive E. coli
(EIEC), encodes for CjrA, CjrB and CjrC, is regulated by iron and is involved in uptake of
colicin Js, although this is likely not its primary function. Similar to EIEC, a putative iron
regulation fur box was located upstream of pUTI89 cjrA. UTI89 CjrB is homologous to
the TonB protein present in many Gram-negative bacteria which has been implicated in
energy translocation between the inner and outer membrane. Furthermore, UTI89 CjrC
shows homology to putative outer membrane siderophore receptors. Many studies have
shown iron’s importance in survival within the urinary tract (24, 38, 48). Due to the
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necessity of iron acquisition, many systems are redundant in bacteria explaining the lack
of complete infection inhibition in the absence of CjrB and CjrC. This study revealed that
pUTI89 is very likely a ‘PAI precursor’ and may be incorporated into the genomes of
future UPEC. Horizontal gene transfer by pUTI89 may therefore play a role in the
creation of new pathogenic variants.
While it is not essential for virulence in UTI89, perhaps in less virulent UPEC
isolates, pUTI89 will facilitate greater invasion efficiency. Thus, strains that otherwise
may not cause disease, with the help of genes on pUTI89, will survive within the urinary
tract. Through this work a virulence enhancer has been identified, however, since it is
not present in all UPEC isolates it cannot, by definition, be added to the urovirulence
profile. One virulence factor that is present in all UPEC isolates is type 1 pili. Thus an
understanding of this adhesive fiber could ultimately lead to a treatment for UTIs.

Type 1 pili
Type 1 pili are essential cystitis virulence determinants (6, 39, 40, 74). Using EM and
the mouse cystitis model, it has been shown that adhesive type 1 piliated bacteria are
able to bind and invade host superficial umbrella cells, while UPEC lacking type 1 pili are
not. Colonization and invasion of the bladder epithelium is dependent on the FimH
adhesin located at the distal end of the pilus which interacts directly with receptors on
the luminal surface of the bladder (Figure 2). Once inside the cell, type 1 pili are
expressed within IBCs as shown by pilus-like fibers radiating from bacteria and
interacting with matrix material (3). Further work confirmed that not only are type 1 pili
essential for binding and invasion, they are required for the survival and proliferation of
UPEC within superficial facet cells, making type 1 pili arguably the most important
virulence factor of UPEC.
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FimH
The proteins involved in biogenesis and composition of type 1 pili are encoded by fimAH of the fim operon (Figure 3), the expression of which is regulated by an invertible
promoter switch element (often termed fimS). Type 1 pili consist of a thicker pilus rod,
composed of FimA, and a thinner tip fibrillum, composed of FimF, FimG and the
adhesin, FimH. The FimH adhesin is a two domain protein, with a receptor binding
domain linked to a typical pilin domain that joins the adhesin to the pilus fiber. Binding of
FimH to its receptor, mannose, initiates a critical initial event in UTI pathogenesis (27).
The mannose binding site of FimH is a deep and negatively charged pocket at the tip of
its receptor-binding domain (Figure 4). The FimH pocket engages in extensive hydrogen
bonding to mannose, which are abundant in the oligosaccharide moieties of uroplakins
that coat the luminal surface of the bladder epithelium. A hydrophobic ridge surrounds
the mannose binding pocket in a manner that may facilitate polar interactions within the
FimH pocket. Mutational studies revealed that each residue is critical in mannose
binding and pathogenesis, emphasizing why the pocket is invariant among UPEC
isolates (12, 27). While the mannose-binding pocket is invariant, residues outside the
binding pocket are not. The panel of 18 clinical isolates described above was used to
assess the role of these variant amino acids. Three of the 18 clinical isolates did not
form IBCs and five more did so poorly. Through FimH sequence alignment it was
identified that the majority of the poor IBC-formers contained a valine at position 27
which was a residue shown to be under positive selection (12). In an effort to
understand the role of FimH in the pathogenic cycle, the clinical isolates with poor ability
to form IBCs were manipulated to contain the FimH of UTI89 in the place of their FimH
on the chromosome, thus under the same regulation and expression. The hypothesis
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being that despite the genetic background, with UTI89 FimH, the clinical isolates will be
able to form IBCs. One isolate, acute4, was tested and while it still did not form IBCs, it
did colonize the bladder significantly better with UTI89 FimH. This result suggests that
there is more to FimH than IBC formation. Additional functions of FimH make it an
extremely enticing drug target.

Small molecule inhibitors
The FimH-mannose interaction was further investigated in an effort to develop potential
ligand-based antagonists of UTIs. The chitobiose unit on oligomannose was found to
bridge various mannose derivatives to the asparagine in the Asn-X-Ser/Thr motif of
FimH resulting in higher affinity binding (71). Crystallization of FimH in complex with
oligomannose-3 revealed the mechanism of this higher affinity binding. The nonreducing Man4 anchors into the mannose-binding pocket while the GlcNAc folds over
Thr51 allowing specific interactions with a hydrophobic tyrosine gate. Heptyl mannoside
mimics the GlcNAc tail of oligomannose-3 and extends it further to increase interactions
outside the binding pocket resulting in high affinity binding (Kd = 5 nM). Based on the
high affinity of heptyl mannose for FimH, its ability to reduce bacterial infection in the
mouse model of UTI was tested. Biofilm formation was evaluated as a surrogate for
IBCs formed in the bladder. Heptyl mannose at 1 mM inhibited UPEC biofillm formation
in vitro suggesting that the mannose binding properties of the FimH adhesin is required
for biofilm formation. Thus, UPEC strain UTI89 was incubated with heptyl mannose prior
to inoculation into the bladders of mice. This resulted in a significant attenuation of
virulence at 6 hours post-infection at 5 mM heptyl mannose. The ability of these
compounds to significantly attenuate virulence establishes mannosides as a potential
treatment for UTI. More potent mannosides can now be developed that mimic the
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natural receptor for FimH but with increased affinity and avidity in order to ultimately
block bacterial colonization, invasion, IBC formation and disease. The ramifications of
this work are immense, since, if effective, these carbohydrate inhibitors of disease can
be translated to multiple organisms. Sugars, such as mannose, are the molecules most
commonly involved in cell recognition playing an important role in microbial adherence.
Thus, carbohydrate derivatives of host ligands can block the adhesive properties of pili
on a multitude of bacterial organisms. In the face of antibiotic resistance, this novel drug
development could treat otherwise resistant infections. While this strategy for bacterial
binding inhibition focuses on occupying the receptor binding pocket with carbohydrates
mimicking host ligands, a second strategy could eliminate pilus formation all together by
blocking the chaperone-usher pathway.

Chaperone-Usher Pathway
Adhesive type 1 pili are prototypic structures of a family of adhesive fibers produced by
diverse Gram-negative bacteria via the chaperone/usher assembly pathway (Figure 5)
(57, 69). The chaperone/usher molecular machine functions to regulate the ordered
secretion, folding and assembly of hundreds of thousands of subunits into defined
architectures on the surface of a bacterium. Hundreds of these operons have been
reported with as many as twelve encoded in one organism. UTI89 encodes 10
chaperone/usher pilus biogenesis systems (13) each encoded by a distinct gene cluster,
which contains a dedicated chaperone and usher. Type 1 and P pilus systems are
prototypes for understanding secretion and assembly via the chaperone/usher pathway.
Chaperones
Periplasmic chaperones function to fold their corresponding subunits, shield interactive
subunit surfaces and deliver the subunits to their outer membrane usher in a process
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termed donor strain complementation (DSC) (55). The highly homologous chaperones
(~25 to 30 kDa) consist of two immunoglobulin-like (Ig-like) domains stabilized by a
conserved salt-bridge in an overall boomerang shape as seen in the crystal structures of
PapD, FimC and SfaE (14, 25, 33, 46). Periplasmic peptidyl-prolyl isomerases and
DsbA were found to facilitate chaperone folding (7, 8, 30, 76). Each chaperone contains
a conserved subunit binding site (29) consisting of two positively charged cleft residues
that hydrogen bond to their target subunits (34, 63) and solvent exposed hydrophobic
residues that participate in DSC (28). In addition to the conserved subunit-binding
surface, each chaperone contains a conserved patch of solvent exposed residues on the
back side of domain 2 (28, 29) shown to be important for usher binding as well as for
subsequent events leading to subunit polymerization (43, 47).

Subunits
Single domain subunits share a homologous structure consisting of an incomplete Ig-like
fold and an N-terminal extension (Nte). The body of each subunit consists of six of the
seven strands of a standard Ig fold. In order to form a stable structure, the
corresponding chaperone for each subunit donates structural information to compensate
for the missing seventh strand of the subunit thereby completing the hydrophobic core in
a process known as donor strand complementation (DSC) (14, 55). During pilus
assembly, the free Nte of one subunit displaces the chaperone bound to another subunit
and serves as the seventh strand of the Ig-like fold, in a process called donor strand
exchange (DSE) (55, 56). While all subunits share an overall structure and mechanism
of polymerization, each subunit is adapted for a particular role, which have been
identified in both the pap and fim systems. Pilin subunits require the function of the
chaperone for folding due to the absence of the seventh C-terminal strand which is
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transiently donated by the chaperone. In the absence of chaperone, subunits misfold
into conformations that drive them ‘OFF-pathway’, resulting in non-productive
interactions and their eventual proteolytic degradation.

Tip adhesins
Unlike the single domain subunits described above, tip adhesins contain two domains.
The C terminal domain is homologous to the single domain subunits (14). The N
terminal domain folds into a ligand binding structure. Crystal structures of PapG and
FimH reveal each adhesin has a unique positioning of the ligand-binding site (17, 27).
These binding domains serve as the functional end of the pilus, recognizing specific host
ligands and influencing bacterial tropism for host tissues.

Ushers
The ushers (~90 kDa) share homology and serve as assembly sites in the outer
membrane for polymerization of the resulting fibers. In the absence of the usher the
corresponding chaperone/subunit complexes accumulate in the periplasm, but are not
assembled into the final fiber (44). Ushers also serve as pores (~2 nm) allowing export
of the growing fiber to the surface of the cell (68). Ushers PapC and FimD have been
shown to discriminately bind the different chaperone/subunit complexes of their
respective systems (16, 58). Once bound by initiating chaperone/subunit complexes,
ushers undergo a conformational change (displacement of the β sandwich plug domain),
which is then maintained throughout fiber assembly such that the polymerized subunits
can transit the channel.
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Pilicides
The chaperone/usher system has been cited as the most mechanistically understood
assembly/translocation process at a structural level (15). The vast understanding of the
molecular structure and function of chaperones important in bacterial pathogenesis
facilitates the development of therapeutics capable of targeting and inhibiting the
formation of these adhesive structures associated with virulence. Increasing antibiotic
resistance among chronic bacterial infections necessitates the identification of new
therapeutic options. Combinatorial chemistry has identified small molecule inhibitors of
pilus biogenesis. The inhibitors were rationally designed based on the knowledge that
thiazolo ring-fused 2-pyridones are highly useful as scaffolds for the development of
compounds that inhibit protein-protein interactions in bacteria (1, 47, 67). The synthetic
pilicides disrupt an essential protein-protein interaction between the chaperone and
usher at a site that has been identified by x-ray crystallography resulting in ‘bald’
bacteria. Lack of type 1 pili production results in inhibition of biofilm formation and
hemagglutination (HA) titer. Considering type 1 pili are essential for colonization of the
murine urinary tract, bacteria grown in the presence of pilicide, FN075, failed to establish
a robust infection in vivo as identified by IBC formation and were significantly reduced in
bacterial colonization (Cegelski et al, submitted). Thus, FN075 was successful at
inhibiting urinary tract infection within the mouse. The efficacy of FN075 within the
mouse model suggests it could be used as a therapeutic against UTIs in humans.
Furthermore, pyridinones are already advantageous because they avoid severe
drawbacks observed upon use of peptides as drugs such as poor absorption after oral
administration, rapid enzymatic degradation and quick excretion (67). This work
identifies a compound that selectively disrupts protein-protein interactions with a strong
potential for therapeutic effects on infection, which due to the ubiquitous nature of
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chaperone-usher systems in Gram-negative bacteria may serve as a broader-range
therapeutic.

Summary
The high prevalence of UTIs necessitates understanding of the molecular mechanisms
associated with virulence and infection. As described above, a multitude of work has
been done to elucidate the pathway of infection within the bladder. Discovery of the
UPEC pathogenic pathway in a multitude of clinical isolates confirmed the relevancy of
this pathway and its importance in persistence. Furthermore, identification of hallmarks
of the UPEC pathway in human urine confirmed that this is not an enigma of the murine
urinary tract. Now that it is clear that UPEC proceed through a surprisingly complex
pathway consisting of extracellular and intracellular niches, one can evaluate each
aspect of infection to determine if certain virulence factors are important to one or a
multitude of components within the UPEC pathway. For example, by examining binding
and invasion, IBC formation, extracellular filaments and reservoir formation and knowing
what enables their development, one can start to target these components to disrupt the
UPEC pathway. Based on this idea, an extrachromosomal element termed pUTI89 was
examined to determine its role in the UPEC pathway. pUTI89 has many characteristics
of a PAI and was, in fact, shown to play a role in virulence. The cjr operon on pUTI89
was implicated in this role in UTI89 infection. Based on the lack of extracellular
filaments and gentamicin protection assays, it appears that Cjr proteins may enhance or
facilitate extracellular survival. Work is underway to understand the role of Cjr proteins
and their expression profile. While a new potential virulence factor, pUTI89, was
discovered, it has long been know that type 1 pili are an essential virulence factor.
Without these adhesive fibers, infection is severely depressed. Thus, due to the
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necessary function of type 1 pili in infection, they were targeted for development of
therapeutics. At the tip of the type 1 pilus is the FimH adhesin. This molecule
selectively binds mannosylated residues exposed by uroplakins that coat the surface of
the bladder. Due to the necessity of this interaction for binding and invasion and its
essential role in IBC formation, exogenous carbohydrates were used to prevent binding.
The rational development of the highest affinity mannose derivatives proved to be
successful at reducing infection load in the bladder. Additionally, understanding of the
chaperone/usher system led to the rational design of 2-pyridone compounds termed
pilicides. Testing in vitro and in vivo revealed that these compounds can eliminate pilus
expression and thus reduce bacterial infection. Thus, the work described above has
enhanced our understanding of UPEC infection which led to the development of
therapeutics to inhibit type 1 pili and reduce infection in vivo. Further work will continue
to evaluate even more potent type 1 pili inhibitors. New mannosides have been
synthesized with much greater affinity for FimH relative to heptyl mannose and
preliminary experiments have shown promising results at infection reduction.
Additionally, once can imagine using a mannoside and a pilicide in synergy: the
manoside preventing binding to uroplakins by occupying the FimH binding pocket while
the pilicide enters the bacterial cell and prevents future pilus production thus eliminating
adherence to urothelial cells and promoting clearance of the bacteria. We are now
beginning to deliver compounds to the mouse prior to or during infection to test efficacy
in a more clinically relevant situation. Ultimately, we hope that our knowledge of UTIs
will lead to the severe reduction in prevalence of this disease.
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Figure 1. UPEC pathogenesis pathway. UPEC utilize a multi-step pathogenic pathway in a
murine cystitis model. Upon introduction into the bladder, UPEC bind to the host urothelium via
type 1 pili and an invasion event ensues. UPEC escape into the facet cell cytoplasm and
replicate to form loosely-packed early IBCs and ultimately tightly packed mid and late IBCs.
Bacteria disperse from the IBC, many in filamentous morphology, bind to another host cell and
can ultimately reenter this developmental pathway. In addition, UPEC are able to form
intracellular reservoirs within different layers of the urothelium that may lead to recurrent
bacteriuria.
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Figure 2. Type 1 pili interact with uroplakins on the bladder surface. EM reveals piliated
bacteria interacting with hexameric uroplakins on the surface of bladder tissue. This interaction
results in the subsequent invasion of the bacterium into the host cell. The FimH adhesin on the
tip of type 1 pili is required for the binding of mannose exposed by the uroplakins. Figure adapted
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in (E) indicates a FimH-containing tip. In (H), type 1 pili span from the host cell membrane
right to the bacterium on the left. Scale bars indicate 5 !m (A and B), 0.5 !m (C and F),
1 !m (D, E, G, and H).
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Figure 3. UPEC type 1 pili encoded by the fim operon. This schematic representation shows
the UPEC fim operon. FimB and FimE are regulatory recombinases controlling the expression of
fimA-H. FimA is the major subunit of type 1 pili and forms the helical rod. FimC acts as a
chaperone, stabilizing subunits prior to secretion through FimD, the outer membrane usher.
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FimF, 20
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is composed of a pilin
domain and an adhesin or receptor binding domain. Figure adapted from (72).
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Fig. 1. Crystal structure of FimCH chaperone–adhesin complex bound to a-D-mannose.
A. Overall structureFigure
of FimCH with
the twoFimH
domainsadhesin
of the chaperone
FimC (purple and pink),
the pilin domain
FimH
(yellow-green)
that is
4. The
accommodates
mannose
inofits
binding
pocket.
The receptor
donor strand complemented by the chaperone (Choudhury et al., 1999) (arrow), and the receptor binding domain (green with blue helices,
secondary structure labelled as described earlier (Choudhury et al., 1999). The receptor-binding domain of FimH is an elongated 11-stranded
b-barrel comprisingbinding
residues Phe1
to Thr158.
D-mannose
the mannose-interacting
residues (green)
and the
residues
of the
domain
ofThe
FimH
has (pink),
a deep
negatively charged
pocket
that
binds
mannose. Outside the
hydrophobic ridge around the pocket (white) are shown in ball-and-stick model.
B. A 90° rotation towards the reader of the receptor binding domain shown in A.
C. Stereo presentation
of omit electron
density
4s (Fo-Fc) for the a-d-mannoside
bound in pocket
of FimH.
The interacting amino
acidsPositively
are
binding
pocket
areathydrophobic
residues making
up the
hydrophobic
ridge.
charged
shown in ball-and-stick, hydrogen bonds are highlighted in purple.
D. The receptor binding domain of FimH displaying the electrostatic potential surface (Nicholls et al., 1991), with positively charged residues
shown in blue, negatively
chargedshown
residues in
and neutral
and hydrophobic
residues
in white. The
of the neutral
hydrophobicand
ridge hydrophobic
residues
inred,
blue,
negatively
charged
residues
inresidues
red, and
around the mannose-binding pocket are labelled.

residues in white. Adapted from (27).
FimH (Martinez et al., 2000). Mice and primates vaccinated with the FimH adhesin are protected from infection
(Langermann et al., 1997). FimH binds to D-mannose and
mannotriose receptors, with the former being more highly
associated with cystitis isolates (Sokurenko et al., 1995;
1997; 1998; 2001). Attachment of uropathogenic E. coli
(UPEC) to the bladder epithelium is proposed to be mediated by FimH binding to the uroplakins 1a and 1b (Wu
et al., 1996). These cellular receptors contain a single N-

linked carbohydrate of the high-mannose type, common
to most glycoproteins recognized by FimH. Several other
reported FimH receptors include Tamm–Horsfall protein
(Pak et al., 2001), CD48 (Baorto et al., 1997), laminin
(Kukkonen et al., 1993), collagen (Pouttu et al., 1999),
fibronectin (Schembri et al., 2000) and abiotic surfaces
(Pratt and Kolter, 1999). Based on inhibition studies, the
carbohydrate binding site of FimH has been suggested to
be an extended pocket with optimal fit for a trisaccharide
© 2002 Blackwell Science Ltd, Molecular Microbiology, 44, 903–915

Figure 5. Chaperone/usher mediated pilus biogenesis as shown for the P pilus system.
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Abstract
Nearly 50% of women experience at least one UTI in their lifetime. Studies in mice have
revealed that uropathogenic E. coli (UPEC) invade superficial umbrella cells that line the
bladder, allowing them to find a safe haven and subvert clearance by innate host
responses. Rapid intracellular replication results in the formation of distinctive
intracellular bacterial communities (IBCs). In this study, we evaluated whether UPEC
strains, cultured from the urine of women and classified as causing acute cystitis,
recurrent cystitis, asymptomatic bacteriuria (ASB), or pyelonephritis, could progress
through the IBC cascade in a well-characterized mouse model of cystitis. Of 18 UPEC
isolates collected from women, 15 formed IBCs. Variations in the size, number, and
kinetics of IBC formation were observed with strains isolated from women with different
clinical syndromes. Two of the three isolates that did not form IBCs when inoculated
alone, were able to do so when co-inoculated with an isolate that was capable of
generating IBCs. The mixed infections dramatically altered the behavior of the coinfecting bacteria relative to their behavior in a single infection. The study also showed
that mice with five different genetic backgrounds can support IBC formation. Although
UPEC differ genetically in their virulence factors, the majority of UPEC from different
syndromes of UTI proceed through the IBC pathway confirming the universality of IBCs
in UTI pathogenesis in mice.

Introduction
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Urinary tract infections (UTIs) account for nearly 7 million office visits per year in
the United States and cost $2 billion annually (4). The majority of community acquired
UTIs occur in women and are caused by uropathogenic Escherichia coli (UPEC) (7).
Greater than 40% of women who experience acute cystitis develop recurrent UTIs
(rUTIs) (12). Uropathogens causing UTIs as well as asymptomatic bacteriuria (ASB) are
generally thought to emanate from the distal gut, colonize the vagina, and ascend to the
bladder via the urethra (4). Likewise, acute pyelonephritis is assumed to be the result of
an ascending infection from the bladder to the kidney. However, this widely accepted
paradigm does not adequately address questions raised by epidemiologic data. Why
does an initial UTI predispose a woman to an increased likelihood of a recurrent
infection? Why are up to 68% of rUTIs caused by E. coli identical to the original infecting
strain (23)? Why are recurrent uropathogens not more representative of the diversity of
E. coli present within an individual’s gastrointestinal tract (2, 21)?
Although it is believed that bladder infection in humans does not involve the
bladder wall, previous studies of human bladders indicated a potential intracellular
component of UTI (3). Cultures of bladder biopsies taken from women with sterile urine
cultures with various urinary tract symptoms revealed the presence of bacteria. Studies
in mice have revealed that bacterial invasion of the epithelium lining the bladder lumen
(urothelium) is an essential component of lower UTI.
In mice, adhesive bacterial fibers known as type 1 pili are necessary for invasion
into the superficial umbrella cells of the urothelium (17, 18). Entry into these host cells
initiates a program that has been extensively characterized in mice using the human
cystitis isolate UTI89 and that results in formation of intracellular bacterial communities
(IBCs). Early IBCs are seen within 6 hours of infection and consist of loosely packed
rod-shaped bacteria (19). Over the next 6 hours, they expand into tightly packed
consortia of coccoid-shaped bacteria (mid IBC) (15). Sixteen hours after infection,
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bacteria detach from the late IBC, elongate into a filamentous form, escape from the
host epithelial cell, and spread in the bladder to re-initiate the IBC cascade in other host
superficial umbrella cells (15, 19). Subsequent rounds of IBC formation allow E. coli to
build up large populations within the bladder. Interestingly, within 12 hours of infection,
virtually all bacteria in the bladder are intracellular, implying that luminal bacteria are
rapidly eliminated (18). One consequence of bacterial invasion is establishment of a
quiescent intracellular reservoir (QIR) in the bladder that can persist for months even in
the face of antibiotic therapy (25). In addition, bacteria in this QIR can revert to an active
metabolic state that is initiated by unknown signals: rapid intracellular bacterial
replication ensues, re-initiating additional rounds of IBC formation, inflammation, and
spread of bacterial infection throughout the urinary tract (20). This model argues that a
portion of rUTIs in humans could be seeded from bacteria present in a QIR in the
bladder.
In this study, we investigated the ability of multiple clinical isolates to form IBCs in
the mouse model. We found that (i) the majority of UPEC isolates proceed through the
IBC pathway; (ii) although isolates from women with ASB, acute UTI, rUTI, and
pyelonephritis all form IBCs, IBCs from acute UTI isolates are significantly smaller; and
(iii) isolates unable to from IBCs alone are able to do so in mixed infections where the
second isolate was an IBC-competent strain. Together, these results confirm that the
ability to form IBCs is a common attribute of UPEC isolates.

Materials and Methods
Patients and strains.
Clinical studies were approved by the University of Washington Institutional Review
Board and written informed consent was obtained from all participants.
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Five isolates causing ASB and four causing first-episode acute cystitis (acute
UTI) were collected from women enrolled in a previously described study at the
University of Washington (5). Briefly, healthy women between 18 and 40 years old who
were about to start or had started a new method of contraception and had no more than
one UTI in the previous year were eligible for enrollment. The study excluded a woman
if she was pregnant, planned to become pregnant, had a chronic illness, had used
systemic antimicrobial agents within 14 days, or had a known anatomical or functional
abnormality of the urinary tract. Enrollees were monitored for 6 months, during which
time urine was collected at monthly clinic visits and whenever patients had symptoms
suggestive of a UTI. Asymptomatic bacteriuria was defined as >105 CFU of a
uropathogen per milliliter of midstream urine documented in at least two separate
cultures obtained at least 24 h apart. A symptomatic, culture-confirmed episode of
cystitis was defined as ≥102 CFU of a uropathogen per milliliter of midstream urine from
a patient with dysuria, frequency, and/or urgency.
E. coli isolates from five women with recurrent cystitis were collected from
another study of healthy women between 18 and 45 years of age who had acute cystitis
and a history of at least one previous UTI in the past year, who were not pregnant and
did not plan to become pregnant, and who had no chronic health problems (T. M.
Hooton, unpublished data). Approximately 110 women have been enrolled in this
ongoing prospective study investigating the temporal associations between bacteriuria
and clinical manifestations of recurrent UTI. The women are being treated and then
followed with daily urine cultures for 3 months, during which time they are seen in the
clinic on a regular basis and whenever they have symptoms suggestive of a UTI. rUTI
isolates used in this study were the initial isolate from a women with same-strain
recurrence. ‘Same strain’ isolates were identified by chromosomal restriction fragment

36

length polymorphism (RFLP) analysis using pulsed-field gel electrophoresis (PFGE)
(23).
E. coli isolates collected from four women between 18 and 45 years old who had
a clinical diagnosis of pyelonephritis were also included in our analysis (T. M. Hooton
and W. E. Stamm, unpublished data). Women were eligible for this study if they had
fever, back pain and/or costovertebral angle tenderness (CVAT), and a positive urine
culture, as defined above.

Virulence factor PCR.
Bacterial chromosomal DNA was isolated using the Wizard® genomic DNA purification
kit (Promega) from each UPEC strain after growth overnight in Luria Broth (LB). PCR
reactions to detect virulence factors were performed as described in Johnson et al. (14).

Western blotting for detecting PapA and FimH protein.
For immunoblot analysis to detect PapA protein in the pyelonephritis isolates, bacteria
were grown on tryptic soy agar (TSA) plates at 37oC for 36 hours, scraped, and
suspended into 1 mL of PBS. Resuspended cells were heated at 65oC to remove bound
pili (9), and the supernatants containing pili were heated in SDS sample buffer (0.25 M
Tris-HCl (pH 6.8), 4% SDS, 20% glycerol, 50 mM DTT, bromophenol blue), 4 M Urea at
95oC and analyzed by SDS-PAGE followed by immunoblotting with antibodies to the P
pilus (11).
For immunoblot analysis of FimH expression, bacteria were grown statically in LB
at 37oC for 24 hours. Equivalent numbers of cells (OD600 ~ 1.0) from each isolate were
suspended in SDS sample buffer, 1 M HCl was added dropwise until pH indicator
(bromophenol blue) turned yellow, and solution was heated at 95oC for 5 minutes. The
samples were then neutralized and analyzed by SDS-PAGE followed by immunoblotting
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with antibodies to FimH (raised in rabbits using purified FimH protein). Specific FimH
proteins were visualized on nitrocellulose membranes by BCIP/NBT Liquid Substrate
System (Sigma), and analyzed for intensity using ImageJ software (rsb.info.nih.gov/ij/).

Hemagglutination assays for detecting bacterial adhesins.
Bacteria were grown statically in LB for 24 hours to induce expression of type 1 pili.
Hemagglutination (HA) assays with guinea pig erythrocytes were performed using wellestablished protocols (10, 26).

Mouse strains and infections.
All studies using mice were approved by the Animal Studies Committee of Washington
University. Eight-week-old female mice, belonging to the inbred C3H/HeN strain, were
anesthetized and inoculated with a 50 ml suspension of ~107 CFUs of a given clinical
isolate (in PBS) via transurethral catheterization (19). Three, 6, 12, 16 and/or 24 h after
inoculation, animals were euthanized, and their bladders harvested, divided in half,
opened, and pinned on dissecting wax. Bladders were washed three times with PBS to
eliminate loosely associated bacteria not likely involved in infection. The splayed
bladders were then incubated for 20 min at room temperature with (i) wheat germ
agglutinin (WGA) (Molecular Probes; 1:1000 in PBS) to stain their luminal surfaces and
(ii) SYTO® 61 red (Molecular Probes; 1:1000 in PBS) to stain IBCs as well as host
urothelial cell nuclei. (Individual bacteria could be visualized in the densely packed
IBCs, thus distinguishing them from the nuclei). Trolox (10 µM: Fluka) was added to the
splayed bladders to reduce photobleaching (24). The total number of IBCs was scored
by confocal microscopy (see below). If all infections were not successful, 5 successfully
infected mice were used for further evaluation. The diameters of a maximum of 25 IBCs
(5 IBCs/bladder/isolate [n = 5 bladders/isolate]) were measured across the width of each
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IBC, averaged, and standard deviations calculated to estimate differences in the sizes of
IBCs. If less than 25 IBCs were observed for a given isolate, the total number of IBCs
observed were used to calculate the average diameter and standard deviation. If IBCs
were not observed in all 5 bladders inoculated with a clinical isolate, more than 5 IBCs
were measured per bladder containing IBCs to obtain 25 measurements. After
microscopy, bladders were homogenized in 1 mL of 0.025% Triton X-100-PBS and
bacterial titers determined by plating serial dilutions of the homogenates on LB agar
plates. Standard gentamicin assays were done to define the number of intracellular
bacteria in the bladder (19).
For the single infections with the two laboratory strains, UTI89 and CFT073 were
genetically engineered to express Green Fluorescent Protein (GFP). Eight-week-old
female mice belonging to inbred C3H/HeN, C3H/HeJ, C57BL/6J, CBA/J, and FVB/NJ
strains were inoculated with UTI89-GFP and CFT073-GFP as above. At 6 and 24 h
after inoculation, bladders were harvested as above, however, the splayed bladders
were fixed and visualized without additional staining due to GFP-expressing UTI89 and
CFT073.

Co-inoculation of clinical isolate and UTI89.
Equal amounts of each clinical isolate and UTI89-gfp (cystitis strain engineered to
express GFP) were mixed to obtain a 50 ml bacterial suspension of ~107 CFUs. The
suspension was then inoculated into C3H/HeN mice and infected bladders were
harvested and visualized as above. UTI89-gfp contains the kanamycin resistance
cassette and thus is KanR, whereas the clinical isolate was KanS. Serially diluted
bladder homogenates were plated on LB agar plates and LB agar plates containing
kanamycin (50 µg/ml) and grown overnight at 37oC. The number of CFU of the clinical
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isolate was determined by subtracting the number of the kanamycin-resistant UTI89
from the total number of CFU on LB medium lacking kanamycin.

Confocal scanning laser microscopy.
Bladders were examined with a Zeiss LSM410 confocal laser scanning microscope
under a 63X objective. WGA and SYTO® 61 were excited at 488- and 633-nm,
respectively. In co-inoculation experiments using GFP-expressing UTI89 and a clinical
isolate that did not form IBCs alone, GFP was excited at 488-nm, the clinical isolate was
stained red by SYTO® 61, and wheat germ agglutinin was omitted.

Statistical analysis.
Observed differences in IBC diameter between isolates representing the four different
types of UTI were analyzed for significance using the nonparametric Mann-Whitney U
test (InStat; GraphPad Software).

Results
Virulence genotypes of the clinical isolates
We studied 18 clinical isolates collected from women enrolled in the three
different studies described above (Table 1). To characterize the isolates, they were first
analyzed in vitro for the presence of 29 putative virulence factors by multiplex PCR, as
previously described (14). The level of type 1 pili expression was then assessed with
hemagglutination assays and an immunoblot using FimH antisera. The isolates were
then analyzed in a murine model to assess their ability to form IBCs within the bladder.
UPEC virulence factors are typically involved in colonization and invasion of the
host and evasion of the immune responses. Each isolate had a unique combination of
virulence factors and their prevalence was similar to a previous study analyzing 63
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UPEC isolates (13), suggesting our small sample size was representative of a larger,
diverse UPEC group (Table 2). The most prevalent virulence factors were fimH (100%
of isolates), fyuA (yersiniabactin receptor; 80%), traT (serum-resistance; 70%), PAI
(CFT073 pathogenicity-associated island marker for a series of genes that provide a
mechanism for horizontal transfer of virulence factor genes; 70%), kpsMT II (group 2
capsule; 70%), sfa/focDE (S/F1 fimbriae; 60%), and hlyA (hemolysin; 50%). The
presence or absence of individual virulence factors could not be correlated with a
particular clinical syndrome.
Surprisingly, none of the four pyelonephritis isolates had genes within the pap
operon which encodes for the production of P pili. Due to the absence of the pap
operon, anti-P pilus antibodies failed to react with these isolates after growth on TSA,
which typically induces P pili production (Figure 1).

Type 1 pilus production in clinical isolates
Hemagglutination (HA) of guinea pig red blood cells (GPRBCs) was performed
as previously described (10) to determine the degree of type 1 pilus production by each
clinical isolate. Type 1-mediated HA is specifically inhibited by the addition of
exogenous mannose and this reaction is referred to as mannose sensitive
hemagglutination (MSHA).
For this study, bacteria were grown in static culture at 37oC for 24 hours to
enhance type 1 production. After 24 hours of static growth, UTI89, a prototypic cystitis
reference strain shown to proceed through the IBC pathway, produced a MSHA titer of
64 (values equal 2x where x equals the last well of agglutination). Comparable MSHA
titers were seen with the ASB isolates, which ranged from 32-128, suggesting a similar
level of type 1 production as UTI89 (Table 2). The first event UTI strains (acute UTI
isolates) produced MSHA titers ranging from 16-64. The rUTI isolates had HA titers
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ranging from 2-8 that could not be entirely inhibited by addition of exogenous mannose.
The persisting HA titers in the presence of mannose suggests expression of a mannose
resistant (MR) adhesin system under these growth conditions. The pyelonephritis
isolates had MRHA titers ranging from 4-16.
To further confirm the results seen with HA titer, anti-FimH antibodies were used
in immunoblots to assess the relative levels of FimH in all of the strains after 24-h growth
in static broth. The intensity of each band was quantitated and expressed as a value
relative to the amount of FimH expressed by UTI89, which was set at 100% (Table 2).
MC4100, which does not produce type 1 pili, was used as a negative control. The
majority of isolates expressed type 1 pili at levels of 50%-99% of UTI89. Only one
isolate, ASB3, expressed type 1 pili at a level substantially higher then UTI89, 150%199%. Strains acute1, rUTI1, and rUTI4 did not express detectable levels of type 1 pili,
and acute3 and CFT073 expressed comparable levels of type 1 pili relative to UTI89 as
determined by our immunoblot analysis. These results suggest UPEC isolates from
different clinical syndromes produce varying degrees of type 1 pili in vitro.

IBC formation by UPEC isolated from women
First the commonality of the IBC pathway in the face of differing host responses
was evaluated. To date the IBC pathway has been best described in the C3H/HeN and
C3H/HeJ mouse strains with UPEC strains UTI89 and NU14 (1, 15, 18). A previous
study evaluated the level of infection and inflammation in different mouse genetic
backgrounds, but did not examine the IBC pathway (8). To determine if the cystitis and
pyelonephritis isolates, UTI89 and CFT073 respectively, form IBCs in various host
genetic backgrounds, three other strains of mice were infected, C57BL/6J, CBA/J, and
FVB/NJ. Mouse strains for use in this study were chosen based on their previous use as
models for host responses to UPEC infection and/or identification of bacterial virulence
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factors (16, 18, 27). At 6 hours post infection, IBCs were detected in all mouse strains
tested with both UPEC strains. IBCs from C3H/HeJ (Figure 2D,I) and C3H/HeN (Figure
2E, J) mice showed the expected IBC morphology inside superficial epithelial cells.
Early IBCs were readily detected in C57BL/6J, CBA/J, and FVB/NJ (Figure 2A-C,F-H)
that were visually indistinguishable from IBCs in C3H genetic background. Occasionally,
some IBCs in C57BL/6J mice had more loosely defined edges. The presence of IBCs at
six hours post infection in five mice strains after infection with UTI89 and CFT073
suggests that the mechanisms utilized for invasion and intracellular replication in vivo
are a conserved feature in these strains.
Next, the commonality of IBC formation among different clinical isolates was
evaluated. Eighteen clinical isolates recovered from women enrolled in three different
UTI studies (Table 1) were evaluated for their ability to form IBCs. Each isolate was
inoculated transurethrally into the bladders of young adult female C3H/HeN mice and the
bladders harvested at 3, 6, 12, 16, and 24 h post infection (n=5 mice/time point/isolate)
(Table 3 and Figure 3).
All five ASB isolates formed IBCs although the time course varied: IBCs were
observed 6 h and 24 h after inoculation of strains ASB1, ASB2, and ASB3 (Figure 3E, F)
while IBCs were only observed at 6 h for ASB4 and at 24 h for ASB5. This suggests that
although IBC formation is common, the rate at which the isolates proceed through the
pathway is potentially strain specific. In UTI89, first round IBCs are observed at 6 h
post-infection and second round IBCs are observed at 24 h post-infection despite
asynchronous micturation among the mice. Since IBCs were not observed at 24 h in
ASB4, it is possible that the second round IBCs were either earlier or later and thus
missed. The fact that ASB5 only formed apparent IBCs 24 h post inoculation suggests
that it either proceeds more slowly through the IBC pathway due to slow replication
within the umbrella cells, or it invades the urothelium at later time points. ASB5
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produces a high MSHA titer (128) and FimH was detectable in the immunoblots (Table
2). These piliation characteristics strongly argue that the observed delay in IBC
formation is not related to type 1 pilus expression of the inoculum. The average
diameter of ASB IBCs was 51 ± 20 µm (5 IBCs/bladder) which is the same as the
prototypic isolate, UTI89, which has an average IBC diameter of 51 ± 9 µm at 6 h post
infection.
Three of the four acute UTI isolates formed IBCs at the time points examined.
Again, there were isolate-specific differences in the time course. IBCs were only
observed at 3 h in acute3 (Figure 3B), 6 h in acute2, and 12 h in acute1 (data not
shown) (n = 5 mice for each group). IBCs in all acute UTI isolates were small with an
average diameter of 20 ± 8 µm (p<0.01 compared to UTI89 and ASB isolates) and
sparse (average 3/bladder compared to ~20-100/bladder with UTI89 and ASB isolates, n
= 15 mice). No IBCs were observed at any of the five time points surveyed for acute4.
However, bacteria were visualized on the luminal surface of the bladder and quantitated
by tissue titer to be greater than 102 CFUs/bladder throughout the time course. With
UTI89, by 12 h virtually all of the bacteria have entered an intracellular niche (19). The
ability of acute4 to persist extracellularly up to 24 hours emphasizes that different UTI
strains may use alternative mechanisms to cause infection. Although acute4 produces
type 1 pili in vitro it is unable to form IBCs. Thus, additional factors must be critical in
IBC formation independent of type 1 piliation. Acute4 is further analyzed in studies
described below and in separate studies to investigate the mechanism by which it
persists in the urinary tract.
IBCs were observed for four of the five recurrent cystitis isolates. IBCs were only
observed at 3 h in rUTI5 (Figure 3A), 6 h in rUTI2 (Figure 3C) and rUTI3, and 24 h in
strain rUTI4 (n = 5 mice for each group), again showing differences in the IBC pathway.
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The diameter of the IBCs observed in all 4 isolates was 41 ± 14 µm, a value that is
significantly greater compared to acute UTI strain IBCs (p<0.05) but not significantly
different compared to UTI89 or the ASB strains (p=0.274). Similar to strain acute4,
rUTI1 bacteria were present in the bladders throughout the time course, as evidenced by
tissue titers (103-104) but no IBCs were observed by microscopy. However, in contrast
to acute4, rUTI1 expressed little to no type 1 pili in vitro (Table 2) even though it contains
the fimH gene. The inability to produce type 1 pili in vitro could possibly explain the
inability of rUTI1 to invade (see below) and form IBCs at the time points tested. Whether
type 1 pilus expression can be induced in vivo at later time points and lead to invasion
and IBC formation is the subject of future studies.
Of the four pyelonephritis isolates, three formed IBCs and did so by 6 h postinoculation (Figure 3D) suggesting similar kinetics in their IBC pathway (n = 5 mice in
each group). IBC diameter (55 ± 10 µm) was significantly larger than in acute UTI
strains (p<0.01). IBCs were not observed with pyelo3, and, similar to rUTI1, MSHA was
not detected after growth in static broth in vitro (Table 2). As seen with the two other
strains unable to form IBCs, acute4 and rUTI1, pyelo3 was unable to invade into the
superficial umbrella cells of the bladder (see below).

Invasion defects in strains unable to form IBCs
Since invasion is a prerequisite to IBC formation, we performed an in vivo
gentamicin protection assay to assess whether any of the three isolates that did not form
IBCs: acute4, rUTI1, and pyelo3, had invasion defects. PCR demonstrated that the fimH
gene was present in all three strains and HA assays revealed that acute4 produced type
1 pili while rUTI1 and pyelo3 produced mannose-resistant fibers. The ability of UPEC to
invade is thought to be dependant on type 1 pili (17). At 1 hour post infection bladders
were removed, bisected, and incubated in gentamicin to kill extracellular bacteria.
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Homogenates of the treated bladders were then cultured since intracellular bacteria
have been shown to survive this treatment (19). Bacterial titers revealed that the three
non-IBC forming isolates were deficient in invasion compared to UTI89 (Figure 4). 4.4%
of adherent UTI89 bacteria (defined as bacteria removed from the lumen after multiple
washes) were able to invade the urothelium (defined as bacteria surviving the
gentamicin treatment). In contrast, the three isolates that did not form IBCs (acute4,
rUTI1, and pyelo3) had invasion percentages of 0.3%, 0.5%, and 1.1%, respectively,
thus potentially explaining their inability to form IBCs.

Mixed infection model of UTI89 with non-IBC forming isolate
Due to the complex nature of the intestinal, peri-anal, vaginal, and periurethral
microbiota, it is likely that the initial inoculum in the human bladder is a mixture of
bacterial strains. We sought to investigate whether one isolate could improve the fitness
or out-compete another isolate in the bladder. Thus, we investigated the outcome of
experiments where UTI89 was genetically engineered to express a readily detectable
green fluorescent protein marker and then co-inoculated with each the three non-IBCforming clinical isolates in equal concentrations. Although IBCs were not observed
during single infection with acute4, when it was co-inoculated with UTI89, acute4 was
able to participate in IBC formation, but only as a mixed IBC with UTI89-gfp IBCs (Figure
5C, D). When rUTI1 was co-infected with UTI89, rUTI1 formed IBCs at 24 h (Figure 5B)
and caused UTI89 to form giant IBCs at 6 h (diameter = 130 ± 25 µm) (Figure 5A).
Pyelo3 was unable to form IBCs in the presence or absence of UTI89 and even
prevented IBC formation in UTI89. In the UTI89/pyelo3 mixed infection, most of the
extracellular (luminal) pyelo3 were filamentous and this same overwhelming
filamentation phenotype was induced in UTI89 (Figure 5E, F). Interestingly, although
two of the three clinical isolates altered the behavior of UTI89, they were present in the
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bladder in quantities 100-1000 fold less than UTI89 at each time point tested (n = 5 mice
in each group). Additionally, all three of the clinical isolates showed altered behavior in
the presence of UTI89 relative to their behavior when inoculated individually. Clinically,
a UTI is often defined as bacteria in the urine in quantities greater than 105 and mixed
infections with different UPEC strains would typically not be detected. Thus, small
amounts of a competing strain in the bladder could possibly have profound and distinct
effects on the outcome of infection.

Discussion
The widely accepted paradigm of acute and recurrent infection is that both are
due to the ascension of bacteria from the gut microbiota to the vagina and then the
bladder. In addition, UTIs have clinically been thought to be due to simple extracellular
colonization of the urothelium by UPEC. However, recently it has been shown in mice
that UPEC invade the urothelium in order to subvert innate defenses (15, 17, 18).
Likewise, intracellular bacteria have been demonstrated in the human bladder following
UTI (3). The discovery and characterization of intracellular bacterial communities (IBCs)
in the murine model of cystitis has challenged the traditional clinical paradigm of UTIs
and revealed a mechanism by which UPEC are able to build up in numbers in the
bladder despite potent innate defenses. The IBC pathway has been well characterized
with the cystitis isolate, UTI89, in the C3H mouse model of cystitis. In this study we
have demonstrated that the IBC pathway is common to most UPEC strains isolated from
humans with different UTI syndromes and in mice of different genetic backgrounds.
We found, through multiplex PCR virulence factor assays, that the isolates
chosen for this study were representative of a larger pool of UPEC isolates (13).
Surprisingly, none of our pyelonephritis isolates contained any genes within the pap
operon and thus did not express P pili. The pap operon encodes for P pili containing a
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distally located PapG adhesin that binds the globoside receptor in the human kidney
which has been shown to be critical for the ability of pyelonephritic strains to colonize the
kidney (22). The four pyelonephritis strains in this study were obtained from patients
that had classic symptoms of pyelonephritis, namely fever and CVAT (Table 1). The
absence of the pap operon in these strains is intriguing, but given the small sample size,
further studies will need to be done to interpret the significance of this finding. In
contrast, all of the pyelonephritis isolates, as well as the ASB, acute UTI, and rUTI
isolates, had the fimH gene. However, expression of type 1 pili after growth in static LB
broth differed among the strains. Strains with varying levels of type 1 pili after in vitro
growth were able to colonize the mouse bladder and form IBCs. It is possible that the in
vivo environment in the bladder altered the type 1 pilus expression profile after
inoculation, thus partially explaining the ability of strains with various levels of type 1 pili
to colonize and form IBCs within the bladder.
In our mouse model of UTI, we demonstrated that 15 of 18 clinical isolates from
various human clinical syndromes proceeded through the IBC pathway when inoculated
as a single strain. However, IBC formation differed among the strains in terms of the
kinetics by which bacterial communities formed, the size of the communities, and the
number of communities. While isolates from each clinical syndrome formed IBCs, the
acute UTI isolates formed significantly smaller and fewer IBCs relative to any other
syndrome. In general, ASB, rUTI, and pyelonephritis strains are associated with longerterm persistence in the host. The ASB, rUTI and pyelonephritis strains produced more
IBCs/bladder and the IBCs were of increased size compared to acute UTI strains. The
differences in IBC behavior of the acute strains compared to the other three groups
could potentially explain why the acute strains are less persistent.
The behavior of the three outlying strains (rUTI1, acute4, and pyelo3) required
more research to better understand their apparent deviations in IBC behavior with
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respect to their group. rUTI1, acute4, and pyelo3 were unable to efficiently invade into
the superficial umbrella cells of the bladder and thus were unable to form IBCs. Lack of
IBC formation in the three isolates could not be associated with a specific virulence
factor due to their differing virulence factor profiles. Likely, there are a multitude of
virulence factors contributing to IBC formation and perhaps some redundancy in the
necessary factors. rUTI1 did not produce any detectable levels of type 1 pili in vitro thus
most likely explaining its inability to invade and form IBCs at the time points tested.
Acute4 was able to produce type 1 pili in vitro at levels equivalent to or better than
isolates able to form IBCs suggesting that type 1 pilus expression is not sufficient for IBC
formation and implicates the importance of other factors in invasion. Pyelo3 produced a
small amount of type 1 as determined by immunoblotting with anti-FimH antisera. No
MSHA was detected in vitro possibly because of the presence of MRHA adhesins that
would potentially mask type 1 mediated hemagglutination. The deficiency of in vivo
invasion of pyelo3 could suggest that either the MRHA adhesins somehow interfered
with the process and/or that pyelo3 lacked other factors involved in invasion.
Given the diverse microbial communities in the rectum and vagina (2, 21), it is
likely that multiple strains of bacteria are simultaneously introduced into the urinary tract
of a woman during the early events that lead to a UTI, such as sexual intercourse. While
mixed infections may select for bacteria with a distinct competitive advantage, they may
also allow less virulent bacteria the opportunity to establish a niche in conjunction with
more efficient UPEC strains. Co-inoculation of UTI89, a known IBC forming strain, with
each of the three isolates that were deficient in IBC formation, resulted in dramatic,
synergistic effects. Of the three isolates in which IBC formation was not detected, two
were able to do so in mixed infections with UTI89 (rUTI1, acute4). This may explain the
seemingly outlying behavior of these strains when analyzed in single infections. The
diagnosis of UTIs rarely delineates whether multiple strains of E. coli are present. Thus,
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strains such as rUTI1 and acute4 could have “piggy-backed” with a more invasive IBC
forming strain that went undetected. UTI89 formed significantly larger IBCs in the
presence of rUTI1. This may be due to potential host responses induced by rUTI1 that
facilitate bacterial replication in the superficial umbrella cells, or possibly that rUTI1
induces signals that prevent or slow the dispersal and fluxing of the bacteria in the IBC.
IBC formation is a clonal process in that each IBC arises from a single bacterium (P. C.
Seed and S. J. Hultgren, submitted for publication). Surprisingly, the mixed infection
with acute4 and UTI89 resulted in non-clonal IBCs. Acute4 only existed as a mixed IBC
with UTI89. The bacteria did not inter-mingle in the IBC but instead each strain seemed
to group together in patches that melded into one IBC. These results argue that UTI89
was able to provide factors in trans that could support acute4 in the intracellular biofilm
matrix.
Pyelo3 was the only strain in our study unable to form IBCs under any of the
conditions tested. Co-inoculation of UTI89 and pyelo3 resulted in massive filamentation
of both isolates. Based on previous work showing that filamentation occurs in response
to an inflammatory response (15), further study is required to assess whether pyelo3 is
triggering a more robust innate response that leads to the massive filamentation
observed. The complexities we have observed with co-infections between the bacteria
and with the host might explain the occurrence of different clinical syndromes manifested
by the same organism (6) or the differing behavior in single versus mixed infections as
described above. Alternatively, it is possible that these isolates could represent a class
of strains that do not use the IBC pathway but instead use a different extracellular
strategy for persistence.
In summary, 15 of 18 isolates causing different clinical syndromes in humans and
possessing various combinations of virulence factors were successful in invading the
bladder epithelium of mice to form IBCs. Two of the remaining three isolates were also
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able to form IBCs in mixed infections with UTI89. These findings demonstrate that the
IBC pathway is common to UPEC pathogenesis. Studies are in progress to determine
whether UPEC forms IBCs in humans and whether they contribute to same-strain
recurrences of UTI. The murine model of IBC formation will allow investigators the
ability to study the intricacies of host-pathogen interactions in the bladder.
Understanding the basis of the intracellular niche occupied by UPEC will lead to the
better evaluation and treatment of UTIs and will foster the development of new
therapeutic strategies.
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Figure 1. Immunoblot of pyelonephritis isolates with antibodies against P pili. P pilus
antibodies were raised against J96 P pili, thus J96 and UTI89 were used as positive controls for P
pili production. Both isolates are positive for P pili due to a PapA-specific band at 16.5 K.
However, the P pilus antibody did not recognize protein at 16.5 K for the four pyelonephritis
isolates, confirming the lack of the pap operon seen with multiplex PCR. Thus, pyelo1, pyelo2,
pyelo3, and pyelo4 do not contain the genes nor produce protein associated with P pili which are
thought to be critical in kidney colonization.
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Figure 2. UTI89 and CFT073 formed IBCs in multiple mouse strains. UTI89 and CFT073, two
commonly used UTI isolates, were inoculated into 5 different mouse strains. At 6 h post-infection
each strain of mice was able to support IBC formation by each UTI isolate. (A-E) represents
UTI89 IBCs and (F-J) represents CFT073 IBCs.
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Figure 3. IBCs were formed by UPEC isolated from women. Clinical isolates (red) were
inoculated into C3H/HeN female mice and bladders were harvested at 3 h, 6 h, and 24 h. Fifteen
isolates produced IBCs at either (A,B) 3 hours, (C,D) 6 hours, or (E,F) 24 hours. Each clinical
syndrome is represented above. The cell surface (green) was stained with WGA and in this
cross-sectional view can be seen bordering the umbrella cells. While the majority of isolates
produced IBCs, size and density of the IBCs varied. Bars = 10 µm.

56

Figure 4. The three non-IBC forming isolates, rUTI1, acute4, and pyelo3, were deficient in
invasion in vivo. C3H/HeN female mice were inoculated with UTI89, rUTI1, acute4, and pyelo3.
At 1 h post-infection bladders were removed and processed. The Luminal fraction represents
luminal bacteria and the Intracellular fraction represents invaded bacteria. One hour after
inoculation, 4.4% of UTI89 bacteria invaded whereas for rUTI1, acute4, and pyelo3 only 0.3%,
0.5%, and 1.1% of luminal bacteria invaded, respectively. Thus, the three non-IBC forming
isolates invade poorly relative to UTI89.
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Figure 5. Co-infection with a clinical isolate and UTI89 altered the behavior of the bacteria.
(A,B) rUTI1 (red) produced IBCs only when co-infected with UTI89 (green) and caused UTI89 to
produce abnormally large IBCs (compare A to C). (C,D) acute4 (red) formed mixed IBCs with
UTI89 (green) which also formed normal IBCs. (E,F) pyelo3 (red) formed large collections of
filaments, induced UTI89 (green) to do the same, and prevented UTI89 IBCs. Bars = 10 µm.
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Abstract
Urinary tract infections (UTIs) afflict nearly 60% of women within their lifetimes, the
majority of which are caused by uropathogenic Escherichia coli (UPEC). Studies in mice
and humans have revealed that UPEC undergo an unexpectedly complex pathogenesis
cycle involving both intracellular and extracellular niches. Despite the commonality of
the UPEC pathogenesis cycle, no specific urovirulence profile has been determined
likely due to the fluid nature of the UPEC genome as the result of horizontal gene
transfer and numerous genes of unknown function. Horizontal gene transfer results in
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the uptake of large pieces of DNA termed genomic islands (GIs). If these GIs contain
one or more virulence genes they are termed pathogenicity islands (PAIs). PAIs can
integrate into the chromosome or remain extrachromosomal as a plasmid. UTI89 has a
large extrachromosomal element termed pUTI89. The pUTI89 plasmid has
characteristics of both F plasmids and other known virulence plasmids. This study
sought to determine if pUTI89 is important for virulence. Both in vitro and in vivo assays
were used to examine the function of pUTI89 using plasmid-cured UTI89. Based on
growth, type 1 pilus expression and function and biofilm formation, there was no
difference between UTI89 and plasmid-cured UTI89. However, upon inoculation into the
mouse model of UTI, there was a significant decrease in bacterial colonization of the
pUTI89-cured strain at early timepoints post-infection. This defect was confirmed using
bacterial load quantification, gentamicin protection assays, confocal microscopy and IBC
quantification. Through directed deletions of specific operons on pUTI89, the cjr operon
was partially implicated in this observed defect. This work implicates pUTI89 in early
aspects of infection.

Introduction
Urinary tract infections (UTIs) represent, by number, the most important bacterial
infectious disease in highly industrialized countries (14). Sixty-percent of all women will
have at least one UTI within their lifetime (16, 46, 52). This infection results in nearly 7
million physicians office visits and $3.5 billion dollars annually in the United States alone
(15). It is thought that acute UTIs develop when bacteria from the fecal flora colonize
the vaginal and periurethral mucosa and are subsequently introduced into the bladder by
urethral ascension. Women who present with an initial episode of acute UTI have a 2544% chance of developing a second and a 3% chance of experiencing three episodes
within six months of the initial UTI (14). Recurrence occurs despite appropriate antibiotic
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treatment and clearance of the initial infection from the urine. A large percentage of
recurrent UTI (rUTI) are caused by the same strain of bacteria as the initial infection.
One study followed 58 women and found that 68% of recurrences were caused by the
same initial index strain of UPEC as determined by restriction fragment length
polymorphism (RFLP) analysis (54). The high frequency of same-strain recurrences
supports the notion that a UPEC reservoir may exist in the affected individual.
Uropathogenic Escherichia coli (UPEC) is the leading causative agent of UTI,
responsible for up to 85% of community-acquired UTI and 25% of nosocomial UTI (51).
Using a well-characterized clinical UPEC isolate, UTI89, in a murine cystitis model, it has
been demonstrated that the pathogenesis of UTI involves intracellular and extracellular
components (27, 28, 38). The bladder surface is covered with a urothelium composed of
very large superficial umbrella cells which are coated with uroplakins that expose a
terminal mannose moiety (64). Type 1 pili and its adhesin, FimH, are required for
attachment and invasion therefore playing a critical role in the infection process (38, 40,
63). The FimH protein has a negatively charged pocket that accommodates a mannose
unit, namely those exposed by uroplakins on the bladder surface (23). Once bound a
signaling cascade is initiated resulting in bacterial internalization (37, 38). Upon
internalization, bacteria rapidly replicate within the umbrella cell forming tightly packed
intracellular bacterial communities (IBCs) (1, 27). These IBCs can be seen throughout
the murine bladder and have biofilm-like properties. Meanwhile, the host is attempting to
eliminate infection by exfoliating the umbrella cells and sending an influx of neutrophils
(40). The bacteria combat these defenses by exiting the IBCs and filamenting (41). The
filamentous bacteria are resistant to engulfment by neutrophils and can go on to bind
other umbrella cells, invade, and form second generation IBCs, perpetuating the
infection (27). Additionally, bacteria can invade the transitional epithelium beneath the
umbrella cells, establish a quiescent intracellular reservoir (QIR) and remain dormant
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until they reemerge and potentially cause a recurrence (42). The IBC/QIR pathway
could partially explain the often observed recurrent UTI with isolates identical to the
primary infection ones (54). Recent work has shown that this is a common pathway
among UPEC isolates (17) and evidence of this pathway also has been observed in
humans (53).
Horizontal gene transfer is the movement of genetic material between bacteria
independent of cell division. It is essential to generating diversity between bacterial
species and, through natural selection, contributes to the evolution of bacterial species
(13, 31, 55). In addition to genetic variability, newly acquired DNA can enable
adaptation to life in a specialized niche through specific factors. The acquisition of DNA
by horizontal gene transfer results in the exchange of large regions of DNA called
genomic islands (GIs) between bacteria. GIs can be acquired in several ways; through
inheritance of a plasmid that can remain autonomous or recombine into the
chromosome, integration of a lysogenic phage into the chromosome, and insertion of a
linear DNA fragment into the chromosome usually by transposition or recombination (12,
34, 58). Some GIs are referred to as pathogenicity islands (PAIs) if they contain large
genomic DNA regions greater than 20 kb that carry at least one virulence gene, are
inserted within or near tRNA genes, contain direct repeats and mobility sequences and
can be identified by a differing G+C content relative to the host bacteria (19).
Additionally, PAIs often do not represent homogeneous pieces of DNA but instead are
mosaic-like structures generated by a multistep process involving genomic acquisition,
loss and rearrangement (20). Since UPEC PAIs are among the best understood, UPEC
is considered the model system for analysis of the genome structure and composition of
PAIs of pathogenic bacteria in general (6). Study of UPEC PAIs has revealed that they
encode adherence factors, toxins and iron uptake systems. Interestingly, these same
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virulence factors can be plasmid or phage encoded on intestinal E. coli isolates whereas
in UPEC they are located chromosomally, i.e. alpha-hemolysin. Thus, UPEC PAIs could
represent former plasmid-derived sequences. Additionally, UPEC PAIs carry many
cryptic genes, open reading frames of unrelated and even unknown functions,
pseudogenes and junk DNA sequences. UPEC isolate, UTI89, carries a large
extrachromosomal element with many characteristics of UPEC PAIs. This plasmid,
pUTI89, has a high proportion of pseudogenes generated by insertion events, open
reading frames homologous to proteins of non-plasmid origin and orthologs of
enteroinvasive E. coli (EIEC) proteins found on a large virulence plasmid (10). These
features describe a UPEC PAI that has potentially not yet incorporated into the genome,
known as a ‘PAI precursor’ (32). pUTI89 is approximately 114 kb and, like plasmid F,
contains the tra operon for conjugative transfer as well as genes associated with plasmid
replication and inheritance.
While UPEC manifest disease in the urinary tract, they normally exist within the
intestinal tract of humans. Thus UPEC are distinct from the commensal E. coli residing
in the GI tract in that they possess virulence factors enabling successful transition to and
colonization of the urinary tract. To date, the factors required for successful infection in
addition to type 1 pili have yet to be fully elucidated (63). While studies have
demonstrated that additional adhesin systems, toxins, autotransporters and iron
acquisition factors may be important in establishing infection, there is also an abundance
of unknown genes labeled as hypothetical or assigned putative functions that may play a
role in virulence (26). This study questions whether pUTI89 is important in the virulence
of UPEC. Evidence of regions of pUTI89 are present in the majority of clinical isolates
tested suggesting maintenance and transmission within the community and importance
in some aspect of virulence. Testing of in vitro and in vivo characteristics reveal that
pUTI89 is involved in an early feature of in vivo infection, while not altering any of the
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tested in vitro behavior. A region on pUTI89 encoding the cjr operon found in EIEC may
be involved in this early defect.

Materials and Methods
Bacterial strains.
E. coli UTI89 is a cystitis-derived isolate of serotype O18:K1:H7 (41). UTI89 was used
for all assays within this study. A panel of clinical isolates was used to identify the
presence of pUTI89. This panel has been previously described by Garofalo et al. (17).

Plasmid purification and PCR to assay for pUTI89.
Bacterial cultures from 18 clinical isolates and UTI89 were incubated overnight at 37oC
under shaking conditions. Cells were harvested at 6000 rpm for 10 min and
resuspended in 25 mM Tris-HCl (pH 8.0), 50 mM EDTA. After the addition of 0.2 M
NaOH, cells were incubated on ice for 10 min followed by the addition of 5 M potassium
acetate. After a 5 min incubation, the solution was spun at 9000 rpm for 15 min.
Isoproponal was then added to the supernatant and incubated at room temperature for
20 min. The solution was spun for 15 min at 3500 rpm at 4oC. The pellet was air-dryed
and resuspended in TE buffer. After resuspension, 10 M NH4OAc was added and
incubated on ice for 20 min. The solution was spun, ethanol was added to the
supernatant and incubated at -20oC for 20 min. DNA was then precipitated, washed
twice with 75% ethanol and resuspended in TE buffer. RNA was eliminated by
incubation with RNase A. 5 M NaCl and 30% PEG-6000 were added to the solution and
incubated for 30 min on ice. After centrifugation, the precipitate was resuspended in TE
buffer and the DNA was extracted using phenol/chloroform. DNA was precipitated with
ethanol, washed twice with 75% ethanol and resuspended in TE buffer. The purified
plasmid DNA was then used for PCR analysis. Using the sequence of pUTI89, primers
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were designed to amplify regions around the plasmid. These 8 primer pairs were named
A-H (Table 1). A primer pair amplifying ompA was used as a control for genomic
contamination. Standard PCR protocols were used. PCR products were run on a 1%
agarose gel and bands were detected by eithidium bromide staining. A band migrating
the correct distance represented a “+” for that region of pUTI89.

pUTI89 curing.
Using the phage lambda Red recombinase system (11), UP062 and UP063 encoding
the stability operon were deleted from UTI89 to make UTI89/pUTI89/ΔUP062-63,
creating a kanamycin-resistant UTI89. This mutant of UTI89 was then cured of pUTI89
by ethidium bromide treatment. Curing was done essentially as described by
Bastarrachea and Willetts (4). Briefly, UTI89/pUTI89/ΔUP062-63 was grown overnight in
LB + 50 µg/ml kanamycin. Approximately 102 to 104 cells/ml of the overnight culture
were inoculated into flasks containing LB + 10 fold dilutions of ethidium bromide
beginning with 100 µg/ml down to 10 µg/ml and shaken at 37oC for 16 hours. Using the
highest concentration of ethidium bromide that sustained growth, the culture was diluted
and plated on to LB agar plates and grown overnight at 37oC. Single colonies were
picked from the LB agar plate and patched on to LB agar plates containing 50 µg/ml
kanamycin. Colonies sensitive to kanamycin were grown overnight in LB and subjected
to plasmid purification and PCR for pUTI89 as described above. Cultures with no
positive reactions in the PCR assay were considered to be cured of pUTI89.

Growth curves.
Standard growth curve assays were performed. Bacteria were grown in LB at 37oC
shaking overnight. Cultures were diluted 1:1000 into either LB or M9 minimal media +
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10 µg/ml niacin and 200 µl was inoculated into a 96 well plate in triplicate. A microplate
reader running the SoftmaxPro program was used to read at 37oC, every 20 min for 10
hours with shaking at OD600. Data from each read was averaged and graphed to obtain
the growth curve.

Immunoblot assay for FimH and FimA.
For immunoblot assays of FimH and FimA expression, bacteria were grown statically in
LB at 37oC for 24 hours to obtain optimal type 1 pili expression. Equivalent numbers of
cells (OD600 = 1.0) from each isolate were suspended in SDS sample buffer, 1 M HCl
was added dropwise until a pH indicator (bromophenol blue) turned yellow, and solution
was heated at 95oC for 5 min. The samples were then neutralized and analyzed by
SDS-polyacrylamide gel electrophoresis followed by immunoblotting with antibodies to
either FimH or FimA (raised in rabbits using purified FimH or FimA protein,
respecitively). Specific FimH or FimA proteins were visualized on nitrocellulose
membranes by using the BCIP/NBT liquid substrate system (Sigma) and analyzed for
intensity using ImageJ software (http://rsb.info.nih.gov/ij/).

Hemagglutination assay.
Bacteria were grown 24h (as described in the immunoblot assay) to induce expression
of type 1 pili. Hemagglutination (HA) assays with guinea pig erythrocytes were
performed using well-established protocols (22). Briefly, equivalent numbers of cells
(OD600 = 1.0) from each isolate were suspended in PBS or PBS + 2% mannose and
added in 2-fold dilutions to V-bottom 96-well plates (Costar). Guinea pig erythrocytes
were cleaned, resuspended in PBS to an OD640 = 1.9 and added to the 96-well plate.
The plate was incubated at 4oC overnight. The HA titer was scored by the last well with
visible agglutination. An HA titer of 1 equals agglutination at a 1:2 dilution whereas an
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HA titer of 9 equals agglutination at a 1:512 dilution indicating a high level of type 1 pili
function.

Biofilm assay.
Bacteria grown overnight in LB were diluted 1:1000 into LB, M9 minimal media + 10
µg/ml niacin, or YESCA broth and added to 96-well PVC microtiter plates. LB and M9 +
10 µg/ml niacin biofilms were grown at room temperature for 48 hours and YESCA
biofilms were grown at 30oC for 48 hours. Plates were rinsed and stained with crystal
violet and biofilms were quantified at OD600 after solubilization in 33% acetic acid as
described (45).

Mouse infections.
All mouse infection studies were approved by the Animal Studies Committee of
Washington University. Eight-week-old C3H/HeN (NCI) female mice were anesthetized
by inhalation of isoflurane and infected via transurethral catheterization with a 50-µl
suspension of ~1 x 107 CFU of a given isolate. Bacteria for inoculation were grown 24
hours at 37oC statically. At the indicated times post-infection, mice were sacrificed by
cervical dislocation under anesthesia, and the bladders were immediately harvested and
processed as described below.

Tissue bacterial titer determination.
To enumerate the bacteria present, bladders were aseptically harvested 6, 24, 48 h and
1 and 2 wk post-infection, homogenized in PBS, serially diluted, and plated onto LB agar
plates. CFU was enumerated after 16 h of growth at 37oC.

Gentamicin protection assay.
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To enumerate the bacteria present in the intracellular versus extracellular
compartments, bladders were aseptically harvested at 1 and 6 h post-infection.
Bladders were then bisected twice and washed 3 times in 500 µl PBS each. The wash
fractions were pooled, lightly spun at 500 rpm for 5 min to pellet exfoliated bladder cells,
serially diluted and plated on LB agar to obtain the luminal fraction. The bladders were
treated with 100 µg/ml gentamicin for 90 min at 37oC. After treatment, the bladders were
washed twice with PBS to eliminate residual gentamicin, homogenized in 1 ml PBS,
serially diluted and plated on LB agar to obtain the intracellular fraction. CFU was
enumerated after 16 h of growth at 37oC.

Confocal scanning laser microscopy.
To visualize bacterial behavior within the bladder, bladders were aseptically harvested at
6 h post-infection. Bladders were bisected and pinned open revelaing the luminal
surface. The splayed bladders were then incubated for 20 min at room temperature with
(i) Alexa Fluor 488-conjugated wheat germ agglutinin (WGA) (1:1000 in PBS; Molecular
Probes) to stain the bladder luminal surface and (ii) nucleic acid dye SYTO61 red
(1:1000 in PBS; Molecular Probes) to stain bacteria and bladder epithelial cell nuclei.
Trolox (10 µM; Fluka) was added to the splayed bladders to reduce photobleaching (56).
Bladders were examined with a Zeiss LSM 510 Meta Laser Scanning inverted confocal
microscope using a 63x oil immersion objective. WGA and SYTO61 were excited at 488
and 633 nm, respectively.
Enumeration of IBCs.
To accurately count the number of IBCs, bladders were aseptically harvested at 6 h
post-infection, bisected, splayed on silicone plates and fixed in 2% paraformaldehyde.
IBCs, readily discernable as punctate violet spots, were quantified by LacZ staining of
whole bladders (29).
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Results
UTI89 contains a plasmid of unique characteristics.
Many E. coli strains possess extra-chromosomal genetic elements carrying
genes encoding for DNA transfer apparatus. These elements include the conjugative
plasmids F and R100. Some other plasmids carried by pathogenic strains, such as
pO157 in EHEC isolates, contain genes encoding for putative virulence factors such as
toxins, type III secretion apparatus and adhesive organelles (8, 35). Many studies have
demonstrated the involvement of these plasmids in EHEC pathogenesis (5, 30, 59, 60).
UTI89 contains an epichromosomal genetic element of 114,230 nt (10). This
plasmid could be divided into two major portions based on their homology with other E.
coli plasmids. One half of the plasmid contains genes involved in plasmid replication
and conjugative DNA transfer similar to those on Plasmid F, an archetypical conjugative
plasmid. A large number of ORFs on the other half of pUTI89 show homology (>70% at
the amino acid level) to genes present on plasmids from pathogenic E. coli plasmids
(Figure 1). Three pUTI89 ORFs were identified to be orthologs of EIEC O164 cjrA, cjrB
and cjrC genes. In EIEC O164, these genes are found on the large virulence plasmid
and encode proteins involved in uptake of colicin Js (57). Expression of these genes
appears to be regulated by both iron and temperature. Similar to their orthologs in EIEC
O164 plasmid, a putative iron regulation fur box was also located upstream of pUTI89
cjrA (nt 21010-21028). UTI89 CjrB is homologous to the TonB protein present in many
gram-negative bacteria which is thought to be involved in energy transduction between
the inner and outer membrane (49). Likewise, UTI89 CjrC shows homology to putative
outer membrane siderophore receptors. Similar to the EIEC O164 large virulence
plasmid, pUTI89 possesses the senB gene, encoding an enterotoxin, downstream of
and partially overlapping the cjrC gene. The senB gene was demonstrated to account
for at least 50% enterotoxic activity of another EIEC strain, EI34 (44).
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Six pUTI89 ORFs also showed high identity to those located on UTI89
chromosome. Four of these were either transposases or hypothetical proteins of
unknown function. Two other ORFs, UP042 and UP043, are homologous to genes
predicted to posses transport functions at the membrane. UP042 exhibited 100% amino
acid identity to a gene encoding a component of a putative ABC transporter system that
is also found in UPECs F11 and UMN026. UP043 was 95% identical at the amino acid
level to an outer membrane heme receptor encoded by the UTI89 chromosome. Similar
to their counterparts on the plasmid, the two homologs to UP042 and UP043 in UTI89
genome (UTI89_C1129 and UTI89_C1130) were also adjacent to each other on the
chromosome. Two transposases adjacent to one another on the plasmid, UP040 and
UP041, also had adjacent homologs (UTI89_C2257 and UTI89_C2258) on the
chromosome. However, while these two sets of ORFs were located near each other on
the plasmid, their homologous sets were actually over 1 megabase apart on the
chromosome. It is unclear if these genes were acquired separately or as a result of a
gene duplication event.
Several ORFs within pUTI89 are homologous to sequences encoding proteins of
non-plasmid origin in the database. These were scsCD [S. typhimurium LT2]), nqrC
(sodium-translocating NADH dehydrogenase (ubiquinone) gamma subunit [V. cholerae])
and iron transporters (putative membrane protein and putative periplasmic protein [Y.
pestis]). Acquisition of these genes likely occurred through evolution of the plasmid
suggesting that pUTI89 is a hotspot for recombination and genetic exchange.
Furthermore, many pseudogenes were present on the plasmid as the result of gene
disruption by insertion and deletion (10). The presence of homologs from pathogenic
bacteria and the fluid nature of the plasmid genome argue that pUTI89 might play an
important role in UTI pathogenesis.
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pUTI89 in UPEC Clinical Isolates.
We sought to determine if pUTI89 and/or its genes were common among UPEC
isolates since strong selection to maintain the plasmid by human strains implies
importance in pathogenesis. We have previously reported on a panel of UPEC clinical
isolates that proceed through the IBC pathway, however differ in time, size, and number
of IBCs (17). This panel of isolates encompasses all clinical syndromes of UTI to obtain
a representative pool of strains from women with UTI. Extrachromosomal DNA was
purified from 18 clinical isolates and PCR amplification of 8 regions on pUTI89 was used
to assess its presence in the clinical isolates (Table 2). Of the 18 isolates, 4 (22%) had
all 8 regions of pUTI89 suggesting the presence of the entire plasmid and 6 (33%) had
no evidence of pUTI89. Of the 12 isolates that had evidence of pUTI89 (67%), 100% of
them had the region containing UP100 and UP101, both hypothetical proteins. This
would suggest that these proteins are an important characteristic of pUTI89 since it is
most commonly maintained in human UPEC isolates. Furthermore, the prevalence of
pUTI89 regions within this panel of clinical isolates (67%) suggests its involvement in
pathogenesis within the urinary tract. Due to small amounts of genomic contamination in
the plasmid preparation it is possible that the regions identified within the clinical isolates
exist on the chromosome of the isolate rather than as an extrachromosomal element.
However, that these regions are still maintained in the population is evidence of their
importance.
Deletion of pUTI89.
Due to the unique characteristics of pUTI89, further study was required to
elucidate its function. We sought to eliminate pUTI89 from UTI89 and assess the
behavior of the bacteria without the plasmid in vitro and in vivo. Currently there are
multiple ways to eliminate a plasmid from its host. Traditional ways of curing involve
intercalating dyes, DNA gyrase inhibitors, Rifampicin, and SDS. More advanced ways
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use transposon-based elimination (25) and SacB curing (24). Unfortunately pUTI89 did
not respond to any of the above methods and was not successfully eliminated from
UTI89. A new approach was taken based on the genes present on the plasmid. pUTI89
contains the stability (stb) locus which is involved in stable inheritance of the plasmid. It
is thought to be involved in the partition of plasmid molecules to daughter cells during
cell division, which is essential for stable plasmid inheritance. Mutations that inactivate
stb function result in plasmid instability, so that plasmid-free cells are segregated at a
rate consistent with random distribution of plasmid copies at cell division (39). We took
advantage of the requirement of these genes for stability to cure pUTI89. First, the
stability locus was deleted using the λ red recombinase system (11).
UTI89/pUTI89ΔstbA/stbB was then subjected to curing by an intercalating dye, ethidium
bromide. At a concentration of 90 µg/mL ethidium bromide, the plasmid was eliminated
from UTI89; this was confirmed by selective plating and PCR (Figure 2). Thus, it
required both gene manipulation and a traditional curing method to delete pUTI89 from
UTI89.

In vitro affect of pUTI89.
Once pUTI89 was successfully eliminated from UTI89, we analyzed its effects on
UTI89 in vitro. In addition to the tra operon, there are several putative outer membrane
proteins that may alter the proteinaceous make up of the bacterial membrane and a
putative regulator that could have an effect on genes expressed under different
environmental conditions. Additionally there are many hypothetical proteins that could
have an effect on growth rate, protein expression and biofilm formation. Upon testing
growth in both rich media (LB) and minimal media (M9 + 10 µg/mL niacin), both UTI89
and ΔpUTI89 grew equally well, suggesting that, under these conditions, the plasmid is
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not essential for bacterial growth (Figure 3A). Type 1 pili are an essential virulence
factor to UTI89 in vivo (63), thus it was very important to identify if expression of the fim
operon was altered by removal of pUTI89. An immunblot using anti-FimH and anti-FimA
antisera showed no difference in expression levels of either protein in UTI89 versus
ΔpUTI89 bacteria (Figure 3B). Since expression does not necessarily confirm function,
the pili were tested for their ability to agglutinate guinea pig red blood cells.
Hemagglutination (HA) titers were analyzed in the presence and absence of mannose to
confirm that agglutination was type 1 specific. Both strains had equal mannose-resistant
and mannose-sensitive HA titers suggesting that pUTI89 is not involved in type 1 pili
expression and function (Figure 3D). Previous work has shown that UTI89 within the
bladder forms biofilm-like intracellular bacterial communities (IBCs) (1). Thus, the ability
of UTI89 and ΔpUTI89 to form biofilms in vitro was evaluated as an indicator of potential
behavior in vivo. Furthermore, F plasmids have been shown to promote biofilm
formation in a K-12 genetic background (18). In both rich media (LB) and minimal media
(M9 + 10 µg/mL niacin), ΔpUTI89 behaved identical to wild-type UTI89 (Figure 3C).
Additionally, it was recently discovered that different media conditions require different
adhesive fibers for robust biofilm formation, so a second measure of biofilm formation
was assayed to look for curli-dependent biofilms (Cegelski et al, submitted). These
biofilms are grown in YESCA media at 30oC. Both strains had equivalent curlidependent biofilm formation (Figure 3C). Taken together, these data suggest that UTI89
and ΔpUTI89 are virtually indistinguishable in these aspects of comparative analysis in
vitro.

In vivo mouse infection.
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Although UTI89 and ΔpUTI89 behaved identical in vitro, the loss of pUTI89 could
have affected the virulence of UPEC in a way that was not measurable by the in vitro
tests. The in vivo pathogenesis was subsequently assessed in the UTI mouse model.
In this infection model, UTI89 as well as multiple clinical isolates proceed through an IBC
pathway (1, 17, 27). C3H/HeN mice were inoculated with 107 of either UTI89 or
ΔpUTI89 and bacterial burden was evaluated at different points during infection. At 6
hours post-infection the bacterial load of ΔpUTI89-infected bladders was significantly
lower (p<0.0001) than UTI89-infected bladders (Figure 4A). To confirm this observation
and minimize the possibility that a secondary mutation contributed to the attenuation,
additional clones of ΔpUTI89 constructed independently also showed a significant defect
in titers at 6 hours post-infection (Figure 4B). Nevertheless by 24 hours, ΔpUTI89 titers
were comparable to UTI89 and remained that way through the entirety of the time
course. These data suggest that genes on pUTI89 may be involved in the early stages
of infection but does not affect the overall outcome of infection.

In vivo survival.
Due to the significant defect during early infection of the ΔpUTI89 strain despite
equivalent in vitro type 1 pili expression, we assessed the bacteria’s ability to bind to and
invade the urothelium in vivo. Bladders from 1 and 6 hour infected C3H/HeN mice were
removed and both the intracellular and luminal populations were enumerated. At both 1
and 6 hours post-infection there were significant decreases in both binding and invasion
of ΔpUTI89 relative to UTI89 (Figure 5). These results suggest pUTI89 is potentially
enhancing invasion, enhancing extracellular survival or aiding in immune evasion. In
order to confirm the phenotype observed in the gentamicin protection assay, we sought
to visually demonstrate a diminished invasion or reduced extracellular colonization by
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confocal microscopy. At 6 hours post-infection, UTI89- or ΔpUTI89-infected bladders
were removed, splayed and stained. Although both strains form IBCs successfully
(Figure 6), the ΔpUTI89-infected bladder had little to no observable extracellular bacteria
and IBCs were less numerous than its wild-type-infected counterpart. In addition,
UTI89-infected bladders had numerous extracellular bacteria, many in filamentous
morphology. In an effort to more accurately enumerate IBCs, we performed LacZ
staining on UTI89- and ΔpUTI89-infected bladders. This quantification revealed a
significant defect in the number of IBCs observed between the two isolates (Figure 6).
These data are consistent with the results from the gentamicin protection assay and
identifies pUTI89 as a potential mediator in invasion, extracellular survival or host
evasion at the early stage of infection.

Identification of virulence factors on pUTI89.
Deletion of pUTI89 alters UTI89’s behavior in vivo. In an attempt to decipher which
region of pUTI89 is responsible for this observed phenotype, we eliminated small
regions of the plasmid and examined their effects in the mouse UTI model. Table 3
specifies the gene, size and predicted function of the regions chosen for deletion. Each
of the constructed deletions was individually inoculated into the mouse and bacterial
load was evaluated at 6 hours post-infection. Of the 7 deletions made, 2 had a
significant decrease on bacterial load relative to UTI89 at 6 hours post-infection (Figure
7). These mutants were ΔUP028-30 and ΔUP062-63. ΔUP062-63 has a 1.4 kb region
deleted encoding for the stbA and stbB genes of the stability operon. These genes are
involved in maintenance of the plasmid. The reduction in bacterial titers upon deletion of
stbA/B confirms the results observed with the ΔpUTI89 mutant (Figure 3); when pUTI89
is not successfully maintained in vivo the bacterial infection is reduced. ΔUP028-30 has
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a 4.7 kb region deleted encoding for cjrB, cjrC and senB. The cjr operon (for colicin Js
receptor) encodes for proteins involved in colicin Js uptake as described above (57).
The operon contains 3 proteins, however it was shown that only CjrB and CjrC are
essential for colicin Js sensitivity. This deletion, however, did not cause as much of a
decrease in bacterial titers as does the loss of pUTI89 which suggests that other genes
on pUTI89 may also be important during UTI pathogenesis. With these deletion
mutants, we have identified at least two regions on pUTI89 that are important for
virulence. This work shows that pUTI89 is used to acquire important virulence factors
for the early stage of infection. Further work will be required to understand the role of
these operons in early infection. Studies are currently underway to examine the
expression patterns of the cjr and sen loci, and their impact on UTI pathogenesis.

Discussion
Virulence in Enterobacteriaceae is associated with the acquisition of large
plasmids that confer distinguishing phenotypic pathogenic traits. These virulence
plasmids are generally low copy number, approximately 60 to 200-kb in size and similar
to F plasmid or R100 plasmid (62). Virulence plasmids of other pathogenic E. coli,
enteropathogenic E. coli (EPEC), enterotoxigenic E. coli (ETEC) and enteroaggregative
E. coli (EAEC) are large F-like plasmids that encode different fimbrial adhesins that give
characteristic modes of colonization of intestinal epithelia (43). UPEC isolate, UTI89,
carries a large F-like plasmid, pUTI89. We attempted to find a role for pUTI89 as a
virulence plasmid in the setting of urinary tract infections. The model used to identify
virulence focused heavily on the IBC pathway within the mouse, looking at interaction
with bladder epithelia and intracellular and extracellular survival.
Our studies of the in vitro effects of pUTI89 on UTI89 showed equivalent
behavior in every aspect tested. However, many of the genes on pUTI89 encode
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hypothetical proteins that could be critical in establishing in vivo infection. A similar
phenomenon was seen with a Chlamydia trachomatis plasmid where there was no
observable phenotype in vitro, however upon in vivo infection in the absence of the
plasmid there was a significantly lower ID50 and lack of glycogen accumulation (9). The
defect was partially attributed to plasmid-dependent regulation of multiple chromosomal
genes. Plasmid control of chromosomally encoded genes is not a unique attribute
among bacteria. Yersinia pestis, EPEC and Bacillus anthracis all have plasmid-encoded
loci controlling chromosomally encoded genes (3, 7, 48). We observed similar altered
regulation of chromosomal genes in the absence of pUTI89, however, the majority of
these genes are hypothetical and will require further examination (data not shown),
nonetheless suggesting that pUTI89 functions in trans to regulate the transcription of
multiple chromosomal genes. Genes on the chromosome were both positively and
negatively regulated. Thus, it is likely that there are multiple transcriptional regulators on
pUTI89. However, it is also possible that one regulator may function as both a repressor
and an activator, as has been reported for some transcriptional regulators (47).
Approximately 76 plasmid genes were differentially expressed in the absence of pUTI89
implying their expression in wild type UTI89. It is clear that all of these genes are not
transcriptional regulators and may participate in in vivo infection.
We have demonstrated that pUTI89 is involved in the early aspect of UPEC
pathogenesis, such as binding, invasion or survival. The reduction of luminal population
at 6 hours post-infection as revealed by gentamicin protection assay and confocal
microscopy (Figures 5-6) suggest the involvement of pUTI89 in extracellular survival
during UPEC infection. There may be more to pUTI89 than just extracellular survival
since upon quantification of IBCs there was a significant reduction in the number
observed at 6 hours post-infection. Interestingly, while there is a reduction in IBC
number there is still chronic-active infection at 2 weeks. This would suggest that while

81

there are less IBCs the threshold of IBC formation has still been reached to enable
UTI89 to establish a foothold within the bladder and carry out long term infections.
Selective deletions of operons on pUTI89 revealed that the cjr operon may be
playing a role in infection. CjrC is homologous to a putative outer member siderophore
receptor and a fur box is located upstream of this operon suggesting it is regulated by
iron. Iron is an essential cofactor of many enzymes and bacteria require iron
concentrations at around 10-7 to 10-5 M to achieve optimal growth. The level of free iron
is estimated to be very low in the environment and biological fluids (10-18 M) (2). Only
bacteria that have strategies to acquire iron sequestered by the host can survive in
specific niches and consequently cause infections. Thus, iron acquisition for the survival
of UPEC within the urinary tract is extremely important (50, 61, 65). A recent study
evaluating the genomic composition specific to UPEC identified that UPEC contain 3-5
iron acquisition systems whereas fecal/commensal isolates contain 2-3 iron-related
operons suggesting that the redundancy in these systems may provide a competitive
advantage to UPEC within the urinary tract (33). A more recent study comparing
siderophore production between urinary and rectal isolates within individual patients
revealed that while all strains produced enterobactin, strong preferential expression of
yersiniabactin and salmochelin were observed among urinary strains (21). Reigstad et
al. showed that in the absence of chuA there is a significant decrease in IBC size but not
an elimination of IBCs (50). This result suggests that the redundancy of the iron
acquisition systems allows alternate systems to compensate for the lack of chuA
highlighting the importance of iron sequestration and transport within the urinary tract.
This is why deletion of one system will not completely eliminate infection capabilities as
seen with the deletion of the cjr operon. Work is currently underway to complement and
characterize this operon to understand its role in the early stage of infection. Perhaps it
is expressed early in infection whereas other iron acquisition systems are expressed
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later, potentially explaining the delayed growth in vivo in the absence of the Cjr proteins
until more systems are turned on.
Strong selection for UTI89 to maintain pUTI89 provides a compelling argument
for its importance in pathogenesis. Large plasmids impose a significant metabolic
burden on the bacteria and, in the absence of selection, may be lost from the host in
spite of plasmid maintenance systems that are assumed to prevent loss (62). pUTI89
has two prominent features, the presence of the tra operon involved in DNA transfer and
the presence of virulence genes found on other pathogenic plasmids, in other
organisms. Plasmid transfer via conjugation is an important mechanism for DNA
exchange or dissemination and accelerates the evolution of bacterial pathotypes (19).
The presence of the tra operon allows pUTI89 to be maintained and disseminated to
other UPEC and Enterobacteriaceae. In addition, the large virulence plasmid serves as
a genetic hot spot where extrachromosomal DNA can be freely acquired without
disrupting essential genes. It is likely that free exchange of DNA between the symbiotic
gut bacteria resulted in the diverse genomes seen in UPEC isolates. The presence of
the cjr operon on pUTI89 as well as on a virulence plasmid in EIEC supports the stated
hypothesis. The plasmid, pUTI89, serves as a genetic hotspot where virulence genes
are acquired and lost without selection in the gut. Only upon invasion and colonization
of the bladder are genes, which increase fitness, selected for. In the example of the cjr
operon the fitness of the UTI89 was increased and thus selected for. This is supported
by nearly 50% of isolates tested showing presence of this operon. This percentage is
surprisingly high due to the redundancy in iron acquisition operons.
The presence of pUTI89-like plasmids in UPEC strains could serve multiple
roles, allowing for efficient incorporation of foreign DNA without disruption of essential
genes. Plasmid stability genes ensure newly acquired genes are replicated without the
strong selective pressure of a bladder environment, while a functional tra operon allows
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for conjugation and dissemination of these genes to other UPEC and
Enterobacteriaceae. All of these activities provide UPEC with a broad arsenal of
proteins, some of which are necessary for colonization of the bladder. Due to the lack of
constant selective pressure, UPEC strains, early in evolution, devised multiple strategies
for colonization of the bladder, resulting in the diverse genomes of UPEC strains seen
today. This process more than likely occurred slowly with virulence plasmids necessary
for bladder survival being lost in the gut, and virulence genes incorporated in the
genome resulting in genomic instability. The acquisition of a large virulence plasmid with
maintenance and stability machinery solved both of these problems. Incorporation of
extrachromosomal DNA did not disrupt essential cellular pathways and a stable plasmid
allowed genes, which increased fitness in the bladder to be passed on in the bladder or
gut. This constant evolution has allowed UPEC to acquire multiple and redundant
mechanisms to adapt and thrive in the urinary tract environment explaining why despite
the well-studied nature of UPEC, especially in regards to virulence factors and
colonization strategies, no single feature accurately defines an isolate as UPEC. The
difficulty of this was evident in a study that determined that half of all UPEC isolates
contain none or only one of the urovirulence determinants to date (36). Instead, UPEC
contains a mosaic genome that is the result of genomic acquisition, loss and
rearrangement.
It remains unclear as to when, evolutionarily, pUTI89 was acquired, and to what
extent it helped shape the landscape of the UTI89 genome by acting as a midway point
for virulence genes incorporation into the genome. We discovered that the presence of
pUTI89 increases the ability of UTI89 to invade and colonize the bladder. Further
investigations will examine how less virulent strains without pUTI89 are influenced by its
addition. Examining a gain of function in less virulent strains could help elucidate at what
stage(s) pUTI89 virulence genes function. Additionally, characterizing plasmids and
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genes from different UPEC will facilitate our understanding of the mechanism of
virulence and the evolution of UPEC, and the design of efficacious strategies to fight
UTI.
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Tables and Figures
Table 1. Primers for plasmid PCR

Gene
scsD
senB
guaA
transposase

Primer sequence (5'-3')

Primer
name

CATACGCTGGACGGGGAAAC

A-forward

GACGCTCTCCCCTTCCGACT

A-reverse

GCAGATTCGCGTTTTGAGCA

B-forward

CGGATCTTTCAACGGGATGG

B-reverse

CCCGTAGTGGGGGTGTTGAG

C-forward

GCCCCTGCCACCTACCTTCT

C-reverse

GCTTCGGGAACGCTGTAACG

D-forward

Size of
product
(bp)

coordinates

143

+4384

302

+25705

375

+49081

414

+60645

CGCCTGGTGGTGAAGGAAAG E-forward

236

+64115

GACCACCTCCCGCAGAACAC
UP100/UP101

531

+75326

111

+89649

190

+106531

-26006
-49456

traU
traI

-61059

E-reverse

TGGGGGCTGAAAACCAGAGA F-forward
ACCGAAGGCACGAACTGCAT

F-reverse

TTCCTTCTCGCCGGTCATGT

G-forward

CCAGCGAGAGCGGGAAAATA

G-reverse

GCGATGCGGTCAGTGTTCTG

H-forward

GGACAGCCGTTCATCCTGCT

H-reverse

1

GenBank accession no. - NC_007941
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1

-4527

AGAAGGCTGCGGTGCTGAAG D-reverse
ycfA

Primer

-64351
-75857
-89760
-106721

Table 2. Evidence of pUTI89 in a panel of clinical isolates.
scsD

senB

guaA

transposase

ycfA

A

B

C

D

E

Strain

UP100/
UP101
F

traU

traI

G

H

IBCs
present
(hrs PI)

ASB1

-

-

-

-

-

-

-

-

6,24

ASB2

+

+

+

+

+

+

+

+

6,24

ASB3

+

+

+

+

+

+

+

+

6,24

ASB4

+

+

+

+

+

+

+

+

6

ASB5

-

-

-

-

-

-

-

-

24(rare)

acute1

-

-

-

-

+

+

+

-

12(rare)

acute2

-

-

-

-

-

-

-

-

6 (rare)

acute3

-

-

-

-

-

-

-

-

3(rare)

acute4

-

-

-

-

-

-

-

-

-

rUTI1

-

-

-

-

-

-

-

-

-

rUTI2

-

-

-

-

+

+

-

-

6

rUTI3

-

+

-

-

+

+

-

-

6(few)

rUTI4

+

+

+

+

+

+

+

+

24

rUTI5

-

+

-

-

+

+

+

+

3

pyelo1

-

-

+

-

+

+

-

-

6

pyelo2

+

+

-

+

-

+

-

-

6

pyelo3

-

+

-

+

+

+

+

+

-

pyelo4

-

-

-

-

+

+

+

-

6
3,6,24

UTI89
%
prevalence

+

+

+

+

+

+

+

+

31.6

47.4

31.6

36.8

63.2

68.4

47.4

36.8

scsD
senB
guaA

secreted copper-sensitivity suppressor D
enterotoxin TieB protein
hypothetical protein
transposase transposase for insertion sequence element IS21
ycfA
hypothetical protein
UP100/101 hypothetical proteins
traU
F pilus assembly protein
traI
DNA helicase I

Table 3: Directed knock-outs on pUTI89.
Gene
Annotation

Size

Gene Name

Function

UP007-UP014

8.4 kb

scsC/D

secreted copper-sensitivity
suppressor, Yersinia export

UP015-UP017

1.6 kb

UP028-UP030

4.7 kb

UP042-UP046

6.8 kb

UP062-UP063

1.4 kb

stbA/B

stable plasmid inheritance
proteins

UP095

0.4 kb

psiB

regulator of SOS induction

UP145

0.2 kb

hmo

putative regulator

ABC transporter, ATP-binding
protein, putative thioredoxinfamily protein
cjrB/C, senB

colicin Js sensitivity protein
and OM receptor, enterotoxin
hemin receptor, serinethreonine protein kinase
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Figure 1: pUTI89 diagram. pUTI89 can be divided into two major portions. One half
contains genes involved in conjugative DNA transfer (in blue) and the other half contains
genes present on plasmids from pathogenic E. coli and other pathogenic bacteria, as
well as genes encoded chromosomally in other bacteria (in red). Indicated next to each
region is the gene name, organism it is also found in and/or operon function.
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Figure 2: Confirmation of pUTI89 curing by PCR. pUTI89 was cured from UTI89 by
ethidium bromide treatment. Plasmid purification followed by PCR with primer pairs A-H
was used to identify plasmid-less strains. UTI89 with intact pUTI89 (top panel) reveals a
banding pattern as observed with very little genomic contamination as evidenced by the
ompA band. PCR of the plasmid-cured strain (bottom panel) revealed no positive PCR
reaction confirming the elimination of pUTI89.
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Figure 3: In vitro characteristics of pUTI89. Plasmid-cured UTI89 behaved identically
to UTI89. (A) Growth of UTI89 and DpUTI89 were equivalent in LB broth (solid line) and
M9 + 10 µg/ml niacin broth (dashed line). (B) Type 1 expression based on FimH and
FimA immunoblots was equivalent in both strains. Densitometry analysis quantified the
bands observed. (C) Biofilm formation under type 1-dependent and curli-dependent
conditions were indistinguishable in UTI89 versus ΔpUTI89. (D) Both UTI89 and
ΔpUTI89 exhibited equal mannose-sensitive HA titers, indicating equal expression levels
and functionality of type 1 pili.
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Figure 4: In vivo timecourse of UTI89 and ΔpUTI89. (A) ΔpUTI89 tested in our mouse
model of UTI revealed a significant decrease in bladder colonization at 6 h post-infection
compared to wild type UIT89 (p<0.0001 by Mann Whitney). However by 24 h postinfection and beyond, colonization was equivalent in both strains. (B) Additional clones
of ΔpUTI89 confirmed that the defect was due to the loss of pUTI89 and not additional
mutations within the genome.
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Figure 5: Colonization and invasion of UTI89 versus ΔpUTI89. One and 6 h
gentamicin protection assays revealed a significant decrease in both the extracellular
(luminal) and intracellular population for ΔpUTI89. A more significant decrease in
luminal colonization with ΔpUTI89 was observed at 6 h post-infection (p<0.001).
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Figure 6: Confocal microscopy and LacZ staining for IBCs. Mice were infected with
UTI89 or ΔpUTI89 and bladder were harvest at 6 h post-infection, splayed and stained
with WGA (green) and SYTO61 (red). Confocal microscopy revealed IBC formation in
bladder infected with either isolate. However, extensive filamentation was only observed
in wild-type UTI89. IBCs were quantitated by LacZ staining revealing a significant defect
in the number of IBCs observed in ΔpUTI89-infected bladders.
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107
106

*

105

***

104
103
102

*p<0.05

***p<0.001

Figure 7: Identification of virulence factors on pUTI89. Regions on pUTI89 were
deleted using the lamda red recombinase system. Deletions encompassing UP028-30
and UP062-63 (open circles) resulted in a significant reduction in bacterial load at 6 h
post-infection. UP062-63 encodes the stability operon and UP028-30 encodes the cjr
operon.
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Abstract
Background. Escherichia coli strains adhere to the normally sterile human uroepithelium
using type 1 pili, that are long, hairy surface organelles exposing a mannose-binding
FimH adhesin at the tip. A small percentage of adhered bacteria can successfully invade
bladder cells, presumably via pathways mediated by the high-mannosylated uroplakin-Ia
and α3β1 integrins found throughout the uroepithelium. Invaded bacteria replicate and
mature into dense, biofilm-like inclusions in preparation of fluxing and of infection of
neighboring cells, being the major cause of the troublesome recurrent urinary tract
infections.
Methodology/Principal Findings. We demonstrate that α-D-mannose based inhibitors of
FimH not only block bacterial adhesion on uroepithelial cells but also antagonize
invasion and biofilm formation. Heptyl α-D-mannose prevents binding of type 1-piliated
E. coli to the human bladder cell line 5637 and reduces both adhesion and invasion of
the UTI89 cystitis isolate instilled in mouse bladder via catheterization. Heptyl α-Dmannose also specifically inhibited biofilm formation at micromolar concentrations. The
structural basis of the great inhibitory potential of alkyl and aryl α-D-mannosides was
elucidated in the crystal structure of the FimH receptor-binding domain in complex with
oligomannose-3. FimH interacts with Manα1,3Manβ1,4GlcNAcβ1,4GlcNAc in an
extended binding site. The interactions along the α1,3 glycosidic bond and the first β1,4
linkage to the chitobiose unit are conserved with those of FimH with butyl α-D-mannose.
The strong stacking of the central mannose with the aromatic ring of Tyr48 is congruent
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with the high affinity found for synthetic inhibitors in which this mannose is substituted for
by an aromatic group.
Conclusions/Significance. The potential of ligand-based design of antagonists of urinary
tract infections is ruled by the structural mimicry of natural epitopes and extends into
blocking of bacterial invasion, intracellular growth and capacity to fluxing and of
recurrence of the infection.

Introduction
Pili and fimbriae on the bacterial cell are virulence factors that mediate
adhesion of pathogenic bacteria to host cell receptors [1]. Urinary tract infections (UTIs)
in humans are frequently caused by uropathogenic Escherichia coli (UPEC) expressing
type 1 pili. The FimH adhesin at the tip of type 1 pili recognizes terminal mannose units
of uroplakin Ia (UPIa), a membrane glycoprotein that is abundantly expressed on
superficial epithelial umbrella cells of the urinary tract [2]. Bacterial attachment
stimulates the innate host immune system in a Toll-like receptor 4 - dependent manner
[3]. This induces the secretion of cytokines by the urothelial cells and recruitment of
neutrophils to the mucosal surfaces for the elimination of the bacteria [4]. A
subpopulation of UPEC escapes this eradication mechanism of the host by invading into
the large superficial epithelial cells in a type 1 pili-dependent mechanism [5,6]. However,
hosts with a robust and timely innate immune response manage to get rid of this
bacterial intracellular nesting by exfoliation of the large, superficial umbrella cells and
discharge of these infected cells with the urine [7,8].
Bacteria within the cytosol of umbrella cells replicate and within hours develop
into tightly packed, biofilm-like intracellular bacterial communities (IBCs) [9]. Upon
maturation of the IBCs, the bacteria disperse from the IBCs and re-emerge in the
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bladder lumen in long, filamentous shapes that helps them to evade neutrophil
phagocytosis [10,11]. They can then reinvade neighbouring epithelial cells to reestablish infection. As such, even after the acute infection is resolved, bacteria can
remain within the bladder for many days to weeks, regardless of standard antibiotic
treatments, and can be implicated in recurrent urinary tract infection (rUTI) [12–14]. Most
UPEC isolates from women with acute or rUTIs, asymptomatic bacteriuria and
pyelonepritis replicate in IBCs in C3H/HeN mice, although IBCs from isolates associated
with acute UTIs remained significantly smaller [15]. UPEC that are unable to express
type 1 pili are dramatically attenuated in their virulence, refrain from intracellular
aggregation and maturation into an IBC and therefore fail to flux back out of the cells
[16].
A different, intracellular path of the bacteria is commenced through the
endocytosis in the fusiform or discoidal vesicles of superficial umbrella cells [17]. The
bacteria make use of the vesicle trafficking in the umbrella cells to escape elimination
during voiding. Endocytosis in the umbrella cells is coupled to exocytosis of secretory
lysosomes [18]. Exocytosis helps to enlarge the apical membrane during bladder filling
under hydrostatic pressure. High intracellular cAMP and calcium levels enhance
exocytosis of the UPECs back into the lumen of the bladder [17]. It is unclear whether
the bacteria are fit enough following their stay in the umbrella cell lysosomes to start
another invasive cycle [19]. The uroepithelial cell layer underlying the umbrella cells can
also be subject to invading bacteria, possibly upon the incomplete elimination of type 1
piliated E. coli during exfoliation of the superficial, highly differentiated umbrella cells [8].
In those immature cells, the bacteria do not reside in the cytosol but rather are
sequestered in late endosomes or lysosomes where they remain in a non-replicating
state [20]. Those quiescent intracellular reservoirs (QIRs) persist for months even in the
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face of antibiotics and the host defense, that mainly attack growing bacteria [8,12,13].
Only upon differentiation of the immature host cells and rearrangement of the
cytoskeleton that tends to inhibit the intracellular replication, the QIRs resolve to develop
intracellular inclusions similar to experimental IBCs [20]. Host cytokeratin intermediate
filaments are closely associated with and probably help with biofilm formation within
these pod-shaped inclusions [20].
The attachment of adhesins on the bacterial cell surface to definite
carbohydrates on the host tissue surface is considered to be an initial and critical step in
pathogenesis. Antibodies that specifically block the binding of FimH to its natural
receptor also prevent infection [21]. Revealing the interaction between FimH and its
structural receptor would allow the design of carbohydrate-based anti-adhesives [22].
The preference of the fimbrial adhesin for structures found in mannosylated N-linked
glycan chains on eukaryotic cell glycoproteins suggested that these structures would
serve as the receptors for type 1-piliated E. coli strains [23,24]. The group of Sharon
described in the early eighties the strong inhibitory potency of Manα1,3Manβ1,4GlcNAc
on the agglutination of red blood cells and yeast cells and suggested that this
trisaccharide would best fit the FimH binding pocket [25]. More recently, equilibrium
dissociation constants (Kd) derived from surface plasmon resonance (SPR) solution
affinity measurements or from the displacement of tritiated mannose from the receptorbinding domain (RBD) of FimH, consistently approved the strong preference of FimH for
oligomannosides exposing Manα1,3Man at the non-reducing end of the D1 arm of highmannose glycans [26]. Mannotriose and mannopentaose do not exhibit a significantly
higher affinity than their linear moiety Manα1,3Man (Kd ~ 200 nM). Conversely,
oligomannose-3 and oligomannose-5, carrying the β1,4-linked chitobiose as an anchor
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to an asparagine in the Asn-X-Ser/Thr motif of N-linked glycoproteins, have another 10fold increase in affinity for the FimH RBD (Kd ~ 20 nM) over Manα1,3Man [26].
Regardless of the well-characterized fine-specificity of FimH, FimH variant strains
have also been categorized into those with a high affinity for D-mannose, predominantly
represented by UPECs, versus fecal, commensal E. coli strains that only displayed an
intermediate affinity for mannotriose (Manα1,6(Manα1,3)Man) [27]. These different
bacterial binding characteristics under static binding conditions had been attributed to
variation in the FimH RBD. Nonetheless, the isolated RBDs of all FimH variants, except
for the enterohaemoraghic isolates carrying the Asn135Lys mutation in their pocket, do
not differ in their affinities for high-mannose glycans [26,28]. Isolated RBDs or fimbrial tip
adhesin that are out of the context of their own fimbriae have recently been suggested to
always occur in a high-affinity conformation [29]. On the other hand, when present within
their endogenous pilus, the adhesin can undergo a transition to the high-affinity
conformation under shear force enhanced adhesion, and it is this phenomenom where
amino acid variation in FimH can give rise to ten-fold differences in bacterial adhesion.
Shear enhanced bacterial adhesion was most pronounced to layers coated with the
weakly binding mannose than to a surface coated with the more specific mannotriose
and involved a minimum of shear for the fecal FimH variant E. coli F18 strain [30].
However, no such shear threshold was observed for type 1-piliated E. coli binding to
mannotriose or for a P-piliated pyelonephritis strain binding to Galα1,4Gal [31]. Thus
changes in the receptor structure, that affect the fine-specificity of FimH, can more
dramatically than FimH variation impact on the colonization behaviour of type 1-piliated
bacteria under flow conditions. In this context, the relevance of a shear threshold
observed for single-exposed mannose is feeble given that mannose, recognized by
FimH at the termini of naturally occurring glycans, is almost invariably involved in a
glycosidic linkage.
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FimH has been reported to bind to several glycosylation-dependent receptors in
the urinary tract, among which are uroplakin Ia (UPIa) [2], Tamm-Horsfall glycoprotein
(THP) [32] and very recently β1 and α3 integrins [33]. Many pathogens gain entry into
target host cells by binding integrins either directly or indirectly via the recognition of
extracellular matrix proteins. UPIa is an integral membrane protein of the large
superficial epithelial cells of the bladder located as a FimH receptor on the six inner
domains of the uroepithelial plaque particle [34]. It belongs to the superfamily of
tetraspanins [35] that are often found to complex with β1 integrin receptors [36]. Mouse
UPIa4 presents high-mannose glycans on Asn169 with a heterogeneity ranging from
Man6GlcNAc2 to Man9GlcNAc2 [37]. The same high-mannose type glycans decorate β1
and α3 integrins [38]. None of these structures expose Manα1,3Manβ1,4GlcNAc,
terminally at the non-reducing end of the glycan branch. Perhaps this is not so striking,
as glycoproteins bearing Man5GlcNAc2 glycans are degraded preferentially [39]. The
only isomer of oligomannose-6 encountered so far on uroplakins covers
Manα1,3Manβ1,4GlcNAc with an extra α1,2-linked D-mannose [37], thus masking the
epitope with high affinity for FimH [40]. THP is secreted in the urine as a natural inhibitor
of type 1-mediated bacterial adhesion through its high-mannosylated Asn251 residue
[41].
UTIs are one of the most prevalent infections for humans. Almost half of all
women will experience at least one UTI in their lifetime. More problematic is the
evolution of acute UTIs into chronic infections, with recurrence of the symptoms two or
more times within months of a primary infection [42]. Modifications in the glycosylation of
FimH receptor proteins on eukaryotic cells may alter the host sensitivity to UTI causing
strains. For example, diabetic patients and elderly women show increased bladder cell
binding by FimH [43] and this is further correlated with an increased frequency of
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asymptomatic bacteriuria [44]. Free Manα1,3Manβ1,4GlcNAc oligosaccharide can be
isolated in abnormally high amounts from urine of patients with mannosidosis [45]. For
mannosidosis patients the abundance of this high-affinity FimH epitope in the urine may
act as a natural inhibitor for urinary tract infections, although a decreased risk of UTIs in
patients with α-mannosidase deficiency has not been described. The high frequency of
recurrent infections and the increasing antibiotic resistances of UPECs [46] highlight the
need for alternative treatments using carbohydrate-derived molecules as potential antiadhesives. Their non-bactericidal effect makes the selection of strains resistant to such
agents much more unlikely than those resistant to antibiotics [22].
Biochemical and docking studies predicted that the enhanced binding of
Manα1,3Manβ1,4GlcNAc is accomplished by interactions of the central mannose and
GlcNAc in the tyrosine gate extending from the FimH mannose-binding pocket [26,47].
To gain insight into the selectivity of FimH for this trisaccharide epitope, we cocrystallized FimH with the trisaccharide-presenting oligomannose-3 and investigated the
importance of the glycosidic linkage of Manα1,3Man with N-acetyl glucosamine
(GlcNAc) of the chitobiose unit of N-linked glycans. The FimH RBD shows high affinities
for alkyl α-D-mannosides, with affinities up to a Kd of 5 nM for heptyl α-D-mannose (HM)
[47]. We set out to explore the inhibitory capacity of HM for lower UTIs caused by type 1piliated UPECs in mice. We find that alkyl α-D-mannosides and other synthetic inhibitors
of FimH confirm binding properties of the high-mannose epitope. The alkyl chain of butyl
α-D-mannose, bound to FimH in two previously determined co-crystal structures, follows
the trail of the α1,3 linkage to the central mannose and the first β1,4 glycosidic linkage to
the chitobiose. The potential of ligand-based design of antagonists of UTIs appears to be
ruled by structural mimicry of specific spots on mannosylated receptors. This anti-
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adhesive ability extends into blocking of bacterial invasion, intracellular growth and
capacity to fluxing and recurrence of the infection.

Materials and methods
Sugar compounds
Oligomannose-3 was custom-synthesized at the Zelinsky Institute of Organic
Chemistry (Russia). Methyl α-D-mannose and D-mannose were purchased from SigmaAldrich. Manα1,3ManβOMe (S. Oscarson, to be communicated) and HM [47] have been
synthesized. Affinity measurements using surface plasmon resonance (SPR) were
performed as described [26]. Briefly, the equilibrium dissociation constants of mannose
derivatives for FimH were determined using competition in solution for FimH binding of
the sugars with an immobilized Fab fragment from the monoclonal antibody 1C10.

Purification of FimH
The receptor-binding domain (RBD) of the FimH protein (residues 1 till 158 of
UPEC J96) was expressed from plasmid pMMB91 transformed into E. coli C43 (DE3)
cells. C43 (DE3) (pMMB91) E. coli cells were grown in minimal medium containing 40
µg/ml of all the amino acids, 0.4% glucose, 2 µg/ml biotin, 2 µg/ml thiamine, 2 mM MgCl2
and 25µg/ml kanamycin at 37°C. At OD600nm = 0,6 the bacteria cells were induced with
1mM IPTG. After overnight incubation at 37°C, cells were collected and the periplasmic
content was extracted. The receptor-binding domain of FimH was purified by dialysing it
4h at 4°C against 20 mM Na formate pH 4 and loading it on a Mono S HR column
(Pharmacia Biotech). The protein was eluted with 20 mM Na formate, 1M NaCl pH 4.
Fractions containing the FimH receptor-binding domain were pooled and dialyzed
overnight at 4°C against 20 mM Hepes pH 8 and 150 mM NaCl, before crystallization.
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Co-crystallization of the FimH RBD with oligomannose-3
Crystallization conditions were screened at the high-throughput crystallization
facility of the EMBL in Hamburg. Crystals grew at 292K, using the vapor diffusion
method with sitting drops composed of 300 nL FimH-oligomannose-3 solution FimH at
13.6 mg/ml mixed with 2 mM oligomannose-3 in a 2:1 molar ratio and 300 nL precipitant
(Figure S1), equilibrated against a 100 µl reservoir of 1.0 M lithium sulfate, 0.1 M TrisHCl at pH 8.5, 0.01 M nickel (II) chloride. To optimize these conditions, hanging drops
were set up consisting of 1 µl FimH at 13.6 mg/ml mixed with 2 mM oligomannose-3 in a
2:1 molar ratio and 1 µl of the precipitant solution, equilibrated against 500 µl of the
same precipitant complemented with 3% glycerol. Glycerol has a beneficial effect on
crystallization by preventing showering of the protein prior to nucleation, allowing a more
controlled crystal nucleation and growth process.

Structure determination and refinement
X-ray data have been collected to 2 Ǻ resolution at the European Molecular
Biology Laboratory (EMBL) beam line X12 at the Deutsches Elektronen Synchrotron
(DESY, Hamburg, Germany). The crystal was flash cooled to 100K in the precipitant
solution complemented with 30% isopropanol. All data were processed with DENZO and
SCALEPACK from the HKL suite [62]. TRUNCATE from the CCP4 suite was used to
calculate structure-factor amplitudes from the intensities. The structure has been solved
by molecular replacement with MolRep [63] using the structure of the receptor-binding
domain of FimH as the search model (PDB entry code 1UWF) [47]. The model was
refined using rigid body refinement and the maximum likelihood function of CNS version
1.1 [64] and Refmac 5.2.0019 [65], with 5% of the data retained for cross-validation
purposes. The initial molecular replacement solution was submitted to simulated
annealing refinement. Successive positional and individual temperature factor
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refinements were alternated with manual model adjustment using TURBO-FRODO [66]
and COOT [67] graphics.

Structure analysis
A Ramachandran plot was drawn using Molprobity [68]. Baverage from the CCP4
suite [69] defined the average B-factors of the main chain atoms of the protein and of the
water molecules. The packing contacts were analyzed using the CCP4 program
CONTACT [69], using an intermolecular cut-off distance of 4 Å. Potential hydrogen
bonds in the FimH-oligomannose-3 complex were identified using HBPLUS [70].
Subsequently, the predicted interactions were carefully checked with Coot [67]. Pictures
have been generated using Pymol version 0.99.

Bacterial binding in vitro to a human urothelial cell line
The E. coli strains AAEC185(pUT2002)(pMMB66) and AAEC185(pUT2002) have
been used in bladder cell binding experiments. AAEC185 E. coli cells are fim-null
mutants [72]. The pUT2002 plasmid carries the complete fim gene cluster with the
deletion of fimH, resulting in FimH-deficient type 1 pili [72]. The fimH gene of J96 E. coli is
located on the pMMB66 plasmid [53]. Strains AAEC185(pUT2002) and
AAEC185(pUT2002)(pMMB66) were grown statically in 100 ml LB for 48 hours at 37°C
to induce pili production. The bacterial cells were harvested under sterile condition by
centrifugation at 3500 rpm for 20 min (Megafuse 1.0R, Heraeus instruments) and
washed two times in phosphate buffered saline (PBS). The expression of type 1 pili was
always checked using haemagglutination [26] prior to the infection of the bladder cells.
Human bladder epithelial cell line 5637 (American Type Culture Collection HTB-9) was
seeded in 12-well plates and cultured in Roswell Park Memorial Institute (RPMI) 1640
medium, supplemented with 10% fetal calf serum (FCS). The cells were maintained 2-4
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days at 37°C in a humidified atmosphere containing 5% CO2 for confluent growth. The
plate was washed 5 times with PBS complemented with 0.5 mM MgCl2 and 1 mM CaCl2
directly before use. Each well was incubated with 0.5 ml of 106 to 107 colony forming
units (cfu) per ml in PBS. The plates were slowly shaken for 15 minutes to allow binding
of the bacteria to the tissue cells. Five washes were performed with PBS to remove
unbound bacteria. Bladder cells were lysed by adding 0.4 ml trypsin/EDTA for 10-15
minutes. Finally, the lysis was stopped by the addition of 10% FCS, when all cells were
released from the plate. The input colony forming units (cfu) and the output cfu in each
well were determined by 10-fold serial dilutions (1, 10-2, 10-3, 10-4, 10-5) in PBS and
spotting 20 µl drops on LB-agar with the appropriate antibiotics. Inhibition of bladder cell
binding was performed simultaneously as binding on the same 12-well plate, but with the
bacterial inoculum pre-incubated with different concentrations of mannose or HM.

In vivo bladder binding
All studies using mice were approved by the Animal Studies Committee of
Washington University. Eight-week-old female C3H/HeN mice (NCI) were anesthetized
and inoculated with a 50 µl suspension of ~107 UTI89 (in PBS or sugar solution) via
transurethral catheterization [12]. Prior to inoculation, the inoculum was incubated for 20
min at 37oC with one of the following: 1 M methyl α-D-mannose, 0.5 mM heptyl α-Dmannose, 5 mM heptyl α-D-mannose. Six hours after inoculation, animals were
euthanized, and their bladders harvested and homogenized in 1 mL of 0.025% Triton X100/PBS. Bacterial titers were determined by plating serial dilutions of the homogenates
on LB agar plates. Duplicate experiments of 5 mice each were performed.

Gentamicin protection assay
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UTI89 was grown overnight in LB and resuspended in PBS to an inoculum of
~107 cfu in 50µl. The inoculum was then incubated for 20 min at 37oC with 5 mM methyl
α-D-mannose, 0.5 mM heptyl α-D-mannose, 5 mM heptyl α-D-mannose, or PBS. After
incubation, 6-7 week old C3H/HeN mice were inoculated via transurethral catheterization
[12]. An ex vivo gentamicin protection assay was performed as previously described
[11]. Briefly, at 1 hour post-infection, the mice were sacrificed and bladders were
dissected aseptically. Each bladder was washed 3 times with sterile PBS. The washes
were collected and plated to obtain the luminal fraction of bacteria. The bladders were
then treated with 100 µg/ml gentamicin for 90 min at 37oC. After treatment, the
supernatant was removed and titered to ensure efficient killing of extracellular bacteria.
The bladders were washed twice more to remove residual gentamicin and homogenized
in 1 mL 0.025% triton X-100/PBS and bacterial counts were determined by plating serial
dilutions on LB agar plates.

Biofilm assay
UTI89 was grown overnight in LB broth at 37oC with shaking and diluted 1:1000
in LB or LB with varying amounts of methyl α-D-mannose or heptyl α-D-mannose. 96well round bottom polyvinyl chloride plates (Falcon) were sterilized in tissue culture hood
under UV irradiation for at least 30 minutes. 100 µl of the solutions were then added to
the sterile PVC plate, 6 wells per variable. LB without bacteria was added to 6 wells as a
blank. The plate was incubated for 48 hours at room temperature, washed 3 times in
PBS and allowed to dry. 125 µl of 1% crystal violet solution was added to each well for
10 minutes. After staining, the plates were washed again in PBS 3 times and allowed to
dry. The crystal violet was solubilized with 150 µl of 33% acetic acid, 100 µl was
transferred to a flat bottom plate and absorbance was read at 600 nm.

116

Protein Data Bank accession number
The coordinates and the structure factors have been submitted to the Protein
Data Bank with accession codes 2vco and r2vcosf respectively.

Results
The chitobiose anchor to Asn-glycosylated FimH receptors is important for specificity
Previous epitope mapping on high-mannose glycan receptors revealed the
highest affinity of the FimH RBD for oligomannose-3 and oligomannose-5 [26]. Both
these oligomannosides expose Manα1,3Manβ1,4GlcNAc at the non-reducing end of the
D1 branch and have an increased affinity for FimH over mannotriose and
mannopentaose that lack the chitobiose unit (Figure 1). The increased affinity was
thought to be due partially to the β-anomeric linkage to the chitobiose
GlcNAcβ1,4GlcNAc. The binding constants of the FimH RBD from the J96 cystitis strain
for Manα1,3ManβOMe and for the anomeric mixture of Manα1,3Man have been
determined using SPR, to investigate the contribution of the glycosidic linkage. This
resulted in affinities of Kd = 112 nM and 281 nM respectively, showing that FimH selects
out the β-anomeric configuration on Man3. It also indicated that the presence of the βlinkage alone is not sufficient to explain the more significant increase in affinity between
on the one hand mannotriose or mannopentaose, and on the other hand oligomannose3 and oligomannose-5 [26]. Thus the chitobiose unit that bridges the mannosides to the
asparagine in the Asn-X-Ser/Thr motif of the glycoprotein receptor contributes more
significantly to the interaction with FimH.

Crystal structure of the FimH receptor-binding domain in complex with oligomannose-3
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Oligomannose-3 has been crystallized in complex with the FimH RBD. This
oligosaccharide exposes the substructure Manα1,3Manβ1,4GlcNAc terminally on its D1
branch (Figure 1). Therefore it is ideally suited to reveal the structural basis of its highaffinity interaction with FimH. Initial crystals have been grown by equilibration through
vapor diffusion and the crystallization condition was optimized through the addition of 3%
glycerol (Figure S1).
The solution of the molecular replacement contains two FimH RBDs per
asymmetric unit in the P3121 space group (Figure 2, Table S1). Upon the first atomic
refinement a clearly interpretable electron density for Manα1,3Manβ1,4GlcNAc was
visible, equally well in both RBDs. Refinement against the crystallographic data with a
2.1 Å high-resolution cut-off led to good protein geometry and oligosaccharide
conformation determination. The root mean square deviation between the two RBDs is
0.56 Å for all main chain atoms. The torsion angles of the Manβ1,4GlcNAc and
Manα1,3Man glycosidic bonds in oligomannose-3 resemble within a few degrees to
those observed in the crystal structure of the Manα1,3Manβ1,4GlcNAc trisaccharide
[48]. Although the ψ torsion angle of Manα1,3Man deviates from the average minimum
energy modelled for these glycans for all distinct conformers of glycosidic linkages found
in either N- or O-linked glycans [49], it falls well within the range of allowed minimum
energy conformations for φ and ψ glycosidic torsion angles [50].
Oligomannose-3 conforms into a relatively planar structure that inserts almost like
a sheet into the tyrosine gate (Figures 2 and 3A), with an angle at both ends. The same
extensive hydrogen bonding, hydrophobic contacts and van der Waals interactions are
achieved by binding of oligomannose-3 in both FimH RBDs of the crystal structure
(Figure 2). The solvent accessible surface area buried through the binding of
oligomannose-3 leads to a reduction of solvent accessible surface area of 312.1 ± 1.3 Å2
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for oligomannose-3 and 462.2 ± 6,6 Å2 for FimH both, using the CCP4 program
NACCESS. Between the two crystallographically-independent FimH RBDs 537.5 ± 6.75
Å2 is excluded from the solvent. This agrees well with the average areas excluded from
the solvent by pairwise interactions (388.1 ± 3 Å2 between FimH and oligomannose-3
and 534 Å2 between the two FimH RBDs) calculated by MSDpisa version v1.14 [51].
The non-reducing end Man4 anchors into the mannose-binding pocket, whereas
the reducing end GlcNAc1 folds over Thr51. Very specific interactions with the tyrosine
gate occur in the mannose-binding pocket itself and all along Manα1,3Manβ1,4GlcNAc
via the α1,3 and the first β1,4 glycosidic linkages. FimH is not directly recognizing the
second non-reducing end mannose, Man4’ (Figure 3). Man4’ and GlcNAc1, the two
saccharides that exit from the receptor-binding site, display a larger flexibility in an
extensively hydrated environment, resulting in less-well defined electron density and
higher temperature factors. Crystal packing contacts with Phe142 and Ile13 of a
symmetry-related RBD with Man4’ bound to the second RBD (forest-green molecule in
Figure 2) stabilize some of these waters, whereas Man4’ bound to the first RBD is fully
solvent exposed.
For the first time in a FimH structure [47,52,53], a nickel ion was observed,
interlinked with the mannose binding pocket by Asp47 (Figure 2). The nickel ion is
ligated in an octahedral setting by the carboxylate group of Asp47, the imidazole group
of His45 and four water molecules. Also unseen before in any FimH structure are two
sulphate ions in a highly charged interface in the crystal packing (Figure 2).
The non-reducing end Man4 of oligomannose-3 (Figure 1) is attracted to the deep,
monomannose-binding polar pocket (Figure 3A, red) through a hydrophobic tyrosine
gate (Figure 3A, blue) to make previously well-defined interactions [47,53]. Eleven
hydrogen bonds are formed between the Man4 and the FimH residues Phe1, Asn46,

119

Asp47, Asp54, Gln133, Asn135 and Asp140 (Figure 4). A water molecule interacting
with O2 of Man4 is a strongly conserved feature in the mannose binding pocket. The
apolar B-face of Man4 provides interaction with Ile13 and Phe142, and its C5-C6 bond
interacts with Ile52. Residues Tyr48, Ile52 and Tyr137 of the tyrosine gate are involved
in several aromatic/hydrophobic and van der Waals contacts with oligomannose-3, thus
stabilizing the glycan-lectin complex (Figures 3 and 4). Man3 hooks over the side chain
of Ile52 while stacking its apolar B-face onto the Tyr48 aromatic side chain (Figures 3AC). A close apolar contact is achieved between C5 of GlcNAc2 and Tyr137. The C6-O6
bond of GlcNAc2 fares well in a hydrophobic environment created by Tyr48 and Ile52
(Figure 4). This could help to orient the strong (2.7 Å) hydrogen bond of the O6 hydroxyl
on GlcNAc2 directly towards the hydroxyl of the Thr51 side chain (Figure 3D). This latter
threonine interacts hydrophobically with the C7-C8 bond of the acetyl group of the
reducing end GlcNAc1. GlcNAc1 intramolecular hydrogen bonds with GlcNAc2 and its
N-acetyl group makes a van der Waals contact with the methyl group of the Thr51 side
chain (Figure 3D). It can be seen that glycosidic linkage of GlcNAc1 via O1 to a
glycoprotein would pull FimH very close to its receptor upon binding (Figure 3D).

Parallels between the binding of oligomannose-3 and alkyl α-D-mannosides with FimH
Butyl α-D-mannose is a high-affinity ligand for FimH (Kd = 150 nM) that was
found serendipitously in two previous FimH crystal structures [47]. We compared the
interaction interfaces between FimH and oligomannose-3 with those between FimH and
butyl α-D-mannose. Superposing the mannose of the butyl α-D-mannosides onto Man4
of oligomannose-3 and application of the transformation matrix to the whole molecules
showed that the butyl chain follows the hydrophobic trail through the tyrosine gate by the
Manα1,3Man and Manβ1,4GlcNAc linkages (Figure 5A). In contrast to the stable
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position of the mannose bound in the monosaccharide-binding pocket, the temperature
factors of the ligand atoms gradually increase beyond the α1,3 position, both for
oligomannose-3 and for butyl α-D-mannose.
The side of oligomannose-3 that is not embraced by the tyrosine gate displays
hydration of the exocyclic glycosidic oxygens (Figures 4 and 5A) that is maintained
between oligomannose-3 and butyl α-D-mannose. The hydration on the α-anomeric
oxygen of the mannose bound into the polar pocket is conserved, as well as its
hydrogen bonding network with Asn138 and Asp140 (Figure 5B) that are residues in the
loop connecting β-strands F and G (Figure 3). Also a water molecule hydrogen bonding
to the exocyclic glycosidic oxygen linking Man3 to GlcNAc2 is maintained (Figures 5 and
6B). It appears that synthetic inhibitors strive for the best mimic of the interactions of
FimH with its natural receptor. Previous solution affinity measurements indicated that
heptyl α-D-mannose is the best-binding alkyl α-D-mannoside (Kd = 5 nM) [47]. A
simulation in which the butyl chain of butyl α-D-mannose was elongated to a heptyl
allowed a conformation in which the elongated tail follows GlcNAc2 further along C4-C5C6, expecting to form the important interactions with Thr51, Ile52 and Tyr48. The antiadhesive proficiency with heptyl α-D-mannose was subsequently tested both on the
human bladder cell line 5637 and in C3H/HeN mice.

Mannose and heptyl α-D-mannose inhibit in vitro adhesion of type 1-piliated E. coli
Type 1 pili-expressing AAEC185(pUT2002)(pMMB66) E. coli cells at 106 cfu/ml
were supplemented with a ten-fold dilution series of D-mannose (Man) or heptyl α-Dmannose (HM) and incubated for adhesion on bladder cell line 5637. Increasing
concentrations of Man or HM caused a significant reduction to complete inhibition of
bacterial bladder cell binding (Figure 6). Adhesion could be completely inhibited by the
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addition of 100 mM Man to the bacterial inoculum, or by a 100-fold lower concentration
of HM. No inhibition was obtained with 100 µM Man, whereas 1 µM of HM still had some
inhibitory effect. Similar data have been obtained with an inoculum of 107 cfu/ml. These
results suggest that HM is more efficient at reducing FimH-mediated bacterial
adherence, in accordance with its higher affinity for FimH.

Heptyl α-D-mannose reduces bacterial levels in a murine cystitis model
Extensive research has shown that type 1 pili and their adhesin, FimH, are
essential for binding and invasion in the murine cystitis model [6,33,53]. It was
hypothesized that blocking of the FimH binding pocket by preferential binding to a
soluble mannose residue would reduce the binding to uroplakins on the epithelial cell
surface of the bladder. This loss of binding would result in less invasion and ultimately a
reduced infection. To test this hypothesis, bacteria were incubated in the presence of a
derivative of mannose prior to inoculation into mouse bladders. Introductory to this
experiment, the intrinsic toxicity of HM was assessed in Female BALB/c mice. HM was
administered at 50 mM concentration through a catheter (50 µl), intranasal (20 µl) and
intravenously (150 µl) to three mice each, but no acute toxicity has been observed. At 6
hours post-infection, the bacteria present within the bladder were enumerated. Wild-type
UTI89 incubated with PBS alone had a mean level of infection of ~3 x 105 cfu/mL (Figure
7). Incubation of UTI89 with 0.5 mM of HM showed no significant decrease in infection.
However, at a concentration of 5 mM HM, there was a significant decrease in infection at
6 hours post-infection (p≤0.0001). Methyl α-D-mannose (MM) gave no decrease in
bacterial numbers at the same concentration. A significant decrease in bacterial burden
was only observed when increasing the concentration of MM to 1M (data not shown), a
200 fold higher concentration then the one sufficient for HM. The tighter binding of HM to
FimH, as compared to MM, could explain this difference. These results suggest that by
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inhibiting the ability of FimH to bind to mannosylated uroplakins, the bacterial infection
can be prevented.

Heptyl α-D-mannose reduces intracellular bacterial levels
Since there is a reduction in the amount of bacteria present in the bladder at 6
hours post-infection with HM incubation (Figure 7), we wanted to assess the amount of
bacteria that went intracellular. Mice were infected with UTI89 in PBS or in a MM or HM
solution. At 1 hour post-infection, the luminal and intracellular bacterial loads were
assessed. There was a significant decrease in the number of luminal bacteria bound to
the uroepithelium when treated with 5 mM and 0.5 mM HM (p≤0.01) (Figure 8). This
same decrease was not seen when using 5 mM MM. Relative to untreated UTI89, UTI89
incubated with 5 mM HM had a significant decrease in intracellular population (p≤0.01).
There was no significant decrease in invaded bacteria treated with 5 mM MM or 0.5 mM
HM. These data indicate that HM is interfering not only with type 1 pili-mediated bacterial
binding but also with type 1 pili-dependent invasion of UPEC.

Heptyl α-D-mannose inhibits biofilm formation in vitro
The development and maturation of IBCs into communities with biofilm-like
properties has been shown recently to depend on type 1 pili [16]. We speculated that
blocking the FimH binding pocket on type 1 pili would inhibit biofilm formation by
inhibiting the adhesive properties of the pili. Bacterial biofilms were grown in the
presence of varying concentrations of either HM or MM to elucidate their biofilm
inhibiting properties (Figure 9). Biofilm of UTI89 E. coli was significantly reduced
(p<0.01) only at the highest concentration of MM, 1 mM. However, in the presence of
HM, there was a significant decrease in biofilm formation at 10 µM (p<0.001) and both 1
mM and 100 µM concentrations (p<0.0001). This suggests that blocking of the type 1 pili
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FimH adhesion with HM inhibits biofilm formation. Interestingly, at the lowest
concentration of HM (1µM) there was a significant increase in biofilm formation
(p<0.001). A low concentration of a weak inhibitor appears to allow the bacteria to
organize into a better matrix through their type 1 pili [54].

Discussion
Adhesion, invasion and the formation of intracellular biofilms
UPEC express type 1 pili which bind to mannosylated residues on the surface of
epithelial bladder cells. Once bound, some bacteria can invade the cells and rapidly
replicate into intracellular bacterial communities, named IBCs, which mature into tightly
packed biofilm-like societies [15,16]. As the infection proceeds, the bacteria filament and
flux out of the cells [7,11]. They can then reinvade neighbouring cells to re-establish
infection [14]. Inhibition of UPEC binding to bladder cells will potentially inhibit invasion
and limit the bacteria’s ability to build up formidable numbers within the bladder. A
competitive sugar could potentially disrupt the IBC pathway.
Blocking bacterial invasion could reduce the infection and decrease recurrences.
It had been demonstrated already from very early on by Sharon’s group that mannose
can inhibit FimH-mediated bacterial adhesion [55]. We looked into the ability of heptyl αD-mannose

(HM) to reduce infection, because HM has an optimized alkyl length for

interaction with FimH [47]. Inhibition by soluble mannose (Man) or methyl α-D-mannose
(MM) or HM of bacterial adhesion to the bladder cel line in vitro or upon transurethral
catheterization into the mouse bladder indicates that the bacteria cannot switch between
HM and the mannosylated uroplakins. Once HM is bound to FimH on the type 1 pili, the
bacteria are irreversibly inhibited in their binding to the bladder surface and the infection
is reduced. However, the weak inhibitor MM has a relatively high efficiency in the
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bladder binding assay that is not in direct correlation with its affinity compared to HM.
The affinity of MM for FimH is 500-times less than this of HM, but a concentration of MM
a 100-fold higher than the inhibitory concentration of HM is sufficient. The explanation
may be in the fact that the in vitro adhesion assay is being performed under shaking
conditions. Nilsson studied the inhibitory effect of MM on binding of type 1-piliated E. coli
to mannosylated surfaces under different shear stress conditions. During rolling, FimH
molecules transiently bind and detach from surface receptors, allowing a weak soluble
inhibitor such as MM to eventually bind to all FimH molecules, thereby preventing further
adhesion [54,56]. In contrast, stationary adhesion is mediated by long-lived adhesinreceptor bonds that prevent inhibitor binding during the time course of the experiments
(~10 min). HM forms such high-affinity intractions with FimH, also under still conditions.
The data on the inhibition by MM or HM of adhesion in the C3H/HeN mice indeed pledge
that, for a free small-molecule ligand to be an efficient FimH anti-adhesive even under
conditions of fluid flow, such as in the bladder, it must bind significantly tighter to FimH
than the binding of FimH to the receptor molecules on the bladder cells, in order to
overcome the shear-enhanced affinity. HM corresponds to these requirements, having
an affinity for FimH higher than any known natural mannosylated receptor. In this context
it is interesting to note that whereas human uroplakin UP1a and integrins only carry
mannose receptors with intermediate affinity for FimH, the abundantly secreted urinary
glycoprotein human THP displays 8% of the high-affinity oligomannose-5 receptors and
75% of oligomannose-6 exposing Manα1,3Man on the D2 branch (Figure 1) [57].
IBCs are biofilm-like groups of bacteria that form upon adhesion, invasion and
replication. Biofilm development requires tight interactions between individual cells in the
community. Biofilm formation and maturation in UPEC IBCs is type 1-pili dependent [16]
and the homotypic interactions between E. coli by means of type 1 pili are glycan
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dependent [58]. Therefore, the ability to disrupt biofilm formation using MM or HM was
evaluated. A significant decrease in biofilm formation was observed with as little as 10
mM HM, a 100-fold lower concentration than was needed with MM. The only other data
that exist on the inhibition of biofilm formation by a glycan are the inhibition of Grampositive and Gram-negative biofilms by a secreted group II capsule polysaccharide [59].
The concentration-dependent inhibition of biofilm formation by mannose glycans
indicates that the FimH adhesin is involved in biofilm formation [58]. Another very
interesting observation is the significant increase in biofilm with very low concentrations
of MM (Figure 9). The presence of low concentrations of a soluble inhibitor such as MM
during a longer period of time (hours) under conditions of low shear can sometimes help
the bacteria to spread further and thus colonize larger surfaces [54]. The absence of
shear and the presence of MM loosen the interactions between the adhering bacteria
and the surface, allowing them to (re-)organize the biofilm. The extent to which the
factors that are important for biofilm formation on abiotic surfaces (our assay) are also
applicable for biofilm formation on biotic surfaces (e.g. in IBCs) needs to be further
studied. However the observation of bacterial biofilm formation on abiotic surfaces is
highly relevant in view of the use of medical implants such as urinary catheters. The
glycan-based inhibition of UPEC biofilms is interesting in view of the thought that
glycoproteins abundantly secreted in the urine, such as THP, could coat the catheter
walls and serve as a glue for type 1-piliated E. coli to initiate biofilm growth.
The IBCs, or the non-replicating bacteria in quiescent intracellular reservoirs
(QIRs), form a repository that can seed a recurrent infection [12]. It was investigated
whether the inhibition of binding and biofilm formation in vitro could also reduce this
intracellular population during UTIs in a mouse model and thus the likelihood of a
recurrence. In the presence of 5 mM HM a significant reduction in bacterial numbers in
the bladders occurred. Two-hundred times more MM was needed to obtain the same
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effect. The results on inhibition with high concentrations of mannose were less
consistent, perhaps because FimH can still switch between the mannose on the
uroplakins and the mannose in the solution. If this switch happens in time, the bacteria
are not urinated out. The adhesin is more tightly bound to HM, thus the bacteria are
urinated out before being able to bind to the uroplakins. The tighter binding of the heptyl
sugar is potentially reducing the number of UPEC able to bind and invade the bladder
cells, and establish a robust infection. To confirm this, an ex vivo gentamicin protection
assay was performed. This allows enumeration of both the extracellularly bound and
intracellular bacteria. There was a significant reduction in both bound and invaded
bacteria in the presence of 5 mM HM. In summary, HM is interfering not only with
binding but also with invasion of UPEC. A 5 mM concentration of HM is needed for full
inhibition of bacterial adhesion in vivo (Figures 7 and 8), versus a 1 mM concentration in
vitro (Figure 6). In the mouse model, there is likely some loss of the sugar due to voiding
or possibly degradation in the bladder. It is also not clear how the number and nature of
mannose receptors in the mouse bladder relate to those on the human bladder cell line
5637. Moreover in the mouse the innate immune responses has an influence on
bacterial adhesion and invasion.
What is clear is that the UTI89 cystitis strain binds HM, which deters binding to
the bladder cells, limiting invasion, and reducing the level of infection. These data
confirm that invasion in bladder cells is type 1-dependent [6], as was demonstrated by
the non-invasive character of FimH mannose-binding pocket mutants [53]. Several
possible invasion pathways for UPECs have been described. Direct binding of FimH to
α3 and β1 integrins has been very recently observed and has been shown to depend
upon the glycosylation of the integrins, because treatment of α3/β1 integrins with
PNGaseF or EndoHf abolished all binding [33]. Bacterial invasion through glycan-
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mediated interactions of FimH with integrins could also happen indirectly via cellular
receptors of differentiated bladder cells, such as CD151, CD46 and UPIa [36].

Structure, specificity and drug design
The type 1 pilus fimbrial adhesin FimH was co-crystallized with oligomannose-3 to study
in detail the interactions with this most specific and natural glycan receptor for FimH. As
expected, the tyrosine gate plays a dominant role in the strength and specificity of these
interactions. A remarkable feature when analysing the PHI/PSI-chology of the FimH
RBD main chain are the tyrosine residues of the tyrosine gate. Both Tyr48 and Tyr137
and even Ile13 are on the borderline for allowed main chain conformations of the
Ramachandran plot [60]. The higher affinity of mannopentaose over mannotriose is not
reflected in the oligomannose-5 versus oligomannose-3 affinities [26]. The lack of an
increased affinity of oligomannose-5 over oligomannose-3 indicates that the choice of
FimH is in both cases directed straightforwardly towards the
Manα1,3Manβ1,4GlcNAcβ1,4GlcNAc epitope at the non-reducing end of the D1 arm in
both oligosaccharides (Figure 1). Further substitution on the α1,6 linked mannose
(Man4’) would at least not hinder binding of oligomannose-5 via the same epitope, as
Man4’ does not interact with FimH and extends into the solvent.
The similarity of interactions found in the crystal structures of FimH with
oligomannose-3 and butyl α-D-mannose is remarkably high. The butyl chain follows the
hydrophobic trail through the tyrosine gate along the α1,3 and the first β1,4 glycosidic
linkage to GlcNAc2 (Figure 5A). The same trail is conservedly hydrated near the
presumable α1,3 and the first β1,4 exocyclic glycosidic linkages (Figure 5B). Finally and
as expected, the extensive hydrogen network around the non-reducing mannose residue
in the mannose-binding pocket of FimH is fully conserved [45].
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Considerable interest exists in the molecular basis for FimH-mediated adhesion,
being fed by long-standing observations that blocking the FimH-receptor interaction
prevents bacterial infection [21,55]. Structural insight in the basis for specificity into the
extended binding site of FimH was lacking until now, seriously hampering and
invalidating structure-based design of anti-adhesive molecules using organic chemistry.
Due to the great need for anti-adhesives to treat and prevent UTIs, the search was
nevertheless continued. Dendrimers of mannose-based inhibitors were most often
unable to act multivalently on E. coli, however the monovalent moiety of the best
inhibitors among those dendrimers contain structures whose interactions can closely
mimic those of oligomannose-3, such as glycocluster 4 in the recent study by Touaibia
[61]. In these inhibitors, the α-anomeric oxygen of the non-reducing mannose is linked to
a phenyl ring, containing an ethyn group in the para position and finalizing in a hydroxyl
or ether function. A cocrystal structure for such a complex is unfortunately unknown,
however it can be easily imagined that the mannose would anchor in the FimH polar
pocket, the α-linkage to the phenyl group would resemble the Manα1,3Man linkage, and
the phenyl group would ideally stack with the aromatic side chain of Tyr48. The phenyl to
ethyn coupling would strengthen the van der Waals contacts that the Manβ1,4GlcNAc
glycosidic linkage makes with Tyr137 (Figure 4). The triple-bond character of the ethyn
could replace the stacking between the C4-C5 bond of GlcNAc2 and the aromatic ring of
Tyr137 (Figure 4). Finally, the methoxy or methanol carbon atom would mimic the
interaction of C6 of GlcNAc2 with Tyr48 and Ile52, and the terminal hydroxyl or ether
oxygen may form a hydrogen bond with Thr51 (Figures 3D and 4).
In conclusion, subnanomolar inhibitors precisely mimic the kind of interactions
FimH makes with oligomannose-3, and do so in an enhanced fashion dependent on the
chemical nature of the synthetic moieties engineered to replace all but the mannoside
that enters the monosaccharide binding pocket. The knowledge of all specific
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interactions between FimH and its natural high-mannose receptor and the possibility to
relate the specificity- and affinity determining spots on the ligand with the efficiency of
synthetic inhibitors can greatly enhance structure-based drug design against lower UTIs.
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FimH as an extended tetrasaccharide, underlined with a red hatched line.

3
April 2008 | Volume 3 | Issue 4 | e2040
Oligomannose-5 (K
d ∼ 12 nM) includes an extra mannotriose core over oligomannose-3

through addition of ManA and ManB (fuchsia). Mannopentaose (Kd ∼ 120 nM) and
mannotriose (Kd ∼ 200 nM) are boxed in fuchsia and blue frames respectively.
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Figure 3. Panel of FimH lectin domain interactions along the oligomannose-3 chain. A, Electron density map, contoured at 1 e/Å3, for
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hydrophilic (red), hydrophobic and van der Waals (yellow) interactions with the
chitobiose. The anomeric O1 of GlcNAc1 would be exchanged for by the nitrogen of the
amide of aspargine on a receptor glycoprotein for FimH.
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Figure 4. Scheme of the interactions in the extended FimH receptor-binding pocket. A network of hydrogen bonds (green dashed lines)
surrounds Man4. Further along oligomannose-3, only water molecules make hydrogen bonds along one side of oligomannose-3 except for the Thr51
side chain. The residues of the tyrosine gate, Tyr48, Ile52 and Tyr137, interact via aromatic stackings, hydrophobic and van der Waals contacts (all
marked in red) mainly with Man3 and GlcNAc2.
doi:10.1371/journal.pone.0002040.g004

Figure 4. Scheme of the interactions in the extended FimH receptor-binding
pocket. A network of hydrogen bonds (green dashed lines) surrounds Man4. Further
along oligomannose-3, only water molecules make hydrogen bonds along one side of
oligomannose-3 except for the Thr51 side chain. The residues of the tyrosine gate,
Tyr48, Ile52 and Tyr137, interact via aromatic stackings, hydrophobic and van der Waals
contacts (all marked in red) mainly with Man3 and GlcNAc2.
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Figure 5. Specificity spots for interaction with FimH. A, Superposing the FimH RBDs with the oligomannose-3 ligand (yellow, PDB entry 2vco,
2.1 Å resolution), with butyl a-D-mannose (magenta, 1uwf, 1.7 Å resolution) and with butyl a-D-mannose (cyan, 1tr7, 2.1 Å resolution). Tyr48 in the
1uwf structure (magenta) adopts a different side chain conformation, for the reason to avoid clashes in the crystal packing. The butyl tail takes on a
conformation that matches the C3-C2-C1 greasy trace of the central Man3 almost precisely. B, Water positions in the crystal structures of the FimH
RBD (green) in complex with the oligomannose-3 ligand (yellow, waters in red and hydrogen bonds in blue dashed lines) match those of the FimH
RBDs of the butyl a-D-mannose-liganded structures (waters in magenta for 1uwf, waters in cyan for 1tr7).

Figure 4. Scheme of the interactions in the extended FimH receptor-binding pocket. A network of hydrogen bonds (green dashed lines)
surrounds Man4. Further along oligomannose-3, only water molecules make hydrogen bonds along one side of oligomannose-3 except for the Thr51
side chain. The residues of the tyrosine gate, Tyr48, Ile52 and Tyr137, interact via aromatic stackings, hydrophobic and van der Waals contacts (all
marked in red) mainly with Man3 and GlcNAc2.
doi:10.1371/journal.pone.0002040.g004
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2.1 Å resolution). Tyr48 in the 1uwf structure (magenta) adopts a different side chain

conformation, for the reason to avoid clashes in the crystal packing. The butyl tail takes
on a conformation that matches the C3-C2-C1 greasy trace of the central Man3 almost
precisely. B, Water positions in the crystal structures of the FimH RBD (green) in
complex with the oligomannose-3 ligand (yellow, waters in red and hydrogen bonds in
blue dashed lines) match those of the FimH RBDs of the butyl α-D-mannose-liganded
structures (waters in magenta for 1uwf, waters in cyan for 1tr7).
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Figure 6. Inhibition of bacterial adhesion to 5637 bladder cells by mannose or heptyl a-D-mannose. Type 1 pili-expressing E. coli were
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model [6,33,53]. It was hypothesized that blocking of the FimH
binding pocket by preferential binding to a soluble mannose
residue would reduce the binding to uroplakins on the epithelial
cell surface of the bladder. This loss of binding would result in less
invasion and ultimately a reduced infection. To test this
hypothesis, bacteria were incubated in the presence of a derivative
of mannose prior to inoculation into mouse bladders. Introductory
to this experiment, the intrinsic toxicity of HM was assessed in
Female BALB/c mice. HM was administered at 50 mM
concentration through a catheter (50 ml), intranasal (20 ml) and
intravenously (150 ml) to three mice each, but no acute toxicity has
been observed. At 6 hours post-infection, the bacteria present
within the bladder were enumerated. Wild-type UTI89 incubated
with PBS alone had a mean level of infection of ,36105 cfu/mL
(Figure 7). Incubation of UTI89 with 0.5 mM of HM showed no
significant decrease in infection. However, at a concentration of
5 mM HM, there was a significant decrease in infection at 6 hours
post-infection (p#0.0001). Methyl a-D-mannose (MM) gave no
decrease in bacterial numbers at the same concentration. A
significant decrease in bacterial burden was only observed when
increasing the concentration of MM to 1M (data not shown), a 200
fold higher concentration then the one sufficient for HM. The
tighter binding of HM to FimH, as compared to MM, could
explain this difference. These results suggest that by inhibiting the
ability of FimH to bind to mannosylated uroplakins, the bacterial
infection can be prevented.

Figure 7. Bacterial load in the mouse bladder 6 hours postinfection. Mice were inoculated with UTI89, either untreated or treated
with MM or HM. At 6 hours post-infection there was a significant
decrease in the amount of bacteria treated with 5 mM HM in the
bladder (p#0.0001 by Mann Whitney test). This same decrease was not
observed with bacteria treated with 5 mM MM. Bacteria treated with
0.5 mM HM were not significantly reduced relative to the untreated
infection.
doi:10.1371/journal.pone.0002040.g007
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observed with bacteria treated with 5 mM MM. Bacteria treated with 0.5 mM HM were
not significantly reduced relative to the untreated infection.
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Supporting Information

Figure S1. Crystals of the FimH receptor-binding domain in complex with
oligomannose-3. The crystals were grown by the vapour diffusion method in 1.0 M
Li2SO4, 0.1 M Tris pH 8.5, 0.01 M NiCl2, A, in sitting drop, diffracting to 2.6 Å resolution,
and B, in hanging drop, optimized by the addition of 3% glycerol to the precipitant and
diffracting to a maximum resolution of 2.0 Å.
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Table S1. Data collection and processing, refinement statistics and model quality
Space group

P3121

Unit cell dimensions (Å)

a = b = 90.562 c = 79.480

Molecules per asymmetric unit

2

Solvent content (%)

55.6

Resolution range (Å)

78.33 – 2.1

Reflections (total/unique)

142,687 / 22,429

Completeness (%)
Rmerge

a

a,b

99.8 (100.0)
0.099 (0.42)

<I/!(I)> a,b

16.0 (5.8)

Rfree

0.241 (0.310)

Rcryst

0.184 (0.228)

Rall

0.187

Ramachandran
% of residues in favored regions

97.12

allowed regions

100.00

Rmsd bond lengths (Å)

0.010

Rmsd bond angles (º)

1.178

Average B-factors main chain

24.4

Average B-factors water

36.1

a

Values in parentheses indicate statistics for the highest resolution shell (2.14 - 2.1 Å). b

Rmerge = "h "i |Ih,i - <Ih>|/ "h "i <Ih>, where Ih,i is the ith observation of reflection h and
<Ih> is the weighted average intensity for all observations i of reflection h.
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CHAPTER FIVE
FUTURE DIRECTIONS AND CONCLUDING REMARKS

Conservation of the IBC pathogenic pathway among UPEC
A study of uropathogenic Escherichia coli (UPEC) clinical isolates from different clinical
syndromes revealed that the intracellular bacterial community (IBC) pathway is a
common pathway of UPEC (18). Additionally, analysis of human urine specimens
suggests an association between IBCs, filamentous bacteria and acute uncomplicated
cystitis in young women (42). The ramifications of this work result in a vastly improved
understanding of urinary tract infections (UTIs) which will ultimately lead to better
therapeutic options and less treatment failures. Clinically UTIs are thought to be due to
simple extracellular colonization of the urothelium by UPEC, however intracellular
bacteria have been found in the human bladder following UTI (15). The notion of an
intracellular niche in human UTI should change the way physicians treat the disease.
Episodes of cystitis caused by UPEC in humans likely involve an IBC pathogenic
pathway similar to that observed in mice. The ability to utilize an intracellular bladder
niche in both murine and human infection may represent an imperative virulence
determinant. Intracellular bacteria are largely protected from host innate immunity.
While in the intracellular niche, bacteria are not subject to the shear forces of urine flow
and are not subject to phagocytosis by host neutrophils or macrophages allowing
bacteria to build up in numbers despite potent innate defenses. Additionally, the
formation of intracellular biofilms may allow bacteria to withstand many antimicrobial
therapies, as is the case for bacteria in extracellular biofilms (14). IBC formation may
also explain how the relatively few bacteria introduced into the bladder with sexual
intercourse (9, 10, 24) are able to survive and replicate to numbers high enough to elicit
symptoms in the host. The introduction of low numbers of bacteria into the bladder is
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likely a relatively common occurrence but controlled by the host immune system and the
ability of urothelial cells to expel invaded UPEC (7). It may be that only in the event of
invasion, escape to the cytosol and IBC formation can bacteria replicate and persist to
sufficiently initiate symptomatic cystitis. In line with this theory, acute UTI isolates
formed significantly smaller and fewer IBCs within the mouse urinary tract indicative of a
less robust infection. In general, ASB, rUTI and pyelonephritis strains are associated
with longer-term persistence in the human, and, in the murine bladder, IBC size and
number were significantly greater in these isolates suggesting that IBCs relate to
persistence. Since IBC formation is a rare event among acute isolates perhaps they are
not meeting the threshold of IBCs to establish a persistent infection. Further
investigation is required to decipher what acute isolates lack preventing robust and
numerous IBCs. Recent studies indicate that complicated signal transduction pathways
are initiated in response to bacterial binding to eliminate colonization. Bacteria must
overcome expulsion in response to increased cyclic AMP (7) and must disrupt F-actin
and escape the vacuole to achieve access to the cytoplasm for IBC formation (16).
Perhaps acute isolates lack the necessary factors to overcome these host factors and
enter their desired niche.
Evaluation of the immune response elicited by the host in the presence of acute
isolates versus UTI89 could indicate essential differences in immune evasion strategies
among acute isolates. It was shown that UTI89 actually dampens the IL-6 response
from the host relative to K-12 E. coli strains (27). Perhaps acute isolates are
unsuccessful at preventing the robust production of IL-6 by the host and are thus
eliminated more quickly from the host, reducing the amount that are able to invade and
form IBCs. Another way to evaluate the reduction in IBC size and number in the acute
isolates would be to transform these strains with a fosmid library of UTI89 and screen for
IBC numbers and size. Those mutants with enhanced IBC number or size would
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potentially identify virulence factors involved in IBC formation. Previously this work was
laborious due to the absence of a tissue culture model, however, it was recently
discovered that treating human urothelial cells with filipin facilitates the development of
IBC-like structures enabling a more feasible screen of mutant bacteria (6). Knowledge
as to why acute isolates are less persistent in regards to immune response and IBC
formation could identify new therapeutic targets to prevent persistent infection observed
with ASB, rUTI and pyelonephritis isolates.
The IBC pathogenic pathway is conserved among UPEC and in human UTI. The
extent of this conservation and the prevalence of this pathway in patients with cystitis
remains obscure, however, the commonality of IBCs among UPEC and in humans is a
remarkable discovery. This finding changes the historical paradigm that UTI is an
extracellular infection and validates the already established murine cystitis model. UTI
pathogenesis is clearly more complex than once considered and these newly elucidated
steps in the infectious process raise several novel questions and may provide additional
therapeutic targets for this common disease.

Evaluation of the Co-infection phenotype
Of the 18 clinical isolates tested for IBC formation, IBCs were not observed in three
isolates and they were thus deemed outliers. An ex vivo gentamicin protection assay
revealed that the three isolates (rUTI1, acute4 and pyelo3) were deficient in invasion.
Multiplex virulence factor PCR revealed no association with lack of IBC formation and
virulence factors. Likely there is a multitude of virulence factors contributing to IBC
formation and perhaps some redundancy in the necessary factors. rUTI1 and pyelo3 did
not persist in the murine bladder however were isolated from a persistent infection within
the human. It is likely that multiple strains of bacteria are simultaneously introduced into

154

the urinary tract of women during the early events that lead to a UTI. The diagnosis of
UTIs rarely delineates whether multiple strains of E. coli are present. Thus, these strains
could have “piggy-backed” with a more invasive IBC-forming strain that went undetected.
In an effort to emulate what may have happened with the three outlying strains, each
clinical isolate was inoculated with equal amounts of UTI89. Upon co-inoculation, each
strain demonstrated altered behavior from their single infection phenotype. These
results demonstrate the complexities of co-infection and might explain the occurrence of
different clinical syndromes manifested by the same organism (25) or the differing
behavior in single versus mixed infections.
While unable to form IBCs alone, rUTI1 formed IBCs in the presence of UTI89,
acute4 formed IBCs mixed with UTI89, and pyelo3 was still unable to form IBCs in the
presence of UTI89. Instead, co-inoculation of UTI89 and pyelo3 resulted in massive
filamentation of both isolates. Since filamentation occurs in response to an inflammatory
response (28), further study is required to assess whether pyelo3 is triggering a more
robust innate response that leads to the massive filamentation observed. Evaluation of
the immune response elicited by single infection bladders versus co-infection bladders
could shed some light on the reason for the filamentation phenotype. First, tissue titers
revealed that upon individual inoculation of UTI89 and pyelo3, UTI89 had higher titers in
the bladder at 6 h, 24 h and 2 weeks post-infection, however kidney titers were
equivalent at all time points post-infection (Figure 1). Upon co-infection, bacterial load in
the bladder resembled a UTI89 single infection suggesting that UTI89 is the dominant
bacteria driving the infection. Next, the immune response in the single infection tissues
versus the co-infection tissues was evaluated to determine if the immune response
mimics the tissue titer observations. While bacterial load differences were only observed
in the bladder, evaluation of 12 cytokines revealed no significant difference in immune
response when single infection of UTI89 and pyelo3 and co-infection were evaluated.
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However, significant differences were observed in 9 of 12 cytokines in the kidney. Of the
observed differences the majority separated UTI89 single infection from pyelo3 single
infection and co-infection. Thus, the immune response of the co-infection more closely
mimicked the immune response of the pyelo3 infection. This is interesting since the coinfection mimicked the UTI89 single infection in regards to tissue titers. In general, the
immune response in the pyelo3 single infection and the co-infection was much more
robust (Figure 2). IL-1β, IL-6, MCP-1 and MIP-1β were significantly elevated in pyelo3
infection and co-infection relative to UTI89. All of the above cytokines are secreted by
macrophages and result in activation of macrophages and lymphocytes, enhancing the
immune response to the pathogen. Although certain cytokines were only significantly
elevated in pyelo3 single infection or co-infection, no cytokines were significantly
elevated in the UTI89 infection. Thus, the hypothesis that pyelo3 is triggering a more
robust innate response that leads to the massive filamentation of both isolates is
possible.
We have confirmed that there is a more robust innate response in the presence
of pyelo3 however, we have not directly identified that it is this response that is driving
the filamentation phenotype. The immune response that leads to massive filamentation
could be teased out using a tissue culture model. Addition of various cytokines shown to
be upregulated upon infection with pyelo3 could be added to urothelial cells along with
bacteria. Filamentation of bacteria could be observed through microscopy and release
of IL-6 and IL-8 could be measured through ELISA assay (22). Since, filamentation is a
mechanism the bacteria employs to evade neutrophil engulfment and persist in the face
of massive immune responses, understanding of this process could identify targets for
therapeutics that inhibit bacterial filamentation and reduce the bacteria’s chances to
perpetuate the infection. It has been shown that the loss of the ability to filament results
in reduced persistence within the bladder (29).
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Work with the co-infection model has even further changed the paradigm of
infection. Not only are UTIs complicated infections involving intracellular and
extracellular niches, they are compounded by the high likelihood of inoculating multiple
strains of E. coli into the bladder at one time. This mechanism of co-inoculation allows
multiple strains to persist that perhaps would be eliminated if inoculated by themselves.
Thus, targeting multiple mechanisms of virulence throughout the UPEC pathogenic
pathway may be necessary to completely eliminate infection and prevent recurrence.
Further understanding of how bacteria interact with one another and what virulence
factors are important to each step in the UPEC pathogenic pathway will facilitate the
development of novel therapeutics that can combat this very common disease.

pUTI89 as a virulence factor
UTI89 contains a 114 kb extrachromosomal element termed pUTI89. pUTI89 is a
unique plasmid containing two regions, the tra operon and genes found on other
virulence plasmids. pUTI89 appears to have many of the characteristics common to
pathogenicity islands (PAIs); it occupies a large genomic region, carries genes encoding
one or more virulence factors and contains cryptic or functional genes encoding mobility
factors such as integrases, transposases, and insertion sequences (20). Yet to be
discovered, is whether it is present in the genomes of pathogenic organisms but absent
from the genomes of non-pathogenic organisms. To assess the presence of pUTI89 in
pathogenic organisms, 18 clinical UPEC isolates were tested for regions of pUTI89 by
plasmid purification and PCR. Evaluation revealed that 67% of UPEC clinical isolates
had evidence of pUTI89 and 22% appeared to have the entire plasmid based on positive
PCR reactions. Due to its maintenance within the population, pUTI89 is likely involved in
pathogenesis in vivo. However, non-pathogenic organisms such as K-12 E. coli were
not tested for the presence of pUTI89. Furthermore, it would be interesting to test
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pathogenic organisms from different families of E. coli, such as enterohemorrhagic E.
coli (EHEC), enteroinvasive E. coli (EIEC), enteroaggregative E. coli (EAEC) and avian
pathogenic E. coli (APEC). Identification of pUTI89 genes in the pathogenic classes of
E. coli but not K-12 E. coli could indentify it as an extraintestinal pathogenic E. coli
(ExPEC) factor for virulence. ExPEC diverge from their commensal cohorts, taking on a
more pathogenic nature and the ability to cause serious disease both within the intestinal
tract and elsewhere within the host (30, 43). On the contrary, if evidence of pUTI89 is
only found in UPEC, then it can be identified as a urovirulence factor. A urovirulence
factor implies the presence of genes on pUTI89 in the majority of UPEC isolates
potentiating the development of a common target for therapeutics.
The mouse cystitis model was used to determine that pUTI89 contains genes
encoding one or more virulence factors. It was shown that pUTI89 enhances survival
early in infection, however, normal infection levels were restored within 24 hours of
infection. Binding and invasion was reduced in the absence of pUTI89. The cjr operon
encoding CjrA, CjrB and CjrC was partially implicated in the observed defect. In EIEC,
CjrA is an inner membrane protein homologous to PhuW of Pseudomonas aeruginosa
with unknown function, CjrB is homologous to the TonB protein which is involved in
energetic transfer between the inner and outer membranes, and CjrC is homologous to
putative outer membrane siderophore receptors (44). Located upstream of the cjr
operon is a fur box implying regulation by iron. Overlapping the cjrC gene is the senB
gene which encodes for an enterotoxin that accounts for 50% of the enterotoxic activity
in EIEC strain, EI34 (38). Further work needs to be done to complement this operon and
see a restoration of infection. Outer membrane proteins can be difficult to complement
since over expression can lead to cell lysis, thus a low copy or inducible plasmid is
important for successful complementation. After successful complementation, the
expression pattern of the cjr operon should be evaluated to determine if and when these
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proteins are expressed. It would be useful to see if their expression profile changes
during different points of the UPEC pathogenic pathway, for example in intracellular or
extracellular survival. Iron acquisition is essential to bacteria residing within the urinary
tract (23, 41) thus this operon regulated by the fur box is very likely to be expressed in
iron limiting conditions such as the urinary tract. Perhaps Cjr proteins are expressed
early in infection whereas other iron acquisition systems are expressed later, potentially
explaining the delayed growth in vivo in the absence of the Cjr proteins until more
systems are turned on.

Immune response in the absence of pUTI89
It is clear that the immune response elicited by the host, and the behavior of the bacteria
in response to it, go hand in hand. UPEC invade to avoid expulsion from the sheer
forces present during urination as well as avoid attack from neutrophils and
macrophages (37). When extracellular, UPEC filament to prevent neutrophil engulfment
(29). Additionally, UPEC dampen the IL-6 response mounted by the host relative to K12 E. coli (27). There are a multitude of other mechanisms that UPEC use to evade the
immune response, thus, due to the necessity of these evasion mechanisms, it is likely
that pUTI89 may play a role in immune evasion. However, it is extremely likely that
immune evasion mechanisms are redundant, thus may not be recognized in a pUTI89
knock-out strain. Measurement of 12 cytokine levels in the bladder of UTI89-infected
and ΔpUTI89-infected bladders at 6 hours post-infection revealed no significant
difference in cytokine levels (Figure 3). Thus, either there are no immune evasion
mechanisms on pUTI89 or the immune evasion mechanisms are redundant on the
chromosome. Deciphering between these two hypotheses will be difficult to do.
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Functional tra operon
As mentioned above, pUTI89 essentially has two regions; one region contains genes
involved in conjugative DNA transfer and the other region contains genes found on
virulence plasmids or in other virulent bacteria. Since the tra operon makes up such a
large portion of pUTI89, it is important to understand if it is functional. Additionally,
conjugative F plasmids promote biofilm formation perhaps through stimulating synthesis
of colanic acid and curli (19, 35). The tra operon promotes transfer of DNA which can
aid in adaptability of bacteria to a certain niche through uptake of genes needed to
overcome environmental restrictions for survival and replication (21). Thus, perhaps
commensal E. coli can become extraintestinal pathogenic E. coli (ExPEC) through the
uptake of DNA by conjugation implying that the conjugation machinery are important in
making virulent bacteria within the gastroinstestinal (GI) tract. It is easy to see how
these functions would benefit UPEC. Not only do they form biofilm-like structures in the
bladder, but they also must survive in a harsh niche within the urinary tract, both
extracellularly and intracellularly.
From plasmid purification and PCR methods, 6 of the 18 UPEC clinical isolates
had no evidence of pUTI89. In order to confirm functionality of the tra operon on
pUTI89, pUTI89 was mated into strains containing no evidence of pUTI89. To do this, a
kanamycin cassette was inserted on pUTI89 and a spectinomycin cassette was
transduced onto the chromosome of the clinical isolates. Three clinical isolates were
successfully transduced with the Spec cassette and all three were recipients of pUTI89
upon plate mating. Mating efficiencies ranged from 2 x 10=10 to 3 x 10-4. The reception
of pUTI89 by clinical isolates not only shows the tra operon is functional it also shows
that pUTI89 is expressed in vitro. While this confirms that the tra operon is expressed
and functional, it does not evaluate its potential role in virulence.
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As a surrogate for IBC formation, which resembles intracellular biofilms, biofilm
formation was evaluated. Since the nutrients within the intracellular environment are not
entirely known, biofilm was grown in minimal and rich media in an effort to mimic the
conditions in vivo. Growth in minimal or rich media was equivalent in the clinical isolate
relative to its pUTI89-containing counterpart as was biofilm formation (Figure 4). Since
lack of pUTI89 does not affect biofilm formation in UTI89, it is not surprising that addition
of pUTI89 to clinical isolates does not enhance biofilm formation. However, lack of
pUTI89 does affect colonization at 6 hours post-infection, which begs the question, does
addition of pUTI89 to clinical isolates enhance colonization at 6 hours post-infection?
C3H/HeN female mice were infected with each clinical isolate and its pUTI89-plus
counterpart and bacterial load was determined at 6 h, 24 h and 2 wk post-infection.
There was no significant difference in bacterial load in the bladder at 6 hours postinfection in the clinical isolates versus its pUTI89-plus counterpart, only acute3 + pUTI89
was close to being significant relative to acute3 (Figure 5). Additionally, there was no
difference in bacterial titers of the clinical isolates with and without pUTI89 at 24 hours or
2 weeks post-infection as was seen with UTI89 in the presence and absence of pUTI89.
There does not seem to be a gain of function effect on the clinical isolates with pUTI89.
However, it is extremely possible that some of the genes on pUTI89 are present on the
chromosome of the clinical isolates since PCR for pUTI89 only tested for 8 small
regions. Since these genes are already present within the genome of the clinical isolate,
adding a second copy from pUTI89 does not, therefore, enhance infection. Since the cjr
operon has been implicated in virulence in UTI89, one can now test each clinical isolate
for the presence of that specific operon. In fact, nearly 50% of the clinical isolates tested
positive for the senB gene found in the cjr operon, implying its role in virulence. Future
investigation is needed to evaluate IBC formation, filament formation and binding and
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invasion in clinical isolates conjugated with pUTI89 to determine if pUTI89 is important in
other UPEC isolates.

pUTI89 has an effect on chromosomal genes
Yersinia pestis, enteropathogenic E. coli (EPEC), Bacillus anthracis and Chlamydia
trachomatis all were shown to have chromosomally encoded genes that are regulated by
plasmid-encoded loci (5, 8, 11, 40). We sought to determine whether chromosomally
encoded genes were affected by the loss of pUTI89. Microarray and 2D gel analysis
were used to identify if the altered regulation is at the transcriptional and/or translational
level. For microarray analysis, we chose to examine bacteria from cultures grown for
inoculation into the murine cystitis model, as we are unable to isolate enough bacterial
RNA from infected bladders. All results presented were obtained from three
independent culture replicates (biological) consisting of three replicates (experimental) of
UTI89 and ΔpUTI89. Principal-component analysis demonstrated a high degree of
replicate grouping. Only those genes that were significantly different were graphed. 76
plasmid genes showed greater than two-fold transcript differential (Figure 6).
Interestingly, repB, rsvB, stbA and stbB were all extremely down in ΔpUTI89 versus
UTI89 suggesting that they are on during growth in wild-type bacteria. Considering
these genes are involved in plasmid replication and stability it implies the plasmid is
expressed in vitro. Furthermore, UP060, UP061, UP097 and UP141 were all extremely
down suggesting that they are highly expressed in wild-type in vitro. These genes are
hypothetical and will require further investigation to determine their function. Of all the
genes on the chromosome, only 24 were significantly different in the absence of pUTI89
(Figure 7) and 14 showed greater than two-fold transcript differential. Seven genes were
extremely downregulated in the absence of pUTI89: yccB, UC1727, ydiA, ydjA, c2508,
ygeA, ygfA and yhfA (Table 1). Again all of these are hypothetical and will require
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further examination. The caveat of this work is that RNA was isolated from cultures
grown in vitro, while the ΔpUTI89 phenotype was only observed in vivo. These data
suggest that pUTI89 functions in trans to regulate the transcription of multiple
chromosomal genes. Their role in pathogenesis is the study of future work.
This work has demonstrated that pUTI89 increases the ability of UTI89 to invade
and colonize the bladder. Additionally, it aids in understanding why UPEC genomes are
mosaic. Perhaps these F-like plasmids are shaping UPEC isolates by facilitating
frequent genomic acquisition, loss and rearrangement. pUTI89-like plasmids could
explain why there is not a list of definitive virulence factors that define an isolate as
UPEC (33). A greater understanding and characterization of these types of plasmids
from different UPEC could facilitate the understanding of their mechanism of virulence
and their evolution, and the design of efficacious strategies to fight UTI.

Type 1 pili as a virulence factor
Type 1 pili are essential cystitis virulence determinants (4, 34, 37, 48). FimH, located at
the tip of type 1 pili, is the essential adhesive domain for binding to mannosylated
uroplakins on the surface of bladder epithelial (urothelial) cells. In the absence of type 1
pili or FimH bacteria are non-invasive, unable to persist in the bladder and are eliminated
by the host. Thus, while there are many other virulence factors involved in infection
such as capsule, siderophores, flagella and certain toxins, type 1 pili are absolutely
required to initiate infection. After infection is initiated by type 1 pili, factors downstream
perpetuate and maintain the infection within the host.
Sequencing of over 300 fimH genes from UPEC has revealed that the mannose
binding pocket is invariant (12). However, amino acids outside the binding pocket vary
and four residues, 27, 62, 66 and 163, are positively selected in UPEC FimH (Figure 8).
Their role in infection is yet undiscovered, but suggests that there is more to FimH than
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just its ability to bind mannose. Alignment of the FimH sequences from the panel of 18
clinical isolates previously studied identified the residues differing from UTI89 FimH
(Table 2). Since the panel of clinical isolates has been characterized in the mouse, we
used them to determine the role of these positively selected amino acids and,
specifically, their role in IBC formation. We hoped to identify if genetic background plays
a role or if FimH is the determinant virulence factor for IBC formation. Based on the
confocal microscopy results from Garofalo et al. (18), those isolates that did poor in vivo
were used for IBC quantification by LacZ staining (Figure 9). Five of the 7 isolates that
were poor IBC-formers had a valine at position 27 instead of an alanine as in UTI89
FimH. Thus, it seems that this residue may be important to IBC formation and/or
colonization of the bladder. We hypothesized that UTI89 FimH in place of clinical isolate
FimH will result in enhanced IBC formation and colonization. The isolates that were
poor IBC formers or did not form IBCs were manipulated to contain the FimH of UTI89 in
place of their FimH on the chromosome, thus under the same regulation. Thus far, one
isolate, acute4, was manipulated to contain UTI89 FimH. IBC quantification revealed
that IBCs were not observed in either acute4 or acute4 + UTI89 FimH (Figure 10A)
suggesting genetic background does play a role in IBC formation. However, bacterial
titers revealed that while there was no difference at 6 hours post-infection, there was a
significant difference at 24 hours post-infection, with acute4 + UTI89 FimH colonizing
nearly 3 logs better than acute4 (Figure 10B). This suggests that FimH is involved in
more than IBC formation. Future studies are needed to identify its role in infection
outside of mannose binding. It was shown that FimH is a potent inducer of innate
antimicrobial responses through direct binding of TLR4 resulting in the production of type
1 interferon (3). It is possible that FimH is modulating the immune system to facilitate
successful colonization of the bladder. Evaluating the immune response elicited by the
host to acute4 and acute4 + UTI89 FimH could address this question. Or perhaps FimH
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makes contact with a secondary receptor outside of its binding pocket to enhance
invasion. Since, in acute4, UTI89 FimH still did not result in IBCs, we can take
advantage of this to find other factors involved in IBC formation. If acute4 is lacking an
essential factor for IBC formation, transformation with UTI89 fosmid library could result in
IBC formation. We can then identify the gene(s) involved in IBC formation. If acute4
possesses a factor that is preventing IBC formation, a transposon mutagenesis could
identify a region that is inhibitory for IBCs. Furthermore, acute4 was unable to form IBCs
so if we put UTI89 FimH into an IBC-competent strain that made IBCs at low numbers
such as rUTI3 or acute3 perhaps we can enhance IBC formation. This would suggest
that if an isolate has all the capabilities to make an IBC, FimH makes the process much
more efficient.
This work has shown that there is more to FimH than mannose binding.
Residues outside the pocket are positively selected in UPEC suggesting and important
role in infection. Additionally, UTI89 FimH in acute4 increased colonization without IBC
formation. Thus, while it is known that type 1 pili are essential for robust UTI, it is not
known what additional role type 1 pili plays outside of binding and invasion. While one
study showed that type 1 pili are expressed inside the IBCs (47), future work is needed
to identify the additional functions of FimH in UTIs. Regardless of the additional function
of FimH, it is clear that it is essential for UTI. Thus, therapeutics are needed to eliminate
binding of UPEC to the urothelium. They have the potential to eliminate this extremely
common disease.

Treatment of UTIs
Urinary tract infections (UTIs) are one of the most common bacterial infections in
industrialized countries and impose a significant financial burden based on physician
visits and treatment (17). Posing an even greater threat is the high incidence of
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recurrence. Nearly 50% of women who get a UTI will get a recurrence. Thus,
treatments that can block a UTI or stop frequent recurrences would be extremely
beneficial to women and the burden UTIs place on society. Currently, antibiotics are
available to treat UTIs, however resistance is rapidly arising. Thus, new strategies must
target virulence factors rather than essential growth factors of the bacteria preventing
selection that requires the bacteria to either evolve or die. Bacterial colonization begins
with adherence to host cells. Disrupting adherence to host cells is an excellent new
strategy for anti-virulence therapeutics. The lack of adherence and subsequent
colonization will give the host time to eliminate the bacteria prior to establishing a
foothold. Strategies to eliminate adhesion involve eliminating pilus function and
biogenesis through carbohydrate mimics and chaperone-usher assembly disruptors.
This general strategy is described in Appendix 1. Instead, this section will focus
specifically on the inhibition of type 1 pili in UTI.

Mannosides
The first strategy involves inhibiting binding to host cells by blocking the mannose
binding pocket on FimH. Based on our extensive elucidation of the UPEC pathogenic
cascade, we have identified critical nodes in pathogenesis that mannosides would target
and thereby have powerful and potent therapeutic ramifications. The first step in the
UPEC pathway involves FimH-mediated colonization of the bladder epithelium via the
recognition of mannose receptors. Bacterial invasion into superficial bladder umbrella
cells can then ensue. By preventing bacterial attachment, mannosides will also inhibit
the subsequent invasion of bacteria into the bladder epithelial cells. Crystallization of
FimH has facilitated a precise understanding of how mannose binds to FimH and the
interactions that result in high affinity binding (26). We can therefore take advantage of
our knowledge of the interactions between mannose and FimH to develop new
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therapeutics. Pre-incubation of bacteria with heptyl mannose resulted in significant
reduction in bacterial load in the murine bladder (46). These results identify mannose
derivatives as a potential therapeutic against UTIs. We can now develop more potent
inhibitors based on the success of heptyl mannose.
Mannoside inhibitors were first examined in vitro. Two FimH function assays
were used to screen mannosides for inhibitory function; (i) hemagglutination of guinea
pig red blood cells by type1 piliated UPEC and (ii) a type 1 dependent biofilm assay.
These assays have shown that 23 of 37 currently synthesized and tested compounds
are more potent inhibitors of HA titer and biofilm formation than anything commercially
available and previously tested, some by as much as 2 logs (Table 3). Future studies
will use a more rigorous assay to test the ability of the strongest inhibitory mannoside
derivatives to reverse hemagglutination of guinea pig red blood cells and to disrupt
preformed type 1 dependent biofilms. The most potent compounds will be subjected to
crystallography to better understand their increased activity and to inform further
chemical synthesis of even better inhibitory compounds. Further, a fluorescent
polarization assay has been developed and miniaturized to monitor the direct binding of
a synthesized fluorescently labeled butyl mannose derivative to the FimH receptor as
well as competitive displacement by other synthetic mannosides. This fluorescent
polarization assay provides a rapid method for monitoring improvements to receptor
affinity during the synthetic process, as well as providing Kd binding affinity
measurements.
After in vitro examination, the most potent mannosides were tested in vivo.
Utilizing a well-established gentamicin protection assay to determine the luminally bound
fraction versus the intracellular fraction, there was a significant reduction in intracellular
bacteria at 1 hour post-infection in the presence of mannosides ZFH177 and ZFH253
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(Figure 11), arguing that the mannosides are disrupting specific type 1-mediated binding
required for subsequent invasion. It is not clear why a reduction was not observed in the
luminal UPEC population. This may be due to contamination from bacteria in the urine
or bacteria that are non-specifically associated with the epithelium. In any case,
blocking invasion blocks the ability of the bacteria to rapidly expand in numbers. This is
due to the ability of the mannosides to block the IBC mechanism. After invasion, UPEC
are able to rapidly replicate to form IBCs, thus dramatically expanding in numbers. The
ability of mannosides to block IBC formation was evaluated based on LacZ staining of
whole mount bladders to enumerate IBCs. Whole bladder titers were also determined
by quantifying colony forming units (CFUs) at 6 hours post-infection and later time
points. In the presence of mannosides ZFH177 and ZFH253 there was a significant
decrease in IBCs observed 6 hours post-infection at concentrations as low as 0.1 mM
and almost no IBCs observed at 1 mM mannoside (Figure 12A). A significant decrease
was also seen in CFUs at 6 hours post-infection with 1 mM ZFH177 and ZFH253 (Figure
12B). These results strongly argue that the mannosides are able to inhibit first round
IBC formation by preventing FimH-mediated binding and invasion into the bladder
epithelial cells. The success of these experiments lead us to believe that these
compounds will have dramatic potential as potent therapeutics for treating UTI.

Pilicides
The second strategy to inhibit pilus mediated adhesion is to disrupt
chaperone/usher pilus assembly using compounds termed pilicides. A pilicide that
inhibits the production of type 1 pili has a powerful potential as a non-antibiotic
therapeutic and such compounds will become more necessary in the face of antibiotic
resistance. Ring-fused 2-pyridones can be found in many biologically active compounds
and natural products ranging from the multi-fused natural product Nauclefine and
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Camptothecin (a potent anti-cancer drug) to bicyclic systems like the 2-pyridone acid
A58365A (an Angiotensin-Converting Enzyme (ACE) inhibitor at nM concentrations) (2,
13, 31) (Figure 13). Thiazolo ring-fused 2-pyridones are highly useful as scaffolds for
the development of compounds that inhibit protein-protein interactions in bacteria (1, 39,
45) and we have already produced more than 250 of these compounds with a variety of
R group constituents (Figure 13). We have done limited screening on a subset of the
available compounds and have identified compounds we call “pilicides” that bind to the
chaperone to inhibit its function. Future work continues to screen these compounds to
identify ones that hold promise as potential novel antibacterial agents that target
bacterial virulence. We have performed limited analysis on a subset of compounds in
the library and showed that many of these compounds affected type 1 piliation in HA and
biofilm assays. Continued research is need to perform extensive studies on the entire
library of compounds, screening for inhibitory activity in type 1 dependent biofilms and
HA assays.
We have assessed the ability of the best pilicides, discovered above, to treat or
prevent UTI in the murine model. UTI89 is grown in the presence of the pilicide prior to
inoculation into the bladders of mice. In the presence of the pilicide FN075, UPEC
colonization and invasion in the murine mouse model as measured by bacterial load and
IBC formation was severely attenuated thus potentiating the therapeutic potential of
pilicides (Figure 14). This experiment confirmed that pilicide FN075 treatment inhibited
IBC formation and thus colonization of the murine bladder thus attenuating virulence.
Future investigation is required to assess the ability of pilicides to function during
infections.
Preliminary studies have revealed that mannosides and pilicides are effective at
reducing infection in vivo. However, many studies remain to prove their efficacy within a
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more clinically relevant setting of UTI. First, studies are needed to evaluate the
bioavailability and toxicity of these compounds. It needs to be determined the best
method of delivery, oral, IP or IV, to obtain high levels of intact compound in the bladder
without detrimental effects to the mouse as measured by weight loss and survival. We
have shown that 1 to 0.1 mM of mannoside is needed to inhibit infection, thus, it needs
to be determined if it is possible to achieve this level of mannoside within the bladder.
However, we have yet to examine synergistic effects of these compounds. Perhaps in
the presence of mannoside and pilicide, less compound will be needed to successfully
inhibit UTI. One could imagine the mannoside first occupying the FimH mannose
binding pocket and preventing initial binding, while the pilicide crosses the membrane
and prevents future pilus synthesis, thus allowing the bacteria to be excreted in the urine
or phagocytosed by macrophages. Additionally, reduced amounts of antibiotics could be
added to further lower the dose required to inhibit bacterial colonization thus reducing
the selective pressure for resistance. Once bioavailability and toxicity have been
determined, a more clinically relevant situation can be evaluated by treating a preexisting UTI with compound and see if the infection can be eliminated. Future studies
are needed to evaluate the dose, frequency and time of treatments post-infection.
Additionally, the prophylatic ability of mannoside could be evaluated to determine if this
could be a daily supplement for women who suffer frequent recurrent UTIs.
Clearly there is a lot of work left to do to determine the efficacy of mannosides
and pilicides. However, these anti-virulence therapeutics have numerous attractive
qualities. There is less selective pressure for the bacteria to evolve resulting in
resistance since unlike traditional antibiotics they do not target essential growth factors
of the bacteria. Additionally, these therapeutics will leave the commensal bacteria
unperturbed. Loss of commensal gut isolates upon treatment with antibiotics usually
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results in side effects including diarrhea and secondary opportunistic infections, such as
yeast infections. Furthermore, since chaperone/usher systems are numerous to a
multitude of Gram-negative pathogens, these strategies can be applied to a multitude of
pathogens. Adhesion is the first step in nearly every bacterial infection, thus a ligandbased approach, such as the mannosides, to infection inhibition could translate to an
even greater expanse of pathogens encompassing Gram-positives as well. In fact,
exogenous sugars have proved efficacious at inhibiting adhesion of Pseudomonas
aeruginosa, Staphylococcus and Streptococcus in vitro (32, 36). The development of
anti-virulence therapeutics indicates a paradigm shift in the understanding of bacterial
pathogens and their interactions with the host and environment. A multitude of virulence
factors in addition to adherence are being targeted such as capsule, flagella,
siderophores, toxins, type III secretion systems (TTSS) and virulence gene regulation.
Vigilance and basic research in the understanding of basic processes associated with
bacterial virulence is the only way to continue the development of novel and effective
therapeutics.

Concluding remarks
In summary, this thesis work set out to better understand the pathogenesis of
UPEC in the urinary tract to facilitate the development of new anti-virulence therapeutics.
Prior studies have revealed that UPEC employs a complex developmental process in
mice, initiated by the intimate contacts between the pathogen adhesive organelles and
the host epithelium, to successfully colonize and persist within the harsh environment of
the urinary tract. The IBC pathogenic pathway is critical in the ability of UPEC to cause
UTI and interferences at any step in this pathogenic cycle could alter the infection
course. This thesis extends our knowledge of the IBC pathogenic pathway in three
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important ways. First, this study has demonstrated the commonality of the IBC pathway
implying its relevance to UPEC and identifying that targets against this pathway will
target a multitude of UPEC isolates. Second, this work identified a virulence plasmid
that enhances early events in UTI89 infection and its tra operon may contribute to the
mosaic nature of the UPEC genome by allowing uptake, deletion and rearrangement of
genes throughout the genome. Third, based on the ubiquitous and essential qualities of
FimH, this work identified novel anti-virulence therapeutics targeted at adhesion
disruption. These findings indicate the importance of thoroughly understanding the
mechanisms that underlie this process and how these differ among UPEC. These
discoveries alter the current paradigm of bacterial pathogenesis in the urinary tract and
could ultimately lead to better treatment modalities for patients suffering UTIs.
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a

Gene transcripts passing all statistical and quality tests performed as described in
Materials and Methods.
b
Change in !pUTI89 signal compared to UTI89 signal.

Table 1. Chromosomal genes demonstrating a twofold or greater transcript
differential via microarray analysisa
Fold
Gene

ORF

changeb

hypothetical

UTI89_C1048

-458.7

hypothetical

UTI89_C3298

-140.7

hypothetical

UTI89_C1896

-130.8

hypothetical

UTI89_C3859

-69.5

hypothetical yfaQ precursor

UTI89_C2508

-43.3

hypothetical

UTI89_C3244

-23.2

conserved protein YdjA

UTI89_C1960

-14.5

hypothetical

UTI89_C4976

-4.7

hypothetical

UTI89_C1130

-3.0

outer membrane heme/hemoglobin receptor

UTI89_C1129

-2.6

lambdoid prophage Qin tail fiber assembly protein-like protein

UTI89_C0564

-2.4

hypothetical

UTI89_C0954

2.5

bacteriophage ST64T antitermination protein gp23

UTI89_C2663

2.8

hypothetical

UTI89_C1727

6.9

a

Gene transcripts passing all statistical and quality tests performed

b

Change in !pUTI89 signal compared to UTI89 signal.

Table 2. Alignment of FimH sequences
Strain
ASB1
ASB2
ASB3
ASB4
ASB5
acute1
acute2
acute3
acute4
rUTI1
rUTI2
rUTI3
rUTI4
rUTI5
pyelo1
pyelo2
pyelo3
pyelo4
UTI89

9
T
T
T
T
T
T
T
T
T
A
T
T
T
T
T
T
T
T
T

Position
IBCs present
27 62 66 70 78 106 117 163 166 195 106 269
(hrs PI)
A
S G S N
A
G
V
R
Y
N
Q
6,24
A
S G N N
A
G
V
R
Y
N
Q
6,24
A
S G N S
A
G
V
H
Y
N
Q
6,24
A
S G N S
T
G
V
R
Y
N
Q
6
V
S G S N
A
G
V
R
Y
N
Q
24 (rare)
V
S G N S
A
G
V
R
Y
N
Q
12 (rare)
A
S G N S
A
G
V
R
F
N
Q
6 (rare)
V
S G N S
A
G
V
R
Y
N
Q
3 (rare)
A
S S S N
A
G
V
R
Y
N
Q
A
S G N S
A
R
V
R
F
S
Q
A
S G N S
A
G
V
R
Y
N
K
6
V
S G N S
A
G
V
R
Y
N
Q
6 (few)
A
S G S N
A
G
A
R
Y
N
Q
24
A
S G S N
A
G
V
R
Y
N
Q
3
A
S C N S
A
G
V
R
Y
N
K
6
A
S G N S
A
G
V
R
Y
N
Q
6
V
S G N S
A
G
V
R
Y
N
Q
A
S G S N
A
G
V
R
Y
N
Q
6
A
A G S N
A
G
V
R
Y
N
Q
3,6,24

Highlighted residues differ from UTI89 residues
Only residues that differ from UTI89 are shown
Bolded residues were identified as positively selected for in UPEC
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Table 3. Structure Activity Relationship
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Figure 1. Bacterial load in the bladder and kidney of UTI89 and pyelo3 in single
and mixed infections. (A) At 6h and 24h post-infection, bacterial load was significantly
lower in the pyelo3-infected bladders than in the UTI89-infected bladders (***p<0.001
and *p<0.05 by Mann-Whitney). Total titers in the mixed infection more closely
resembled UTI89 infected bladders. (B) There was no significant difference at any
timepoint between any infection in the kidneys.
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Figure 2. Cytokine levels in the kidney of UTI89, pyelo3 and co-infections.
Cytokines IL-1β, IL-6, MCP-1 and MIP-1β were elevated in pyelo3- and co-infected
kidneys relative to UTI89-infected kidneys. Thus, co-infection immune response more
closely mimics pyelo3 immune response.
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Figure 3. Immune response at 6h in UTI89 and ΔpUTI89 infected bladders. There
was no significant difference among any of the cytokines tested in UTI89-infected versus
ΔpUTI89-infected bladders.
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Figure 4. Biofilm formation in the presence or absence of pUTI89. Blue bars
represent biofilm formed in LB and red bars represent biofilm formed in M9 + 10 µg/ml
niacin. Acute3+, ASB1+ and rUTI+ all represent strains that have received pUTI89. In
the presence of pUTI89 there was difference in biofilm formation in LB or M9 media.
Additionally, there was no difference in biofilm formation in either media in the absence
of pUTI89 from UTI89.
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Figure 5. Bacterial load in the bladder of clinical isolates with and without pUTI89.
Acute3+, ASB1+ and rUTI1+ represent strains that received pUTI89. At 6 h, 24 h, and 2
wk post-infection there was no significant difference in bacterial load of each isolate with
their pUTI89+ counterpart.
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Figure 6. Plasmid genes demonstrating greater than two-fold change in ΔpUTI89
signal compared UTI89 signal. repB, rsvB, stbA and stbB were all down suggesting
they are expressed in vitro and encode plasmid replication and maintenance proteins.
UP060, UP061, UP097 and UP141 were also down suggesting their expression in vitro
and are all hypothetical proteins requiring further study.
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Figure 7. Chromosomal genes demonstrating greater than two-fold change in
ΔpUTI89 signal compared UTI89 signal. In the absence of pUTI89 24 chromosomal
genes showed significantly altered regulation. The most significantly different
expression levels were down in the absence of pUTI89.
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Figure 8. FimH residues under positive selection. FimH is in green and FimC (the
chaperone) is in gray. In red are residues under positive selection. In blue are residues
not under selection. Mannose is bound at the tip of FimH. All of the positively selected
residues are located outside the mannose-binding pocket.
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Figure 9. Quantification of IBCs at 6h post-infection from bladders infected with
clinical isolates. Below each isolate is listed the amino acids that differ from UTI89.
Amino acids at position 27, 62 and 66 are under positive selection. Isolates with * had
significantly fewer IBCs than UTI89 (p<0.05 by Mann-Whitney). Five of the 7 isolates
that were significantly different from UTI89 had a valine at position 27 instead of the
alanine that is in UTI89.
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Figure 10. acute4 + UTI89 FimH alters colonization but not IBC formation. (A) IBC
quantification at 6h post-infection showed no difference in acute4 and acute4 + UTI89
FimH. (B) Tissue titers at 6h post-infection revealed equal levels of colonization.
However, at 24h post-infection, acute4 + UTI89 FimH significantly colonized bladders
better than acute4 (p<0.01 by Mann-Whitney).
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Figure 11. Mannosides ZFH177 and ZFH253 reduced intracellular bacteria at 1
hour post-infection. A 1 hour gentamicin protection assay was used to evaluate the
amount of bacteria present in the luminal versus intracellular fraction in the presence of
mannosides ZFH177 and ZFH253. A small decrease was seen in the luminal fraction in
the presence of ZFH177 (p<0.05) whereas a significant decrease was seen in the
intracellular fraction in the presence of either mannoside (p<0.0001).
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Figure 12. Mannosides ZFH177 and ZFH253 reduce infection capacity in vivo. (A)
6 hour LacZ reveals significantly reduced IBCs at 1mM and 0.1mM mannoside for both
ZFH177 and ZFH253 (p<0.0001). (B) 6 hour bacterial load quantification reveals
significantly reduced colonization with 1mM ZFH177 and 1mM ZFH253 treated bacteria,
p<0.001 and p<0.01, respectively.

Figure 13. Structures of 2-pyridone compounds. (A) Chemical structure of a ringfused 2-pyridone with substituent addition sites (R1-R4). (B) Chemical structures of
biologically active ring-fused 2-pyridone compounds. Naucietine (1),Camptothecin (2)
and A58365A (3). The 2-pyridone core is shown in red.
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Figure 14. FN075 has an effect on UTI89 bladder colonization in vivo. When
inoculated in the presence of FN075, UTI89 makes significantly less IBCs in the bladder
(A) and has a significantly reduced bacterial load within the bladder at 6 hours postinfection (B). p<0.0001

187

1.

Aberg, V., F. Norman, E. Chorell, A. Westermark, A. Olofsson, A. E. SauerEriksson, and F. Almqvist. 2005. Microwave-assisted decarboxylation of
bicyclic 2-pyridone scaffolds and identification of Abeta-peptide aggregation
inhibitors. Org Biomol Chem 3:2817-2823.

2.

Abreu, P., and A. Pereira. 2001. New indole alkaloids from Sarcocephalus
latifolius. Nat Prod Lett 15:43-48.

3.

Ashkar, A. A., K. L. Mossman, B. K. Coombes, C. L. Gyles, and R.
Mackenzie. 2008. FimH adhesin of type 1 fimbriae is a potent inducer of innate
antimicrobial responses which requires TLR4 and type 1 interferon signalling.
PLoS Pathog 4:e1000233.

4.

Bahrani-Mougeot, F. K., E. L. Buckles, C. V. Lockatell, J. R. Hebel, D. E.
Johnson, C. M. Tang, and M. S. Donnenberg. 2002. Type 1 fimbriae and
extracellular polysaccharides are preeminent uropathogenic Escherichia coli
virulence determinants in the murine urinary tract. Mol Microbiol 45:1079-1093.

5.

Bai, G., E. Smith, A. Golubov, J. Pata, and K. A. McDonough. 2007.
Differential gene regulation in Yersinia pestis versus Yersinia
pseudotuberculosis: effects of hypoxia and potential role of a plasmid regulator.
Adv Exp Med Biol 603:131-144.

6.

Berry, R. E., D. J. Klumpp, and A. J. Schaeffer. 2009. Urothelial cultures
support intracellular-bacterial community formation by uropathogenic Escherichia
coli. Infect Immun.

7.

Bishop, B. L., M. J. Duncan, J. Song, G. Li, D. Zaas, and S. N. Abraham.
2007. Cyclic AMP-regulated exocytosis of Escherichia coli from infected bladder
epithelial cells. Nat Med 13:625-630.

188

8.

Bourgogne, A., M. Drysdale, S. G. Hilsenbeck, S. N. Peterson, and T. M.
Koehler. 2003. Global effects of virulence gene regulators in a Bacillus anthracis
strain with both virulence plasmids. Infect Immun 71:2736-2743.

9.

Bran, J. L., M. E. Levison, and D. Kaye. 1972. Entrance of bacteria into the
female urinary bladder. N Engl J Med 286:626-629.

10.

Buckley, R. M., Jr., M. McGuckin, and R. R. MacGregor. 1978. Urine bacterial
counts after sexual intercourse. N Engl J Med 298:321-324.

11.

Carlson, J. H., W. M. Whitmire, D. D. Crane, L. Wicke, K. Virtaneva, D. E.
Sturdevant, J. J. Kupko, 3rd, S. F. Porcella, N. Martinez-Orengo, R. A.
Heinzen, L. Kari, and H. D. Caldwell. 2008. The Chlamydia trachomatis plasmid
is a transcriptional regulator of chromosomal genes and a virulence factor. Infect
Immun 76:2273-2283.

12.

Chen, S. L., C. Hung, J. Pinkner, J. N. Walker, C. K. Cusumano, Z. Li, J.
Bouckaert, J. I. Gordon, and S. J. Hultgren. 2009. Positive selection identifies
an in vivo role for FimH during urinary tract infection in addition to mannose
binding. Proc Natl Acad Sci U S A Accepted.

13.

Clive, D. L., D. M. Coltart, and Y. Zhou. 1999. Synthesis of the AngiotensinConverting Enzyme Inhibitors (-)-A58365A and (-)-A58365B from a Common
Intermediate. J Org Chem 64:1447-1454.

14.

del Pozo, J. L., and R. Patel. 2007. The challenge of treating biofilm-associated
bacterial infections. Clin Pharmacol Ther 82:204-209.

15.

Elliott, T. S., L. Reed, R. C. Slack, and M. C. Bishop. 1985. Bacteriology and
ultrastructure of the bladder in patients with urinary tract infections. J Infect
11:191-199.

189

16.

Eto, D. S., J. L. Sundsbak, and M. A. Mulvey. 2006. Actin-gated intracellular
growth and resurgence of uropathogenic Escherichia coli. Cell Microbiol 8:704717.

17.

Foxman, B. 2002. Epidemiology of urinary tract infections: incidence, morbidity,
and economic costs. Am J Med 113 Suppl 1A:5S-13S.

18.

Garofalo, C. K., T. M. Hooton, S. M. Martin, W. E. Stamm, J. J. Palermo, J. I.
Gordon, and S. J. Hultgren. 2007. Escherichia coli from urine of female patients
with urinary tract infections is competent for intracellular bacterial community
formation. Infect Immun 75:52-60.

19.

Ghigo, J. M. 2001. Natural conjugative plasmids induce bacterial biofilm
development. Nature 412:442-445.

20.

Hacker, J., G. Blum-Oehler, I. Muhldorfer, and H. Tschape. 1997.
Pathogenicity islands of virulent bacteria: structure, function and impact on
microbial evolution. Mol Microbiol 23:1089-1097.

21.

Hacker, J., and J. B. Kaper. 2000. Pathogenicity islands and the evolution of
microbes. Annu Rev Microbiol 54:641-679.

22.

Hedges, S. R., M. Bjarnadottir, W. Agace, L. Hang, and C. Svanborg. 1996.
Immunoregulatory cytokines modify Escherichia coli induced uroepithelial cell IL6 and IL-8 responses. Cytokine 8:686-697.

23.

Henderson, J. P., J. R. Crowley, J. S. Pinkner, J. N. Walker, P. Tsukayama,
W. E. Stamm, T. M. Hooton, and S. J. Hultgren. 2009. Quantitative
metabolomics reveals an epigenetic blueprint for iron acquisition in
uropathogenic Escherichia coli. PLoS Pathog 5:e1000305.

24.

Hooton, T. M., S. Hillier, C. Johnson, P. L. Roberts, and W. E. Stamm. 1991.
Escherichia coli bacteriuria and contraceptive method. JAMA 265:64-69.

190

25.

Hooton, T. M., D. Scholes, A. E. Stapleton, P. L. Roberts, C. Winter, K.
Gupta, M. Samadpour, and W. E. Stamm. 2000. A prospective study of
asymptomatic bacteriuria in sexually active young women. N Engl J Med
343:992-997.

26.

Hung, C. S., J. Bouckaert, D. Hung, J. Pinkner, C. Widberg, A. DeFusco, C.
G. Auguste, R. Strouse, S. Langermann, G. Waksman, and S. J. Hultgren.
2002. Structural basis of tropism of Escherichia coli to the bladder during urinary
tract infection. Mol Microbiol 44:903-915.

27.

Hunstad, D. A., S. S. Justice, C. S. Hung, S. R. Lauer, and S. J. Hultgren.
2005. Suppression of bladder epithelial cytokine responses by uropathogenic
Escherichia coli. Infect Immun 73:3999-4006.

28.

Justice, S. S., C. Hung, J. A. Theriot, D. A. Fletcher, G. G. Anderson, M. J.
Footer, and S. J. Hultgren. 2004. Differentiation and developmental pathways
of uropathogenic Escherichia coli in urinary tract pathogenesis. Proc Natl Acad
Sci U S A 101:1333-1338.

29.

Justice, S. S., D. A. Hunstad, P. C. Seed, and S. J. Hultgren. 2006.
Filamentation by Escherichia coli subverts innate defenses during urinary tract
infection. Proc Natl Acad Sci U S A 103:19884-19889.

30.

Kaper, J. B., J. P. Nataro, and H. L. Mobley. 2004. Pathogenic Escherichia coli.
Nat Rev Microbiol 2:123-140.

31.

Kessel, D. 1971. Some determinants of camptothecin responsiveness in
leukemia L1210 cells. Cancer Res 31:1883-1887.

32.

King, S. S., D. A. Young, L. G. Nequin, and E. M. Carnevale. 2000. Use of
specific sugars to inhibit bacterial adherence to equine endometrium in vitro. Am
J Vet Res 61:446-449.

191

33.

Marrs, C. F., L. Zhang, P. Tallman, S. D. Manning, P. Somsel, P. Raz, R.
Colodner, M. E. Jantunen, A. Siitonen, H. Saxen, and B. Foxman. 2002.
Variations in 10 putative uropathogen virulence genes among urinary, faecal and
peri-urethral Escherichia coli. J Med Microbiol 51:138-142.

34.

Martinez, J. J., M. A. Mulvey, J. D. Schilling, J. S. Pinkner, and S. J.
Hultgren. 2000. Type 1 pilus-mediated bacterial invasion of bladder epithelial
cells. EMBO J 19:2803-2812.

35.

May, T., and S. Okabe. 2008. Escherichia coli harboring a natural IncF
conjugative F plasmid develops complex mature biofilms by stimulating synthesis
of colanic acid and Curli. J Bacteriol 190:7479-7490.

36.

McEwan, N. A., G. Kalna, and D. Mellor. 2005. A comparison of adherence by
four strains of Staphylococcus intermedius and Staphylococcus hominis to
canine corneocytes collected from normal dogs and dogs suffering from atopic
dermatitis. Res Vet Sci 78:193-198.

37.

Mulvey, M. A., Y. S. Lopez-Boado, C. L. Wilson, R. Roth, W. C. Parks, J.
Heuser, and S. J. Hultgren. 1998. Induction and evasion of host defenses by
type 1-piliated uropathogenic Escherichia coli. Science 282:1494-1497.

38.

Nataro, J. P., J. Seriwatana, A. Fasano, D. R. Maneval, L. D. Guers, F.
Noriega, F. Dubovsky, M. M. Levine, and J. G. Morris, Jr. 1995. Identification
and cloning of a novel plasmid-encoded enterotoxin of enteroinvasive
Escherichia coli and Shigella strains. Infect Immun 63:4721-4728.

39.

Pinkner, J. S., H. Remaut, F. Buelens, E. Miller, V. Aberg, N. Pemberton, M.
Hedenstrom, A. Larsson, P. Seed, G. Waksman, S. J. Hultgren, and F.
Almqvist. 2006. Rationally designed small compounds inhibit pilus biogenesis in
uropathogenic bacteria. Proc Natl Acad Sci U S A 103:17897-17902.

192

40.

Porter, M. E., P. Mitchell, A. J. Roe, A. Free, D. G. Smith, and D. L. Gally.
2004. Direct and indirect transcriptional activation of virulence genes by an AraClike protein, PerA from enteropathogenic Escherichia coli. Mol Microbiol 54:11171133.

41.

Reigstad, C. S., S. J. Hultgren, and J. I. Gordon. 2007. Functional genomic
studies of uropathogenic Escherichia coli and host urothelial cells when
intracellular bacterial communities are assembled. J Biol Chem 282:2125921267.

42.

Rosen, D. A., T. M. Hooton, W. E. Stamm, P. A. Humphrey, and S. J.
Hultgren. 2007. Detection of intracellular bacterial communities in human urinary
tract infection. PLoS Med 4:e329.

43.

Russo, T. A., and J. R. Johnson. 2000. Proposal for a new inclusive
designation for extraintestinal pathogenic isolates of Escherichia coli: ExPEC. J
Infect Dis 181:1753-1754.

44.

Smajs, D., and G. M. Weinstock. 2001. The iron- and temperature-regulated
cjrBC genes of Shigella and enteroinvasive Escherichia coli strains code for
colicin Js uptake. J Bacteriol 183:3958-3966.

45.

Svensson, A., A. Larsson, H. Emtenas, M. Hedenstrom, T. Fex, S. J.
Hultgren, J. S. Pinkner, F. Almqvist, and J. Kihlberg. 2001. Design and
evaluation of pilicides: potential novel antibacterial agents directed against
uropathogenic Escherichia coli. Chembiochem 2:915-918.

46.

Wellens, A., C. Garofalo, H. Nguyen, N. Van Gerven, R. Slattegard, J. P.
Hernalsteens, L. Wyns, S. Oscarson, H. De Greve, S. Hultgren, and J.
Bouckaert. 2008. Intervening with urinary tract infections using anti-adhesives
based on the crystal structure of the FimH-oligomannose-3 complex. PLoS ONE
3:e2040.

193

47.

Wright, K. J., P. C. Seed, and S. J. Hultgren. 2007. Development of
intracellular bacterial communities of uropathogenic Escherichia coli depends on
type 1 pili. Cell Microbiol 9:2230-2241.

48.

Wu, X. R., T. T. Sun, and J. J. Medina. 1996. In vitro binding of type 1fimbriated Escherichia coli to uroplakins Ia and Ib: relation to urinary tract
infections. Proc Natl Acad Sci U S A 93:9630-9635.

194

APPENDIX I
BACTERIAL ADHESION – A SOURCE OF ALTERNATE ANTIBIOTIC TARGETS
Manuscript in preparation: Cusumano and Hultgren (2009) iDrugs.
Corinne K Cusumano1 and Scott J Hultgren1*
1

Washington University School of Medicine, Department of Molecular Microbiology and

Microbial Pathogenesis, 660 S. Euclid Ave, St. Louis, MO 63110, USA
*To whom correspondence should be addressed
Author contributions: CKC and SJH wrote the paper.
Abstract
The prevalence of antibiotic resistance among microorganisms that cause
infectious diseases has necessitated the use of new strategies for the development of
novel therapeutics. In an effort to thwart this resistance, novel therapeutics are being
developed that target bacterial virulence factors as an alternative to the traditional
antibiotics which target essential microbial processes promoting bacterial evolution
resulting in resistance. While many anti-virulence targets exist, this feature will discuss
adhesion as an anti-virulence target using pili of uropathogenic E. coli as a model
system. The two strategies of drug development discussed in this review involve
inhibition of bacterial binding to the host tissue by the addition of exogenous sugars and
the disruption of chaperone-usher (CU) pilus assembly through disruption of proteinprotein interactions. However, the commonality of adhesion to infectious disease
processes and CU pili to many pathogens makes these strategies discussed here
translatable to a multitude of organisms.
Keywords
Antibiotic resistance, drug discovery, microbial adhesion, novel therapeutics, biofilm
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Introduction
More than a century ago, the discovery of Penicillin marked a significant, albeit
not immediately recognized, advance in the field of medicine. By the middle of the 20th
century this naturally occurring fungal antibiotic had single-handedly vanquished the
biggest wartime killer -- infected wounds. Just four years after the mass production of
penicillin began in 1943, resistant microbes started to appear beginning with
Staphylococcus aureus, followed shortly thereafter by Streptococcus pneumoniae and
Neiserria gonorrheae. Today this list includes antibiotic resistant Enterococcus,
Salmonella, Mycobacterium tuberculosis and Escherichia coli, to name just a few. The
bacterial infections which contribute most to human disease are also those in which
emerging and microbial resistance is most evident: diarrheal diseases, respiratory tract
infections, urinary tract infections, meningitis, sexually transmitted infections, and
hospital acquired infections. Thus, there is dire need for new therapeutics to save the
lives and ease the suffering of millions of people.

Rising antibiotic resistance
The antibiotics that are available today are primarily variations on a single
theme—bacterial eradication based on inhibition of essential molecular processes
required for bacterial growth (bacteriostatic) or cellular maintenance (bactericidal).
Some target cell-wall biosynthesis, whereas others inhibit protein synthesis or DNA
replication. These life or death treatments put selective pressure on the bacteria to
adapt or die, selecting for antibiotic resistance. Second generation drugs were
developed to combat the resistances that arose, however, they employed the same
general mechanism of action. In addition, while some last resort drugs have minimal
resistance thus far, they are much more expensive, often are more toxic and typically
unavailable to many countries around the world. Consequences of treatment failure due
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to antibiotic resistance are high with greater morbidity, mortality and transmission of the
resistant organism. Even if pharmaceutical companies increased efforts to develop next
generation replacement drugs, bacterial evolution is outpacing drug development for
these classes of antibiotics. We are nearing an end to the seemingly endless flow of
antimicrobial drugs. We are now faced with a long list of microbes that have found ways
to circumvent different structural classes of drugs and are no longer susceptible to most,
if not all, therapeutic regimens. New tactics and weapons are needed to combat
bacteria that are, owing to evolution and selection, moving targets.

Alternative antibiotic targets
Targeting bacterial virulence is an alternative approach to the development of
new classes of antimicrobials that can be used to specifically target and disarm
pathogens in the host, while leaving commensal bacteria unperturbed. Prevention of the
activity of virulence factors will render the bacteria less able to colonize and give
beneficial symbionts and the host immune system time to eradicate the disease causing
pathogen prior to colonization or facilitate clearing of an established infection.
Furthermore, stripping microorganisms of their virulence properties without threatening
their existence may offer a reduced selective pressure for drug-resistant mutations and
provide increased potency. Upon exposure to the host, bacteria respond by the
production of an arsenal of virulence factors to combat host immune responses and
facilitate persistence in their desired niche. There are many examples of virulence
factors that represent potential therapeutic targets. Polysaccharide capsules prevent
phagocytosis. Siderophores facilitate iron acquistion. Flagella promote motility and
chemotaxis. Some bacterial species secrete toxins that alter and disrupt the eukaryotic
host cell resulting in disease. Yet another strategy employed by bacteria is the
production of a molecular syringe, known as a type three secretion system, that injects
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effectors into the host cell causing disease. Another fundamental virulence property of
nearly all microbes is their ability to adhere to host cells. This step is typically crucial in
pathogenesis and without it bacteria are more likely to be eradicated by the host.
Bacterial adhesins typically mediate attachment to a specific receptor with
stereochemical specificity, a process that is thought to determine the host and tissue
tropisms of a pathogen. While many virulence factors may represent attractive
therapeutic targets, this review will focus on two strategies to develop anti-virulence
therapeutics based on targeting adhesive pili using uropathogenic E. coli (UPEC) as the
model system. The first strategy depends on competitively inhibiting bacterial binding to
host cells through addition of exogenous carbohydrates that mimic host ligands. The
second strategy targets the mechanism by which adhesive pili are assembled thus
inhibiting bacterial adhesion to host cells. Thus, both strategies could be used in
synergy: the first compound prevents bacterial attachment and colonization by
occupying the binding pocket of the bacterial adhesin while the second compound enters
the cell and prevents future pilus production. Such a two-pronged approach could
eliminate adherence to host cells and promote clearance of the bacteria.

Pili in bacteria
Pathogens are capable of presenting multiple adhesins that can be expressed
differentially to permit binding in specific sites and at particular times over the course of a
complex infectious cycle. To achieve this, many bacterial species possess long
filamentous structures known as pili or fimbriae extending from their surfaces. Pili are
extracellular polymers that also have been shown to play a role in invasion, biofilm
formation, cell motility, and protein and DNA transport across membranes. Pilus
formation is common to many pathogenic bacteria, both Gram-negative and Grampositive pathogens. Despite the diversity in pilus structure and biogenesis, assembly
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mechanisms among Gram-negative and Gram-positive bacteria are conserved within
each group. Gram-positive pili are formed by covalent polymerization of pilin subunits in
a process that requires a dedicated sortase enzyme. In contrast, Gram-negative pili are
typically formed by non-covalent homopolymerization of major pilus subunit proteins.
This review will focus on a major family of adhesive pili in Gram-negative bacteria that
are classified by their mechanism of assembly; the so-called chaperone/usher (CU) pili
(Table 1).
In Gram-negative bacteria, one of the best-characterized pilus assembly systems
is the CU pathway. Hundreds of operons encoding CU systems have been reported in a
plethora of pathogenic organisms with as many as twelve encoded by a single organism.
Examples of CU-assembled adhesive virulence fibers include: Type 1 and P pili
predominately on UPEC that cause urinary tract infection (UTI), S pili of E. coli strains
that cause sepsis, meningitis and UTI and Hif pili of Haemophilus influenza which
causes otitis media. The causative agents of whooping cough (Bordetella pertussis),
gastroenteritis (Salmonella typhimurium), and pneumonia (Klebsiella pneumoniae) also
assemble fibers through the CU pathway. Additionally there are ‘non-pilus adhesins’
assembled by the CU pathway that are generally homopolymers composed of a single
protein subunit, like the Afa/Dr family of adhesins of E. coli and the polymeric F1
capsular antigen of Yersinia pestis. The ubiquitous nature of this pathway paves the
way for a potentially broad-spectrum anti-virulence therapeutic that disrupts the
assembly of the pilus fibers thus eliminating bacterial colonization.

Pili in UTI
Of the CU pathway assembled pili, P and type 1 pili are the most extensively
characterized. Type 1 pili are expressed throughout the Enterobacteriaceae family but
have been shown to be essential for UPEC in colonization of the urinary epithelium.
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UPEC is the leading causative agent for greater than 80% of UTIs which is one of the
most common bacterial infections in industrialized countries. UTIs are a significant
burden, resulting in more than 8 million outpatient visits per year in the United States
and expended costs of US $3.5 billion annually for evaluation and treatment. Women
are the most frequent sufferers – a female has a 60% chance of suffering from at least
one UTI in her lifetime. Additionally, up to 44% of women who present with an initial
episode of UTI will experience recurrence. While the increased likelihood of recurrence
it not entirely understood, data suggests that bacteria can persist within bladder tissue
despite antibiotic treatments, and may serve as bacterial reservoirs for recurrent
infections.
Type 1 pili are expressed by virtually all UPEC isolates. The FimH adhesin at the
tip of type 1 pili achieves specific binding to host cells within the urinary tract. FimH
specifically binds mannose groups that abundantly decorate uroplakins on the luminal
surface of the bladder. A deep, negatively charged pocket in the N-terminal receptorbinding domain of FimH accommodates the mannose with stereochemical specificity.
Once bound, a pathogenic cascade is initiated that involves several distinct phases as
examined in the murine cystitis model and human UTIs. Numerous innate defenses are
activated early in an attempt to stem off the infection. These defenses include, cytokine
induction followed by inflammation, iron sequestering, exfoliation of the colonized
epithelial cells and sheer forces elicited by urine flow. Even if UPEC successfully invade
into a bladder epithelial cell, the bladder cell has been shown to be able to expel UPEC,
potentially serving as an additional innate defense. However, if UPEC are able to
escape into the cytoplasm of superficial umbrella cells, they are able to rapidly replicate
to form tightly packed intracellular bacterial communties (IBCs) with biofilm-like qualities.
Within the urothelial cells, the bacteria are protected from the flow of urine and host
defenses. Eventually UPEC detach from the IBC, disperse and initiate new rounds of
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IBC formation. This represents a mechanism by which a single invasion event
dependent on type 1 pili adhesion can lead to rapid bacterial expansion and colonization
of the urinary tract. IBC formation occurs in the acute states of infection. One long-term
outcome of infection is that UPEC are also able to form a quiescent intracellular
reservoir (QIR) within the bladder. Bacteria in the QIR do not rapidly replicate, but
remain dormant, hidden from the immune system and antibiotics. They are then able to
reestablish an infection at later timepoints post-treatment resulting in a recurrence. Due
to this alternative pathway of continuous colonization, UTIs are more frequently being
identified as chronic infections. Detailed analysis of the UPEC pathogenic cascade has
identified several potential targets to inhibit virulence, such as siderophores, capsule and
flagella. However, type 1 pili represent a particularly attractive drug target because they
are ubiquitous among UPEC, and are required to initiate a pathogenic cascade that
evades the host immune system and can lead to acute, chronic, persistent or
asymptomatic infection. Disruption of type 1 pili function could break the cycle of chronic
infection.

New drug development strategies to inhibit pilus mediated function
Carbohydrates of various forms are abundantly expressed on the animal cell
surface. Microbes have taken advantage of this property and evolved with the ability to
adhere to sugar receptors in an organ-specific manner for colonization and infection.
Sugars are commonly involved in cell recognition and communication playing important
roles in microbial adherence and uptake, colonization and biofilm formation, and in
virulence. Since bacterial adhesion to host cells is extremely specific, exogenous sugars
can block binding to carbohydrate receptors and competitively displace or inhibit bacteria
from attachment to cells. The ability to impair bacterial adhesion represents an ideal
strategy to combat bacterial pathogenesis because it targets an important early step in
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the infectious process, and would also be suitable for use as a prophylactic to prevent
infection. In the case of UPEC, knowledge of the structural basis of how FimH
recognizes the mannose receptor, has lead to the development of a ligand-based
antagonist, termed mannoside, that mimics the natural receptor for FimH but with
increased affinity and avidity. Mannosides effectively block the adhesive properties of
type 1 pili by inhibiting bacterial colonization, invasion, IBC formation and disease.
Furthermore, the sequence of approximately 300 fimH genes of clinical UPEC isolates
showed that the mannose-binding pocket is invariant. Thus mannosides are a powerful
new class of therapeutics that could have a potent therapeutic effect by preventing
UPEC pathogenesis and disease. This approach can be readily extended to other
adherent organisms by tailoring the anti-adhesive compounds to antagonize their
specific receptor-ligand interactions (Figure 1). Indeed, sugars designed to target
adhesive structures of organisms such a Pseudomonas aeruginosa, Stapyhlococcus
and Streptococcus have already proved efficacious at inhibiting adherence in vitro.
The goal of the second strategy is to interrupt pilus assembly, which, like the first
strategy, blocks pilus-mediated adhesion and subsequent disease. To disrupt pilus
assembly, one must first understand the mechanisms employed by bacteria to form
fibers. Chaperone-usher mediated assembly prevents premature subunit aggregation
and facilitates the ordered secretion, folding and assembly of hundreds of thousands of
subunits into fibers on the surface of a bacterium. Components of the pilus are secreted
through the general secretory pathway into the periplasm. Once in the periplasmic
space, a specific chaperone binds each pilus subunit to facilitate proper folding and
prevent premature assembly of subunits. Each subunit consists of six of the seven
strands of a standard immunoglobulin (Ig)-fold and an N-terminal extension (Nte) (Figure
2A). In order to form a stable structure prior to incorporation into the growing fiber, the
chaperone donates structural information to each subunit, its G1 β strand, to
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compensate for the missing seventh strand of the subunit in a process called donor
strand complementation (DSC) (Figure 2B). DSC prevents aggregation of the subunits
prior to fiber formation. The pilin/chaperone complex is then delivered to the usher,
which is a pore in the outer membrane and serves as a platform for pilus assembly.
During pilus assembly, the free Nte of one subunit displaces the chaperone bound to
another subunit and serves as the seventh strand of the Ig-like fold in a process called
donor strand exchange (DSE) (Figure 2C). DSE leads to the polymerization of the fiber
extending from the bacterium. Since chaperone-usher systems are necessary for the
assembly of extracellular adhesive organelles in a wide range of pathogens, inhibitors
may serve as broad-range anti-virulence therapeutics, an attractive feature that would
enhance the marketability of an effective drug.
Pilicides are a class of pilus inhibitors that target chaperone function and inhibit
pilus biogenesis. A recent study (Pinkner JS et al: PNAS (2006) 103(47):17897-17902)
identified a new class of pilicides based on a bi-cyclic 2-pyridone chemical scaffold that
inhibit pilus assembly by binding to the chaperone and disrupting the chaperone-usher
interaction. As a result, pilicides inhibit pilus dependent activities such as colonization,
invasion and biofilm formation. Biofilms are structured communities of microorganisms
encapsulated within a self-developed polymeric matrix that defends them against
antibiotics and the host immune system. They are of great medical importance,
accounting for over 80% of microbial infections in the body. Pilicides target regions on
the chaperone that are highly conserved among chaperone-usher pathways and are
thus able to inhibit assembly of multiple pilus systems (type 1 and P pili of E. coli)
(Figure 1). Pyridinones also avoid the severe drawbacks observed for peptide-based
drugs; poor absorption after oral administration, rapid enzymatic degradation, and quick
excretion.
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Another distinct mechanism of adhesive fiber assembly among Gram-negative
bacteria is fibers assembled by the extracellular nucleation/precipitation pathway (curli).
Curli are proteinaceous fibers found on enteric bacteria such as E. coli and Salmonella
spp. Despite curli’s unclear role in pathogenesis, their biochemical and structural
properties resemble eurkaryotic amyloid fibers found in neurodegenerative diseases,
such as Alzheimer’s, Parkinson’s, and prion diseases making them an ideal model
system to study amyloid biogenesis. Curli are heteropolymers that consist of a major
subunit, CsgA, and minor subunit, CsgB. CsgA and CsgB are secreted into the
extracellular milieu via the outer membrane pore, CsgG. With the help of two
chaperone-like proteins, CsgE and CsgF, CsgA is nucleated into a fiber by CsgB. Curli
fibers have been implicated in biofilm formation, environmental survival and resistance to
sanitizing agents. A recent study (Cegelski L et al: submitted) showed that derivatives of
the 2-pyridone compounds mentioned above were able to inhibit curli assembly giving
them the name curlicides. The lack of curli fibers prevented curli-dependent biofilm
formation and reduced infection load in vivo as measured by the murine model of UTI.
Pilicides and curlicides selectively disrupt a protein-protein interaction required for the
biogenesis of a bacterial virulence factor instead of targeting a process essential for
survival.
Employing both anti-virulence strategies, inhibition of receptor binding and
disruption of pilus assembly, could result in very potent anti-adhesive therapeutics. For
example, synergistic effects could be obtained by inhibiting pre-existing type 1 pilus
function through mannosides while also eliminating the ability to produce new pili
through pilicides. Furthermore, if infection is not entirely controlled by the two-pronged
approach, antibiotics can be added, however, at much lower concentration to reduce the
opportunity to develop resistance. Type 1 pili are an essential virulence factor for
colonization of the urinary tract and are the most extensively studied chaperone-usher
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fimbrial system. Thus, they have been described in this review as an excellent target
resulting in the development of new prototypic therapeutics to treat UTIs. This new drug
class could translate into a multitude of other therapies for Gram-negative infections.

Conclusion
While this review focuses on the development of therapeutics to inhibit adhesion,
there are many other virulence factors employed by bacteria to colonize and persist
within the host. The general strategy of inhibiting virulence factors rather than essential
growth factors changes the paradigm of drug development and reduces the evolutionary
pressure for bacteria to develop resistance. Bacteria can survive in the presence antivirulence drugs, but will be eliminated by the host immune system prior to establishing a
foothold. Furthermore, since a complex virulence mechanism is targeted, if mutants
arise, they will most likely be avirulent. If the host immune system cannot resolve any
residual infection, it is possible to couple anti-virulence therapeutics with traditional
antibiotics although at lower doses thus reducing resistance potential. A commitment to
developing therapeutics that target virulence requires a serious change in our
perspective for treating infectious diseases and increased efforts should be focused on
bringing these new therapeutics from bench to bedside.
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Chaperone-usher assembled pili
Adhesive fiber

Major
pilin

chaperone/
usher

Adhesin

Organisms

Disease

Type 1

FimA

FimC/FimD

FimH

Escherichia coli, Klebsiella
pneumoniae, Salmonella
species

cystitis, sepsis, meningitis

P

PapA

PapD/PapC

PapG

Uropathogenic E. coli (UPEC)

pyelonephritis

Prs

PrsA

PrsD/PrsC

PrsG

E. coli

cystitis

S

SfaA

SfaE/SfaF

SfaS

E. coli

UTI, meningitis, sepsis

Hif

HifA

HifB/HifC

HifE

Haemophilus influenzae

otitis media, meningitis

Type 2 and 3

Fim2 &
Fim3

FimB/FimC

FimD

Bordetella pertussis

whooping cough

Pef

PefA

PefD/PefC

unknown

Salmonella typhimurium

gastroenteritis

Long polar fimbriae

LpfA

LpfB/LpfC

unknown

S. typhimurium

gastroenteritis

MR/K

MrkA

MrkB/MrkC

MrkD

K. pneumoniae

pneumonia

Myf fimbriae

MyfA

MyfB/MyfC

unknown

Yersinia enterocolitica

enterocolitis

PMF

PmfA

PmfC/PmFD

PmfF

Proteus mirabilis

UTI

Dr

DraA

DraB/DraC

DraE

UPEC

pyelonephritis

Diffuse adhereing E. coli
(DAEC)

cystitis

UPEC

cystitis, diarrhea

Yersinia pestis

plague

Afa

AfaA

AfaB/AfaC

F1

Caf1

Caf1M/Caf1A

AfaE

Alternative chaperone pathway
Adhesive fiber

Major
pilin

Assembly
proteins

Adhesin

Organism

Disease

CS1 pili

CooA

CooB/CooC

CooD

E. coli

diarrhea

Extracellular nucleation-precipitation pathway
Adhesive fiber

Assembly proteins

Adhesin

Organism

Disease

Curli

CsgB (nulceator), CsgE
and CsgF (assembly) and
CsgG (secretion)

CsgA
(major
subunit)

E. coli

sepsis

Salmonella spp.

gastroenteritis, sepsis

Table 1. Representative adhesive fibers, fiber classification and disease association
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Figure 1. Two strategies to inhibit bacterial binding to host cells. The schematic
diagram shows the model of chaperone-assisted pilus assembly and the mode of
mannoside (left panel) and pilicide (right panel) action. During normal pilus biogenesis,
newly synthesized pilus subunits cross into the periplasm via the Sec secretion pathway.
These pilus subunits bind to their periplasmic chaperone proteins (orange molecules)
and fold into correct confirmations (1). In the absence of the chaperones, pilus subunits
are degraded (*). Chaperone-subunit complexes (2) are transported to the outer
membrane usher proteins (blue cylinders) for assembly (3). Pilus assembly follows an
ordered process with the chaperone-adhesin complexes as the initiators (4). As subunits
are assembled into the growing pilus, accompanying chaperones disassociate from the
membrane complexes (5), which could potentially be recycled to bind newly synthesized
subunits. Mannosides (teal triangles) interact with the pilus adhesin and prevent binding
to mannosylated residues (light brown triangles) on the surface of epithelial cells.
Pilicides (yellow circles) can cross freely through bacterial outer membranes and bind to
periplasmic chaperones (B). Pilicides block the interaction of chaperone-subunit
complexes with the outer membrane usher (C) and prevent pilus assembly (D).
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Figure 2. Chaperone-subunit donor strand exchange (DSE) and donor strand
complementation (DSC). (A) Each subunit consists of six of the seven strands of a
standard immunoglobulin (Ig)-fold and an N-terminal extension (Nte). (B) In order to
form a stable structure prior to incorporation into the growing fiber, the chaperone
donates the missing seventh strand of the subunit in a process called donor strand
complementation (DSC). (C) During pilus assembly, the free Nte of one subunit
displaces the chaperone bound to another subunit and serves as the seventh strand of
the Ig-like fold in a process called donor strand exchange (DSE).
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